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ABSTRACT

Beck, Daniel Edward. Ph.D., Purdue University, August 2015. Design, Synthesis, and
Biological Evaluation of Novel Indenoisoquinolines as Potential Anticancer Agents.
Mark Cushman.

The research in this thesis is focused on the design, synthesis, and biological
evaluation of indenoisoquinolines that inhibit the human topoisomerase IB enzyme
(Top1). At present, there are only two FDA-approved cancer chemotherapeutic drugs
that target this enzyme. These agents bind to a covalent Top1-DNA cleavage complex
intermediate that is formed when Top1 relaxes supercoiled DNA. The effect of this
stabilization is that a DNA replication fork can “collide” with the cleavage complex,
which produces cytotoxic DNA damage products. Although the present arsenal of Top1
inhibitors is effective in the treatment of solid tumors, their common camptothecin-based
structure is plagued by physicochemical and pharmacological issues. For these reasons,
alternative structures with Top1 inhibitory activity are currently needed. The objectives
of this research were to:

(1) establish new and improved synthetic routes to three

clinically studied Top1 inhibitors that are based on an indenoisoquinoline scaffold; (2)
investigate the structure-activity relationships (S.A.R.) of indenoisoquinolines substituted
with carbohydrate-derived and carbohydrate-mimetic moieties; (3) seek out bioisosteric
replacements for the nitro group in the highly active 3-nitroindenoisoquinoline Top1
inhibitor series; and (4) design and test dimeric indenoisoquinolines that could

xviii
potentially inhibit both Top1 and DNA repair enzyme tyrosyl DNA phosphodiesterase 1
(TDP1).
Three compounds discovered in the Cushman laboratory are under investigation
in humans and canines as potential anticancer drugs.

Indotecan (LMP400) and

indimitecan (LMP776) are being studied in Phase I clinical trials, and one of these two
agents may be promoted to a Phase II trial in the future. LMP744 is being studied in
canines, and it will likely be studied in man. As the three agents enter into and progress
through clinical trials, increasing supplies of the drugs will be required to support their
studies. New synthetic routes to the three drugs were devised to overcome problems with
their

present

manufacturing

routes,

including

the

requirement

for

column

chromatography purifications. The new routes overcome several problems and provide
the drugs in greater overall yields.
In the second effort, thirty-two new indenoisoquinolines substituted with linear
and cyclic carbohydrate-derived or carbohydrate-mimetic moieties were designed and
synthesized as potential Top1 inhibitors. The rationale for this substitution and the
design process were aided by the X-ray crystal structures of an indenoisoquinoline and an
indolocarbazole glycoside bound separately to the Top1-DNA cleavage complex.
Aromatic ring substitution with 2,3-dimethoxy-8,9-methylenedioxy or a 3-nitro group
was found to exert beneficial effects on antiproliferative and Top1 inhibitory activities.
While the length of the linear carbohydrate side chains clearly correlates with
antiproliferative activity, the relationship between stereochemistry and biological activity
is less clearly defined. The potencies of 12 of the new indenoisoquinolines equaled or
exceeded that of camptothecin.

xix
The third effort was focused on making improvements to a promising class of
indenoisoquinoline Top1 inhibitors, albeit one with a potentially serious toxicology risk.
3-Nitroindenoisoquinolines often exhibit potent antiproliferative effects on cancer cells
and display high Top1 inhibitory activity; however, their 3-nitro group could be reduced
in vivo to species with nonspecific and harmful protein and DNA reactivity.

The

undesirable nitro toxicophore was replaced by ten other functional groups that could
retain the desired biological activities and minimize potential safety risks. The data
reveal that fluorine and chlorine may substitute for the 3-nitro group with minimal loss to
Top1 inhibitory and antiproliferative activities. The new information gained from these
efforts was then used to guide the design of additional novel indenoisoquinolines that, in
some cases, exhibit growth and Top1 inhibitory activities on par with analogous 3nitroindenoisoquinolines.
Finally, in the fourth effort, dimeric indenoisoquinolines were designed using the
available S.A.R. data for their Top1 and TDP1 inhibitory activities. The dimers, or
bis(indenoisoquinolines), were decorated with the 2,3-dimethoxy-8,9-methylenedioxy
aromatic ring substitution pattern on each monomer with the expectation of conferring
high Top1 inhibitory activity. The polyaminoalkyl linker chains uniting two monomers
were modulated to vary both the number of basic amines and length.

Contrary to

expectation, the Top1 inhibitory activities of the new compounds were weaker than those
for aromatic ring-unsubstituted analogues. However, each of the dimeric compounds did
exhibit inhibitory activity towards TDP1. These results can educate the future design of
improved dual Top1-TDP1 inhibitors.

1

CHAPTER 1. INTRODUCTION TO THE TOPOISOMERASE IB ENZYME

1.1

Structure and Function

Human topoisomerase type IB (Top1) is essential for the proper functioning of all
vertebrate cells. Lacking it, mice do not survive to birth. Human Top1 knockdown cells
exhibit gravely impaired replication and gene expression patterns.1 The enzyme removes
the excessive supercoiling from DNA that naturally results from replication, transcription,
and chromatin remodeling. Removal of the excessive supercoiling allows each of these
processes to continue to occur.2 Over the past three decades, the structural and functional
details of Top1 have been learned through experimental studies, and they have enabled
the discovery of effective and commonly used anticancer drugs.
The structures of Top1 and Top1-DNA complexes are well-known from several Xray crystallographic studies.3 Top1 is a 100 kDa, bilobal enzyme, containing 765 amino
acids organized into four distinct domains: N-terminal; core; linker; and C-terminal.
Top1 is uniquely found in the nucleus because of the nuclear localizing effect of its Nterminal domain. The core subdomains I and II form a “cap lobe” that holds Top1’s
DNA substrate in place. Core subdomain III and the linker and C-terminal domains form
a “catalytic lobe” that contains the residues involved in the reactions catalyzed by Top1.
A large portion of the surface area of Top1 is enriched in positively charged residues
which stabilize the DNA substrate.4 The positions for each of these latter
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three domains in a non-covalent Top1-DNA complex are shown in Figure 1. The Nterminal domain is a largely disordered region,4 and this may explain why it is truncated
from the enzyme for X-ray crystallography studies.

Figure 1. Two views of an X-ray crystal structure of a non-covalent Top1-DNA complex
(PDB code 1A36).4 The smaller structure, at right, has been rotated 90° along the
horizontal axis to show the hollow pore where the DNA oligonucleotide binds.

The details of the Top1-mediated DNA relaxation process were learned of
through a series of X-ray crystallographic and biochemical studies.4, 5 Initiation of the
enzyme-catalyzed process begins with the enzyme clamping around its duplex DNA
substrate (A and B, Figure 2). With the substrate bound, Top1 catalytic residue Tyr723 is

3
appropriately positioned for nucleophilic attack on one strand of the DNA. In this
reaction, known as the cleavage step, Tyr723 attacks a phosphodiester linkage of the
DNA backbone, thus attaching the enzyme to the DNA 3’-end and ejecting its 5’-end (C,
Figure 2; Figure 3). Once this covalent intermediate, or “cleavage complex,” is formed,
the free 5’-end rotates about the uncleaved strand to relieve torsional strain. This process,
known as “controlled rotation” (D, Figure 2), does not require an outside energy source.
In fact, single molecule experiments have shown that the energy released by DNA
relaxation drives the process forward.6 With each relaxing rotation, Top1 positions the
scissile strand 5’- and 3’-ends close to one another to favor religation. After relaxation
has occurred, the 5’- and 3’-ends of the cleaved strand are rejoined in the religation step
(F, Figure 2). Finally, Top1 releases a newly-relaxed DNA duplex (G, Figure 2).4

4

Figure 2. A macromolecular view of the Top1-mediated DNA relaxation mechanism.
Adapted with permission from Science 1998, 279, 1534–1541. Copyright 1998, The
American Association for the Advancement of Science.

A detailed, atomic level view of the chemical reactions occurring in steps B  C
and E  F of Figure 2 is shown in Figure 3. The cleavage reaction occurs at a much
slower rate than the religation reaction and therefore the equilibrium for this reaction lies
far to the left, in favor of intact DNA.7 A constellation of basic amino acids (Arg488,
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Arg590, and His632; unshown) surrounds the phosphodiester linkage and stabilizes the
transition state of the reaction through hydrogen bonding and electrostatic interactions.
His632 or a water molecule may serve as a general base by accepting the proton from the
attacking Tyr723 hydroxyl.4, 5

Figure 3. Nucleophilic substitution reactions that occur in the cleavage and religation
steps in the Top1-mediated DNA relaxation mechanism.

1.2

Cancer Target

Top1 is the target enzyme for several experimental and FDA-approved anticancer
drugs. Cancer chemotherapeutic drugs known as Top1 poisons trap Top1-DNA cleavage
complexes, an effect which ultimately results in cell death. Top1 poisons trap cleavage
complexes by inhibiting the religation step (Figure 3). Normally, this step occurs rapidly
enough that cleavage complexes are undetectable in cells. Because of the longer lifetime
of a trapped cleavage complex, replication forks proceeding along the DNA are more
likely to “collide” with the complexes. Transcription complexes can also collide with
trapped cleavage complexes.

However, the contribution of transcription complex
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collisions to the anticancer effects of camptothecins is much less than that of replication
in rapidly proliferating cancer cells.2 The effect of each of these types of collisions is that
they produce double-strand breaks resulting in irreversible Top1-DNA cleavage
complexes.
The conversion of a Top1 poison-bound cleavage complex to an irreversible
complex is necessary for these drugs’ cytotoxic effect. In collisions between replication
forks and Top1-DNA cleavage complexes, DNA polymerase proceeding along a Top1attached leading strand encounters the cleavage complex and cannot go further. The
newly synthesized DNA is left with a double-strand break and is incomplete, and requires
double-strand break repair (Figure 4). Meanwhile, Top1 remains covalently attached to
the scissile strand. This covalent adduct, also called a protein-linked DNA damage
product, requires its own repair mechanism to free the DNA from Top1. If the cell is
unable to properly deal with the induced DNA damage caused by Top1 poisons, then it
enters apoptosis.2

7

Figure 4. Generation of cytotoxic DNA double-strand breaks from the collision of a
DNA replication fork with a Top1-DNA cleavage complex. Adapted with permission
from Nature Rev. Cancer 2006, 6, 789–802. Copyright 2006, Nature Publishing Group.

Top1 poisons have differential cytotoxicity towards cancer cells and normal,
slower dividing cells. First, cancer cells replicate DNA and express higher levels of Top1
more frequently than normal cells. The combination of these characteristics increases the
likelihood of a Top1 poison trapping a Top1-DNA cleavage complex and inducing DNA
replication fork collision in a cancer cell. Second, a cell that suffers from such a collision
must competently repair both the DNA double strand break and remove the Top1-DNA
covalent adduct. Although appropriate repair mechanisms do exist in human cells, a
hallmark of cancer cells is that they have compromised checkpoint and DNA repair
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abilities.8 As a result of these differences, cancer cells are more susceptible to the effects
of Top1 poisons.

1.3

Poisons

Top1 poisons based on the core structure of camptothecin are the most successful
thus far. Two have achieved FDA approval for common cancer indications. Although no
non-camptothecin Top1 poisons have achieved regulatory approval as cancer
chemotherapeutics, it is not for a lack of trying. Indeed, several non-camptothecin Top1
poisons are in clinical development at present, and academic and industrial laboratories
remain interested in discovering others.

1.3.1

Camptothecins

Camptothecin is the founding member of the Top1 poison class of cancer
chemotherapeutic agents. The famed natural products researchers Drs. Monroe Wall and
Mansukh Wani first isolated the pentacyclic alkaloid in 1965 from a sample of
Camptotheca acuminata, a tree native to China. Preclinical testing in mice showed that
purified camptothecin could effectively treat leukemias. In 1970, the ring-opened sodium
carboxylate salt of camptothecin was studied in man. Although some responses were
observed, poor efficacy and toxicity issues brought its clinical study to an end in 1974.9, 10
In the mid-1980’s, a team of researchers investigated camptothecin’s mechanism
of action. It was known that the drug could arrest DNA replication and transcription, and
cause DNA damage. Hsiang and coworkers discovered that camptothecin was not a
Topoisomerase II poison, like the epipodophyllotoxin drugs known at the time—instead,
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they showed that it poisoned Top1.11 Following the identification of its novel anticancer
activity, medicinal chemistry campaigns took off in search of water-soluble camptothecin
derivatives. Two such compounds were discovered by the early 1990’s with improved
efficacy and safety as anticancer agents. The two drugs, irinotecan and topotecan, gained
FDA approval in 1996 and remain in use for the treatment of colorectal (irinotecan) and
ovarian, cervical, and small-cell lung cancers (topotecan).

At present, numerous

chemically modified camptothecins are under clinical investigation.
Although the camptothecins are able to limit the growth of solid tumors, none are
curative, and most members of this class have significant drawbacks including: (1) doselimiting side effects including bone marrow suppression and severe diarrhea; (2)
susceptibility of the lactone to rapid ring-opening hydrolysis at physiologic pH, which
produces a carboxylate form that binds to blood plasma proteins; (3) the requirement of
prolonged infusion times owing to the rapid reversibility of the camptothecin-bound
cleavage complex; (4) susceptibility to point mutations in Top1 that confer drug
resistance; and (5) recognition by and removal from cells by ABCG2 multidrug efflux
pumps.2,
sought.
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For these reasons, newer generations of camptothecin Top1 poisons were
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Figure 5. Progress in the development of small-molecule Top1 poisons based on the core
structure of camptothecin.

Chemotypes that are based on the camptothecin core structure, but have modified
lactone rings, have shown promise in preclinical studies.
homocamptothecin class representative.

Diflomotecan is a

Its expanded, seven-membered lactone ring

undergoes ring-opening hydrolysis less rapidly than regular camptothecins; however, its
hydrolysis is essentially irreversible. S39625 lacks the lactone functionality completely,
and so it cannot undergo hydrolysis.2 The clinical development status of these drugs at
present is unknown.
1.3.2 Indenoisoquinolines and Others
An altogether different strategy for overcoming the challenges associated with
camptothecins is to develop structurally dissimilar Top1 inhibitors. Top1 poisons based
on different chemical scaffolds include the dibenzonaphthyridinones and the
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indolocarbazole glycosides (Figure 6).2, 13 Each of these two classes is a potential source
of therapeutic Top1 inhibitors which can overcome some of the problems with
camptothecins. Two dibenzonaphthyridinones, topovale (also known as ARC-111) and
Genz-644282 advanced to human clinical study, although their fates are unknown.
Edotecarin, an indolocarbazole glycoside, advanced as far as a Phase III clinical trial,
where it unfortunately failed. One possible explanation for edotecarin’s failure is offtarget binding to DNA.1

Figure 6. The structures of some clinically studied non-camptothecin Top1 inhibitors.

Top1 inhibitors based on the indenoisoquinoline core scaffold can also offer
solutions to the problems posed by the camptothecins. The indenoisoquinolines have a
number of positive attributes, which include: (1) chemical stability; (2) cleavage site
specificity that is different from camptothecin, which may translate to distinct tumor
responses; (3) longer residence times in the cleavage complex binding site; (4) ability to
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overcome some of the Top1 mutations that confer resistance to camptothecins; and (5)
that they are seldom or are not substrates for drug efflux pumps (i.e., MDR-1 and
ABCG2) that efficiently remove camptothecins from cancer cells.2, 14, 15
Our group designed and synthesized two indenoisoquinolines, indotecan
(LMP400)16 and indimitecan (LMP776)16, which are being studied in Phase I clinical
trials at the National Institutes of Health.17,
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These agents are well tolerated, and

preliminary evidence of efficacy has been found.19 Their side chain analogue MJ-III-65
(LMP744)12, 20 is under consideration for human clinical study (Figure 7).

Figure 7. The structures of three clinically studied indenoisoquinoline Top1 inhibitors.

An X-ray crystal structure of the indenoisoquinoline MJ-2-38 bound to the Top1DNA cleavage complex was reported in 2005 (Figure 8).21 The planar, polycyclic
scaffold interacts with the flanking base pairs in the cleavage site through “pi-stacking”
interactions. The carbonyl forms a hydrogen bond with Arg364 in the minor groove of
the DNA. Finally, the side chain projects into the solvent-filled major groove of the
DNA.
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Figure 8. Two-dimensional (top) and three-dimensional (bottom) close-up views of
indenoisoquinoline MJ-2-38 bound to the Top1-DNA cleavage complex (PDB code
1SC7).21 A potential hydrogen bonding interaction is indicated by the dashed line. The
heavy atom distance appears next to the dashed line. The stereoview is programmed for
wall-eyed (relaxed) viewing.

The X-ray crystal structure above (Figure 8) and previous structure-activity
relationship (S.A.R.) studies of indenoisoquinolines as Top1 poisons15, 16, 22-33 can guide
the design of new compounds.

Some of the most important features of

indenoisoquinolines for potent Top1 inhibition and cytotoxicity are summarized in the
graphic below (Figure 9).
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Figure 9. Summary of important S.A.R. data collected for the indenoisoquinolines as
cytotoxic Top1 poisons. The rings of the indenoisoquinoline system, and numbers of
important positions on the scaffold, are indicated.

At the outset of this research, the S.A.R. data for the indenoisoquinoline Top1
poisons had been highly developed at a small number of positions, especially the 6-16, 29,
31, 34

, 9-28 and 11-23, 33, 35 positions. This left ample opportunity to rationally probe the

effects of substitutions at other positions of the indenoisoquinoline system, including the
backbone atoms. In this research, the S.A.R. data for the 2-, 3-, and 6-positions were
expanded or clarified over the course of several systematic studies. The new data can
therefore aid in the design of new and improved indenoisoquinoline Top1 poisons—and
those based on completely different scaffolds, as will be shown.
A related and more recent motivation for continued investigation of
indenoisoquinoline Top1 poisons is that some can also inhibit the DNA repair enzyme
tyrosyl DNA phosphodiesterase 1 (TDP1). As mentioned in Section 1.2, a cell can
counteract the cytotoxic effects of a Top1 poison by competently repairing the DNA
damage that is induced.

There are several pathways that remove the irreversible,
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covalent Top1-DNA adducts induced by a Top1 poison, and TDP1 plays a critical role in
one. TDP1 is the main enzyme in the cell that hydrolyzes 3’-phosphotyrosyl linkages
between Top1-derived peptides and DNA.36 It would be advantageous to administer a
single indenoisoquinoline chemotherapeutic agent that has both Top1 poisoning and
TDP1 inhibitory activities. The S.A.R. of indenoisoquinoline TDP1 inhibitors is at an
early stage of development,37, 38 and therefore all of the compounds described in this
thesis were tested for both Top1 and TDP1 activities.

* * * * *
The following chapters are adapted with permission from J. Med. Chem. 2014, 57,
1495–1512, DOI: 10.1021/jm401814y, Copyright 2014, American Chemical Society;
and J. Med. Chem. 2015, 58, 3997–4015, DOI: 10.1021/acs.jmedchem.5b00303,
Copyright 2015, American Chemical Society. The following applies to Chapters 2–4 of
this thesis: “This is an unofficial adaptation of an article that appeared in an ACS
(American Chemical Society) publication. ACS has not endorsed the content of this
adaptation or the context of its use.”
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CHAPTER 2. ALTERNATIVE SYNTHESES OF THREE CLINICALLY STUDIED
TOPOISOMERASE I INHIBITORS

2.1

Introduction

Two compounds discovered in this laboratory, called indotecan (LMP400, 20) and
indimitecan (LMP776, 21), are currently being investigated in human Phase I clinical
trials as anticancer agents.17, 18 A third compound known as MJ-III-65 (LMP744, 22) is
being studied in canines with lymphoma and plans are being formulated for its future
clinical study in man. As clinical studies of these three agents progress, there will be an
increasing demand for the active ingredients.
The current manufacturing routes to compounds 20–22 (Scheme 12) have several
drawbacks.

One is the necessity for column chromatography purifications.

It is

undesirable to purify by this method on process scales owing to the large amounts of
material consumed. Another drawback is that the current routes deliver the compounds
in approximately 20% overall yields over seven total steps. This presents an opportunity
to increase yield and step economies.

New synthetic routes to the experimental

anticancer agents (Schemes 1 and 11) were designed and developed in response to these
challenges and have delivered alternatives to the current manufacturing routes that offer
several advantages.
The new synthetic routes also gave ready access to several potential side chain
metabolites of indotecan and indimitecan. The metabolism of these drugs in rodents was
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investigated contemporaneously, and potential metabolites were prepared to assist with
those studies.

2.2

Development of a Route to the Common Intermediate

The new synthetic routes provide 20–22 in a single step from a common
intermediate, lactone 9.

Lactone 9 was prepared by the condensation of 3-

hydroxyphthalide 4 and phthalide 7, and subsequent dehydrative cyclization of the
unisolated condensation product 8 (Scheme 1). The synthesis of 4 began with veratric
acid (1), which was alkylated with formaldehyde under acidic conditions to give
phthalide 2.39 Phthalide 2 was brominated by free-radical halogenation to provide
unisolated 3-bromophthalide 3, which was hydrolyzed in refluxing water to provide 3hydroxyphthalide 4.40 The synthesis of phthalide 7 started with piperonol (5), which was
brominated with NBS to give 6. Compound 6 was treated with n-BuLi at -78 C to effect
a halogen-lithium exchange, and the lithiated intermediate was quenched with CO2 and
then treated with aqueous HCl to provide phthalide 7.41 The two intermediates 4 and 7
were condensed using freshly prepared NaOMe in refluxing EtOAc-MeOH to give
indanedione 8, which was then cyclized in refluxing Ac2O to yield lactone 9.42, 43
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Scheme 1. Synthesis of 9a

a

Reagents and conditions: (a) 37% HCHO, 37% HCl, 90 °C; (b) NBS, CCl4, hν, reflux;

(c) H2O, reflux; (d) NBS, CH2Cl2; (e) i. n-BuLi, THF, -78 °C, ii. CO2, Et2O, iii. 37% HCl;
(f) i. NaOMe, MeOH, EtOAc, reflux; ii. Ac2O, reflux.

Intermediate 6 was also synthesized from piperonal (10, Scheme 2). First, 10 was
brominated to give benzaldehyde 11.44 Reduction of intermediate 11 with NaBH4
afforded benzylic alcohol 6.45

Scheme 2. Alternative Synthesis of 6a

a

Reagents and conditions: (a) Br2, AcOH, Fe, 15 °C to rt; (b) NaBH4, EtOH, 5 °C to rt.
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The route shown in Scheme 3 can also be used to produce intermediate 7. The
chemistry in this reaction is a Rosenmund-von Braun cyanation followed by nitrile
hydrolysis and lactonization.46

Scheme 3. Alternative Synthesis of 7 from 6a

a

Reagents and conditions: (a) CuCN, H2O, DMF or formamide, 160 °C; ii. NaCN, H2O,

110 °C to room temp.

Yet another alternative route to 7 makes use of phthalide 2, an intermediate in the
synthesis of 3-hydroxyphthalide 4 (Scheme 4). Phthalide 2 was demethylated with BBr3
to provide phthalide 12. The catechol functionality of 12 was re-alkylated with CH2Br2
under basic conditions to provide phthalide 7.

Scheme 4. Synthesis of 7 from 2a

a

Reagents and conditions: (a) BBr3, CH2Cl2, -78 °C to room temp.; (b) Cs2CO3, CH2Br2,

DMF, 95–100 °C.
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Alkylation of piperonylic acid (13) under acidic conditions with formaldehyde
delivered phthalide 7 in only 3% yield (Scheme 5). This result was unexpected, given
how phthalide 2 was produced from veratric acid (1) in 75% yield using similar
conditions. It was necessary to use AcOH as an organic cosolvent here because the
starting material is insoluble in the aqueous solution of formaldehyde and HCl.

Scheme 5. Synthesis of 7 from 13a

a

Reagents and conditions: (a) 37% HCHO, 37% HCl, AcOH, reflux.

Phthalides 4 and 7 could also be prepared in a single step using a C-H bond
activating method known as palladium(II)-catalyzed ortho alkylation of a benzoic acid
(Scheme 6). This method appeared attractive because it is catalytic and it produces the
desired product in a single step from a readily available benzoic acid-derivative starting
material.
A possible mechanism for palladium(II)-catalyzed ortho alkylation of a benzoic
acid with an alkyl halide47 is shown in Scheme 6.

It is based on experimental

observations made by Yu and coworkers.47 The palladium catalyst, Pd(OAc)2, cycles
through Pd(II) and Pd(IV) oxidation states. The solvent, CH2Br2, also functions as the
alkylating agent.

The base is carefully chosen to minimize competing substitution

reaction of the benzoate anion with solvent.

The metal cation, either sodium or
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potassium, that is derived from the base weakly coordinates the carboxylate, and is
necessary for the C-H bond activation step.47, 48

Scheme 6. Possible Mechanism of Pd(II)-catalyzed ortho Alkylation of a Benzoic Acid

The synthesis of phthalide 7 by Yu’s method is reported to proceed in 78% yield
(Scheme 7).49 This yield is within the 47–92% yield range reported by the reaction’s
discoverers.47 In the initial attempts, the product was isolated in a maximum yield of 13%
(Table 1). Forgoing the Celite filtration step during product purification was acceptable
because inorganic byproducts were visibly trapped by silica gel column chromatography
alone. This change greatly increased the product yield, which rose to 35% (Entry 1).
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Scheme 7. Alternative Synthesis of 7 from 13a

a

Reagents and conditions: (a) CH2Br2, K2HPO4 (base), Pd(OAc)2 (15 mol %), 140 °C, 2 d.

1-2 g scale

100-200 mg scale

Table 1. Optimization of Pd(II)-catalyzed ortho Alkylation Synthesis of 7 from 13

a

Entry

Changes

Isolated yield of 7

1

none

35%

2

base = KHCO3

31%

3

add 2.4 eq AgOAc

29%

4

9:1 TFEa-CH2Br2

0%

5

4d

62%

6

6d

32%

7

4d

11–12%

8

4 d, add 20 eq. t-BuOH

9%

TFE = 2,2,2-trifluoroethanol.

A variety of parameters were tested next to probe for opportunities to increase the
isolated yield of 7 (Entries 2–6). Use of 2.5 eq KHCO3 in place of 3 eq K2HPO447 did not
improve the yield (31%). Addition of 2.4 AgOAc to the reaction mixture50 was not
advantageous. Changing the solvent system to 9:1 TFE51-CH2Br2 appeared to totally
impede the reaction, and 7 was not isolated. Doubling the reaction time to 4 d increased
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the isolated yield to 62%, which is comparable to the 65% yield over 2 steps in the
synthesis of phthalide 7 shown in Scheme 1. Further extension of the reaction time to 6 d
was detrimental to the yield (32%). It was thus found that use of 3 eq K2HPO4 and a 4 d
reaction time were the optimal conditions for this reaction on sub-gram scales.
When the reaction was scaled-up to the one- or two-gram scales, and the optimal
conditions employed, the reaction’s efficiency was diminished (Entries 7 and 8). These
poor yields could not be improved through the addition of 20 eq. t-BuOH as a cosolvent,
or by thoroughly pulverizing each of the starting materials and drying them under high
vacuum beforehand.
Three different byproducts were detected in the product mixtures obtained from
this reaction (Figure 10). The sole isolated byproduct for Entry 7 was the dimer 7a,
which was isolated in 3% yield. Although it was not isolated as a pure substance, a small
amount (22%) of byproduct 7b was detected in the 1H NMR of one sample of 7 following
silica gel column chromatography. The observation of a regioisomeric byproduct is in
disagreement with the original literature report,47 whose authors suggest that a steric
effect prevents the more crowded regioisomer from being formed. Finally, ester 7c was
isolated (25%) along with dimer 7a (8%) when employing the conditions shown in Entry
4. The amounts of the isolated and unisolated byproducts do not account for the poor
material balance of this reaction. Starting material could not be recovered from any of
the product mixtures, although its presence could be detected post-reaction by thin-layer
chromatography (TLC).
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Figure 10. Byproducts isolated from or detected in product mixtures for the C-H bond
activation synthesis of 7 from 3.

The synthesis of 5,6-dimethoxyphthalide (2) shown in Scheme 1 delivers the
product in a single step in 75% yield, although it uses formaldehyde, which is a known
human carcinogen. In response, an alternative synthesis of 2 from 3,4-dimethoxybenzoic
acid (1) that uses C-H bond activation methodology47 was investigated (Scheme 8). After
an optimization campaign was carried out for this reaction at sub-gram scales, the
maximum yield that could be achieved was 32% (Table 2). Modifications such as
extension of reaction time and substitution of K2HPO4 with different bases were not
beneficial. Furthermore, it was necessary to purify the product mixtures obtained from
this reaction by column chromatography, which is unnecessary in the original synthesis
of 2. The poor yields and extra effort required to isolate 2 were the key factors in the
decision to cease this reaction’s development.

Scheme 8. Alternative Synthesis of 2 from 1a

a

Reagents and conditions: (a) CH2Br2, K2HPO4 (base), Pd(OAc)2 (15 mol %), 140 °C, 2 d.
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Table 2. Optimization of Pd(II)-catalyzed ortho Alkylation Synthesis of 2 from 1
Entry

Changes

Isolated yield of 2

1

none

24%

2

4d

21%

3

base = KHCO3

32%

4

4 d, base = KHCO3

10%

5

base = NaHCO3

12%

The substitution of CHCl3 or CHBr3 for CH2Br2 in the Pd(II)-catalyzed ortho
alkylation reaction for benzoic acids was investigated for the synthesis of 3hydroxyphthalide 4 because it could install the aldehydic carbon in its desired (+1)
oxidation state, thereby eliminating the need for the NBS oxidation step (Scheme 9). The
intermediate 4 could be produced in only two steps, following hydrolysis of the carbonhalogen bond.

In practice, the substitution of CHCl3 or CHBr3 for CH2Br2 was

ineffectual. Starting material and traces of unidentified products were obtained when
CHCl3 was used as the alkylating reagent. In the case of CHBr3, 1H NMR and mass
spectrometry support the identity of the sole isolated product as ester 3a.

The

introduction of ethyl is likely due to EtOH, which is present in the CHBr3 as a stabilizer.
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Scheme 9. Attempted Synthesis of 3-Halophthalides from 1 by Pd(II)-catalyzed ortho
Alkylationa

a

Reagents and conditions: (a) CHCl3 or CHBr3, K2HPO4, Pd(OAc)2 (15 mol %), 140 °C,

2 d.

Finally, Vilsmeier-Haack formylation52 of the methyl ester of 1 (15) was
attempted (Scheme 10).

Only starting material was recovered when the maximum

reaction temperature was 80 °C; an inseparable black tar was formed when the reaction
mixture was heated to reflux. Successful formylation of 15 by other means is reported in
the literature.53

Scheme 10. Attempted Synthesis of 4 via 15a

a

Reagents and conditions: (a) POCl3, DMF, 0 °C then 80 °C or reflux; (b) hydrolysis.
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2.3

Synthesis of the Drugs from the Common Intermediate

Lactone 9 was condensed with commercially available primary amines 3morpholinopropylamine

(17)

or

3-imidazolylpropylamine

(18)

or

2-(3-

aminopropylamino)ethanol (19) to provide anticancer agents 20, 21, and 22, respectively
(Scheme 11). The completed synthetic route (Schemes 1 and 11) to each drug includes
eight total steps, and their longest linear sequences are each six steps.

Scheme 11. Synthesis of 20–22a

a

Reagents and conditions: (a) CHCl3, reflux.

The overall yields for each drug by the current manufacturing routes (Scheme 12)
and the new routes (Schemes 1 and 11) are given in Table 3. The yields shown in
Scheme 12 have previously been reported54 or were obtained in the Cushman laboratory.
Overall yields were calculated based upon the longest linear sequence of each route. For
the new routes, this was six steps, beginning from 3,4-dimethoxybenzoic acid (1). For
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the current manufacturing routes, this was also six steps, but instead beginning from 3,4dimethoxyhomophthalic acid (23). The new routes produce 20, 21, and 22 in 31%, 26%,
and 24% overall yields, respectively, from starting material 1 (Schemes 1 and 11). The
previously developed routes afforded 20, 21, and 22 in 16%, 18%, and 17% overall yields,
respectively, starting from 23 (Scheme 12). The overall number of steps for each route
does not differ greatly, with eight in the new ones and seven in the current ones.

Scheme 12. Current Manufacturing Routes to 20–22a

a

Reagents and conditions: (a) 37% HCHO, 37% HCl, AcOH, 75 °C; (b) i. KOH, H2O; ii.

KMnO4, H2O; (c) AcCl, reflux; (d) 3-bromopropylamine hydrobromide, CHCl3, NEt3,
Na2SO4; (e) CHCl3; (f) SOCl2, reflux; (g) morpholine, K2CO3, 1,4-dioxane, 100 °C; (h) i.
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imidazole, K2CO3, 1,4-dioxane, 100 °C; ii. HCl, Et2O, CHCl3; (i) ethanolamine, K2CO3,
1,4-dioxane, 100 °C.

Table 3. Comparison of Yields of 20–22 from New and Current Routes
Yield of longest linear sequence, %

a

Route

20

21

22

Schemes 1, 11

31

26

24

Scheme 12

16

18a

17

Prepared as hydrochloride salt.

Although the new routes to drugs 20–22 can provide the three drugs in greater
overall yields, they require the use of pyrophoric n-BuLi solution under cryogenic
conditions. Another disadvantage is that one additional overall step is required in the
new routes. However, the lack of column chromatography purifications in the new routes
increases their attractiveness for future manufacturing.

2.4

Synthesis of Potential Drug Metabolites from the Common Intermediate

Contemporaneous with the synthetic studies detailed above, research into the
murine metabolism of Phase I drugs 20 and 21 was also being conducted. Metabolites of
the drugs were collected and analyzed using liquid chromatography-mass spectrometry
(LC-MS). These data provided some clues (i.e., molecular mass and fragmentation
patterns) as to the structure of the metabolites, and thus guided the synthesis of several
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putative metabolites. Unfortunately, none of the synthetic metabolites (Scheme 16) were
confirmed as actual metabolites in these studies.35
Several potential metabolites were prepared from lactone 9. Each differs from the
parent drugs at the lactam side chain. Most of the side chains are commercially available,
while several others (primary amines 31, 35, and 38) needed to be prepared in one or two
steps.
Side chains produced by the oxidative cleavage of the C-N bond that connects the
propylene chain to the morpholine or imidazole rings were needed.

To install a

propanoic acid side chain, it was necessary to first protect β-alanine (30) as its methyl
ester 31 (Scheme 13), prior to its condensation with lactone 9.

Scheme 13. Synthesis of 31a

a

Reagents and conditions: (a) SOCl2, MeOH, reflux.

Primary amine 35 was used to install a side chain that could result from cleavage of
the morpholine ring present in 20. Secondary amine 33 and acrylonitrile (32) underwent
conjugate addition in the first step to provide nitrile 34. The nitrile group of 34 was
reduced with allane, which was generated in situ from LiAlH4 and H2SO4, to yield
primary amine 35 (Scheme 14).
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Scheme 14. Synthesis of 35a

a

Reagents and conditions: (a) EtOH, reflux; (b) LiAlH4, H2SO4, -5 °C to room temp.

Primary amine 38 was made because it, like 35, could provide the side chain of 20
that results from morpholine ring cleavage—albeit by cleavage of an intra-heterocycle NC bond, rather an intra-heterocycle C-O bond of the ring.

The chemistry used to

synthesize 38 is identical to that shown in Scheme 14, except for the substitution of
primary amine 36 for secondary amine 33 (Scheme 15).

Scheme 15. Synthesis of 38a

a

Reagents and conditions: (a) EtOH, reflux; (b) LiAlH4, H2SO4, -5 °C to room temp.

Lactone 9 was condensed with primary amines 31, 35, and 38–42, to furnish
potential metabolites 44–46 and 48–51 either directly or after an additional deprotection
step (Scheme 16). The last metabolite, 9-keto-metabolite, was prepared by selective
ketone reduction of lactone 9 with NaBH4 in CHCl3-MeOH.55
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Scheme 16. Synthesis of Potential Drug Metabolites from 9a

a

Reagents and conditions: (a) i. CHCl3, (MeOH), reflux; ii. TFA (51); (b) i. LiOH, THF,

H2O, reflux; ii. HCl; (c) TFA, CHCl3, reflux; (d) NaBH4, CHCl3, MeOH.
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2.5

Conclusion

New synthetic routes to current or potential Phase I clinical drugs 20–22 have been
devised. Each of the drugs is produced by routes that diverge at a late-stage from
advanced intermediate 9. Overall yields to each of the three drugs have been improved,
and the total number of steps and longest linear sequences are not lengthened appreciably.
It is unknown at present whether the new routes will be selected for future manufacturing
of the drugs.
The same intermediate that was pivotal in the establishment of the new synthetic
routes to the three drugs, lactone 9, also proved useful in the rapid production of a series
of potential metabolites of the drugs. Although none of the potential metabolites were
confirmed as actual ones, these compounds may be useful for future studies.
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CHAPTER 3. DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NEW
INDENOISOQUINOLINE GLYCOSIDES

3.1

Introduction

Hybridization of two or more chemically distinct scaffolds to improve or change
the biological activity of a molecule is widely practiced in medicinal chemistry. This
tactic has been successfully employed in several different ways.

Homodimers can

achieve improved affinity and/or selectivity over their monomeric subunits.
Heterodimeric molecules may interact with more than one target.56 A third way to
hybridize molecules is to “mix and match” structural fragments of two or more molecules.
Rather than generating a high molecular weight dimer, a chemically distinct hybrid is
created that may have improved physicochemical or pharmacological properties over its
parents.
The idea to hybridize the structures of indenoisoquinoline and indolocarbazole
glycoside Top1 poisons is supported by structural and pharmacological observations.31
Alignment of the X-ray crystal structures of the indenoisoquinoline MJ-2-38 or the
indolocarbazole glycoside SA315F bound to the Top1-DNA cleavage complex reveals
similarities in the binding modes for the two small molecules (Figure 11). The polycyclic
cores of each ligand intercalate at the cleavage site, and their side chains (butanoic acid in
MJ-2-38, β-glucopyranosyl in SA315F) project into the major groove of the DNA.

35
The lactam nitrogen of the indenoisoquinoline is situated close to the glycosylated indole
nitrogen of the indolocarbazole in the structural alignment. This position on the former
scaffold could theoretically be glycosylated and retain the crystallographically observed
binding mode.

Figure 11. (Above) Chemical structures of MJ-2-38 and SA315F. (Below) Overlay of the
X-ray crystal structures of the ternary Top1-DNA-drug cleavage complexes containing
MJ-2-38 (PDB ID 1SC7, purple)21 or SA315F (PDB ID 1SEU, green).21 The stereoview
is programmed for wall-eyed (relaxed) viewing.
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In addition to the structural basis for attachment of a carbohydrate to the
indenoisoquinoline system, there is reason to suspect that pharmacological activity can be
favorably modulated by doing so.

Glycosylation is critical for the Top1 inhibitory

activity of the indolocarbazole class, and its absence severely compromises this activity.57
Substitution of indenoisoquinolines at the lactam nitrogen with side chains containing
hydrogen bonding groups is necessary for potent Top1 and growth inhibitory activities,22
and carbohydrates inherently fulfill this requirement. Glycosylation could also result in
more selective uptake of these compounds by cancer cells overexpressing glucose
transporters.58
Only three previously studied indenoisoquinoline glycosides have aromatic ring
substitution, and these three exhibit superior biological activities to the other
glycosides.31 Most of the latter compounds have micromolar or worse mean graph
midpoint (MGM) GI50 values and Top1 inhibitory activity that is only 50–75% that of 1
µM camptothecin. Aromatic ring substitution patterns of the indenoisoquinolines and
their effects on biological activities have already been the subject of extensive
investigation. The 2,3-dimethoxy-8,9-methylenedioxy pattern was previously found to
improve Top1 and growth inhibitory potencies when added to unsubstituted analogues.22
Prior studies have also shown a substantial contribution to the same biological activities
by a 3-nitro substituent.26 The present investigation was therefore undertaken to
determine whether or not the combination of cyclic and noncyclic carbohydrate-derived
and carbohydrate-mimetic moieties with the 2,3-dimethoxy-8,9-methylenedioxy or 3nitro substitution patterns could yield new indenoisoquinoline glycosides with greatly
enhanced activities.54 Several azaindenoisoquinoline glycosides were also prepared, and
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these novel glycosides are among the first azaindenoisoquinolines with a nitrogen atom
replacement in the A-ring.
Since certain indenoisoquinolines have been found to possess dual activities
versus Top1 and TDP1, the compounds in the present project were tested versus both
enzymes. There has been recent interest in multiple targeting as a strategy to improve the
therapeutic effects of drugs.

3.2

Synthesis of Indenoisoquinoline Glycosides

Nitrated lactone 5759 was produced as shown in Scheme 17. Beginning with
phthalide (52), sequential aromatic nitration, radical bromination, and alkaline hydrolysis
provided 3-hydroxyphthalide 55, which was condensed with phthalide (52) and cyclized
in refluxing Ac2O to produce lactone 57.
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Scheme 17. Synthesis of Nitrated Lactone 57a

a

Reagents and conditions: (a) KNO3, H2SO4, 0 °C to room temp.; (b) NBS, AIBN, CCl4,

reflux; (c) H2O, reflux; (d) i. NaOMe, MeOH, EtOAc, reflux; ii. Ac2O, reflux.

Eight different primary amines derived from aldopentose and aldohexose sugars
were prepared according to published procedures.31, 60 Reaction of hydroxylamine with
five- and six-carbon D-aldose sugars yielded the corresponding oximes, which were
reduced to primary amines by hydrogenation over PtO2. Commercially available glucopyranose nitromethane (79) was hydrogenated over PtO2 to yield cyclic -glucose
derivative 80 (Scheme 18).
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Scheme 18. Synthesis of Carbohydrate-Derived Side Chainsa

a

Reagents and conditions: (a) i. NH2OH·HCl, NaOMe, MeOH or EtOH; ii. D-sugar,

70 °C; (b) H2 (40 psi), PtO2, AcOH, H2O; (c) H2 (balloon), PtO2, MeOH, H2O.
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The side chains prepared in Scheme 18, as well as three commercially available
aminosugars (81–83), were condensed with lactone 9 (from Scheme 1) to yield
carbohydrate-substituted

indenoisoquinolines

bearing

the

methylenedioxy aromatic ring substitution pattern (Scheme 19).

2,3-dimethoxy-8,9-
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Scheme 19. Synthesis of Indenoisoquinolines Bearing Sugar-Derived Side Chainsa

a

Reagents and conditions: (a) MeOH, CHCl3, H2O, reflux.
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Carbohydrate-mimetic groups were also attached to the 2,3-dimethoxy-8,9methylenedioxy substituted system. Commercially available primary amines 95–102
were condensed with lactone 9 to provide this second series (Scheme 20).

Scheme 20. Synthesis of Indenoisoquinolines with Carbohydrate-Mimetic Side Chainsa

a

Reagents and conditions: (a) CHCl3, reflux; (b) DMF, 100 or 120 °C.
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Most of the aminosugars that were condensed with lactone 9 (Scheme 19) were
also condensed with nitrated lactone 57 to provide the third series (Scheme 21).

Scheme 21. Synthesis of Indenoisoquinolines Bearing Sugar-Derived Side Chainsa

a

Reagents and conditions: (a) MeOH or MeOH-H2O or MeOH-H2O-CHCl3, reflux.
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Four aza-A-ring indenoisoquinoline glycosides were prepared. Each of these
compounds is substituted with the (S)-2,3-dihydroxypropyl side chain. The unshown,
initial steps in Schemes 22–25 that led to the starting materials were completed by former
Cushman group postdoctoral researcher Dr. P. V. Narasimha Reddy.
Aza-3-hydroxyphthalide 120 was condensed with phthalide (52) under basic
conditions, and the intermediate was cyclized in Ac2O at reflux to yield lactone 121
(Scheme 22). Primary amine 82 was condensed with 121 to provide novel glycoside 122.

Scheme 22. Synthesis of 122a

a

Reagents and conditions: (a) i. NaOMe, MeOH, EtOAc, reflux; ii. Ac2O, reflux; (b)

CHCl3, MeOH, reflux.

Amine 82 was condensed with lactone 123 to yield glycoside 124 (Scheme 23).

Scheme 23. Synthesis of 124a

a

Reagents and conditions: (a) CHCl3, MeOH, reflux.

45
Azaindenoisoquinoline glycoside 127 was synthesized by the three-step sequence
shown below (Scheme 24). First, azaindenoisoquinoline 125 was hydrolyzed with KOH
in aqueous MeOH to yield a 1,3-indanedione intermediate (not shown). The former was
treated with Ac2O to restore the lactone ring (126). Finally, lactone 126 was condensed
with amine 82 to yield glycoside 127.

Scheme 24. Synthesis of 127a

a

Reagents and conditions: (a) KOH, H2O, MeOH, reflux; (b) Ac2O, room temp. to 70 °C;

(c) CHCl3, MeOH.

A fourth aza-A-ring indenoisoquinoline glycoside, 129, was prepared in a single
step from the condensation of amine 82 and lactone 128 (Scheme 25).

Scheme 25. Synthesis of 129a

a

Reagents and conditions: (a) CHCl3, MeOH, reflux.
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3.3

Biological Results and Discussion

The antiproliferative activities of the new indenoisoquinolines were evaluated in
the National Cancer Institute’s NCI-60 screen, which evaluates the cytotoxicities of
compounds in 60 different human cancer cell lines.61 The NCI-60 screen first evaluates
new compounds at 10-5 M in a one-dose assay to measure average growth percent of
treated versus untreated cells. Compounds that display significant growth inhibition at
this concentration are promoted to a five-dose assay where testing concentrations range
from 10-8 to 10-4 M. A repeat of the latter assay may be carried out if the first five-dose
assay shows potent growth inhibition. Mean graph midpoint (MGM) values from the
five-dose assays, as well as values for selected cell lines, are reported in Table 4. The
MGM value is similar to an average GI50, except that in situations in which the GI50 falls
below or above the testing concentration range of 10-8 or 10-4 M, it is recorded as 10-8 or
10-4 M.
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Table 4. Antiproliferative and Top1 and TDP1 Inhibitory Activities of Carbohydrate-Substituted Indenoisoquinolines
Cytotoxicity (GI50, µM)
Lung
side chain

compd

3-Nitro

2,3-Dimethoxy-8,9-methylenedioxy

CPT

Top1
Cleavagea
++++

TDP1
Inhibitionb

Mean
Growth %c

CNS

Melanoma

Ovarian

Renal

Prostate

Breast

HOP-62

HCT-116

Colon

SF-539

UACC-62

OVCAR-3

SN12C

DU-145

MCF7

MGMd

0.01

0.03

0.01

0.01

0.22

0.02

0.01

0.01

0.0405  0.0187

rac. propanediol

84

++++

0

27.11

0.031

0.026

0.023

0.023

0.052

0.035

0.036

0.021

0.065  0.011

S-propanediol

85

++++

0

7.10

0.028

0.021

0.025

0.017

0.048

0.030

0.034

0.010

0.049  0.003

R-propanediol

86

++++

0

31.56

0.036

0.036

0.032

0.025

0.037

0.040

0.029

0.166  0.005

arabityl

87

+++

0

52.80

50.1

0.355

0.174

0.155

50.1

0.234

50.1

0.148

5.62  0.18

ribityl

88

+++

+

46.90

0.251

0.148

0.028

0.062

0.022

0.229

0.479

0.059

1.43  0.44

lyxityl

89

++++

0

34.68

0.676

0.891

0.214

0.195

0.794

0.457

2.51

0.079

2.94  0.52

xylityl

90

++++

0

5.32

0.027

0.059

0.021

0.052

0.096

0.085

0.138

0.034

0.150  0.012

galactityl

91

++

+

82.29

glucosyl

92

+++

0

87.53

mannityl

93

++++

0

79.47

glucopyranosyl

94

++

+

97.65

rac. propanediol

111

+++

0

-17.51

0.324

0.138

0.339

0.479

0.355

0.363

0.060

0.389  0.013

R-propanediol

112

+++

0

-26.99

0.347

0.138

0.309

0.398

0.380

0.427

0.056

0.332  0.022

arabityl

113

++++

+

-9.21

1.91

1.35

1.45

1.70

2.69

3.16

0.912

1.58

0.525

0.380

0.550

0.145

0.508  0.041

2.14

2.69

3.47

0.501

1.66

ribityl

114

++++(+)

0

-27.46

0.407

0.219

0.234

lyxityl

115

++++

++

-16.07

1.74

1.20

1.74

xylityl

116

++++(+)

+

-14.59

0.363

0.141

0.214

0.407

0.295

0.457

0.096

0.372  0.024

galactityl

117

++++

0

51.53

5.13

3.39

2.57

6.03

4.27

9.55

2.95

7.94

mannityl

118

++++

+

73.17

>100

3.39

3.39

3.47

5.25

>100

0.724

16.6

glucopyranosyl

119

++

++

77.36

S-propanediole

130

++++

0.089

0.025

0.157

0.098

0.309

0.241

0.040

0.016

0.156  0.061

glucosyle

131

++++

7.35

5.08

2.61

2.98

4.26

17.7

4.76

0.88

4.60  0.53

58.05

1.10

47

48
Table 4 footnote
a

Compound-induced DNA cleavage due to Top1 inhibition, with scores given according

to the following system based on the activity of 1 µM camptothecin: 0, no inhibition; +,
between 20 and 50% activity; ++, between 50 and 75% activity; +++, between 75 and 95%
activity; ++++, equal activity; ++++(+), greater activity; bTDP1 inhibition scores are
given according to IC50: 0, > 111 µM; +, 37–111 µM; ++, 12–37 µM; +++, 1–12 µM;
++++, < 1 µM; cGrowth percent of cultured cells of ~60 cancer cell lines treated with 10
µM compound relative to vehicle-treated control; dMean growth midpoint of growth
inhibition from 5 dose assay, ranging from 10-8–10-4 M; eData from Peterson et al.31

The compounds were also tested in the Top1-mediated DNA cleavage assay,7 and
the resulting data are presented in Table 4 and Figure 12. The ability of a test agent to
induce the formation of DNA cleavage products was scored according to a rubric that is
based on the activity of 1 µM camptothecin. In the assay, test agents are incubated at 0.1,
1, 10, and 100 µM concentrations with a 3'-[32P]-labeled double-stranded DNA fragment
and Top1 enzyme for 20 minutes near or slightly above room temperature. If a test agent
is a Top1 poison, it binds to and traps Top1-DNA cleavage complexes.

At the

termination of the assay, cleaved DNA strands are separated on a denaturing PAGE gel to
reveal the DNA cleavage pattern. The number and intensity of the bands observed in test
agent lanes is compared to that seen with 1 µM camptothecin, and is used to assign a
semiquantitative score which ranges from 0 (no activity) to ++++ (activity equal to that
of 1 µM camptothecin; see Table 4 caption for complete rubric).
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Figure 12. Top1-mediated DNA cleavage assay gel. From left: lane 1, DNA alone; lane
2, DNA and Top1; lane 3, DNA and Top1 and 1 µM camptothecin (CPT); lane 4, DNA
and Top1 and 1 µM MJ-3-65; lanes 5–28, DNA and Top1 and indicated concentration
(µM) of test compound. The numbers and arrows at the left indicate cleavage site
positions (see Experimental Section). Gel-based assays are commonly performed twice
for each compound, and they are always run with positive controls, including
camptothecin and MJ-3-65.

The new compounds were also evaluated for TDP1 inhibition activity. TDP1 is
one of the most important enzymes involved in the removal of stalled Top1-DNA
cleavage complexes stabilized by Top1 poisons. Specifically, the enzyme catalyzes the
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hydrolysis of the 3’-phosphotyrosyl linkage between a Top1-derived peptide and DNA.36
Inhibition of TDP1 denies the cell the ability to repair such adducts by this mechanism
and may therefore sensitize cells to the effects of Top1 poisons.
Since the discovery of TDP1 in 1996,62 a variety of inorganic and organic
inhibitors have appeared in the literature.38, 63-67 Most of the known inhibitors exhibit
micromolar IC50 concentrations, and several are based on notorious pan-assay
interference

scaffolds

(PAINS).68

The

structure-activity

relationships

of

indenoisoquinoline TDP1 inhibitors are being developed by our laboratory, and already
several promising dual inhibitors of Top1 and TDP1 have been identified.37, 38, 69, 70 The
structural features that contribute to TDP1 inhibitory activity vs Top1 inhibitory activity
are of current interest because they might allow selective modulation of each type of
activity. Inhibitory activity against recombinant TDP1 was measured in a gel-based
assay,71 and these data are presented in Table 4 and Figure 13.
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Figure 13. TDP1 inhibition assay gel.
indicated above each lane.

The concentrations of test compounds are

N14Y is 5’-end labeled DNA oligonucleotide with 3’

phosphotyrosyl, and N14P is 5’-end labeled DNA oligonucleotide (see Experimental
Section). Gel-based assays are commonly performed twice for each compound, and they
are always run with positive controls.

In the 2,3-dimethoxy-8,9-methylenedioxy linear sugar side chain series (Scheme
19), six of the ten compounds scored ++++ for Top1 inhibition, three earned +++, and the
remaining one received ++.

Significantly, these compounds do not suppress Top1-

mediated DNA cleavage at high drug concentrations (Figure 12). Two compounds, 91
and 94, secured a TDP1 inhibition score of +, while the remaining compounds were
inactive vs TDP1. The number of carbons in the side chain does not appear to correlate
with Top1 or TDP1 inhibition. Interestingly, the only compounds in this series not
promoted to the NCI-60 five-dose assay due to low growth inhibition were the three

52
featuring six-carbon side chains. Cells treated with 93, 91, and 92 in the one-dose assay
displayed growth percentages 79.47%, 82.29%, or 87.53%, indicating weak growth
inhibition, especially in comparison with the most potent growth inhibitors in this series,
90, 85, and 84, whose growth percentages were 5.32%, 7.10%, and 27.11%, respectively,
at 10 µM concentration.
In general, the 3-nitro-substituted compounds (Scheme 21 and Figure 14)
appended with linear sugar side chains outperformed the 2,3-dimethoxy-8,9methylenedioxy-substituted series in both Top1 inhibition and growth inhibition, and a
higher percentage of its members inhibit TDP1, although very weakly, at concentrations
below 111 µM. Two molecules in the series outscored camptothecin in Top1 inhibition
at ++++(+), six were equipotent to camptothecin at ++++, and two others scored +++.
Four compounds scored at least + in TDP1 inhibition, with 115 securing a ++ score. The
most potent growth inhibitor (114) in the series at 10 µM is one of the two most potent
Top1 inhibitors reported in this study. The molecules in this series fall neatly into two
separate groups based on their growth inhibitory activity. Those with six-carbon side
chains delivered positive growth percentages between 51.53% and 73.17%, and the six
compounds with three- or five-carbon side chains have negative growth percentages
ranging from -27.46% to -9.21%. The weak growth inhibitory activities displayed by 3nitro compounds with six-carbon carbohydrate side chains mirror the low activities of
91–93 in the 2,3-dimethoxy-8,9-methylenedioxy series. This trend occurs even though
the six-carbon carbohydrate series contains potent Top1 inhibitors.
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Figure 14. Previously reported nitrated indenoisoquinoline glycosides.31

The nitrated indenoisoquinoline glycoside containing a xylityl side chain (116) is
among the most potent indenoisoquinoline Top1 inhibitors reported to date, and it was
therefore selected for a docking study in an attempt to rationalize its exceptional activity
(Figure 15). On the basis of molecular modeling studies, both hydrogen-bonding and
electronic effects have been proposed to explain the role of 3-position in nitration in
conferring high Top1 inhibitory activity.26,

27

First, the nitro group may engage in

hydrogen bonding interactions with nearby Top1 enzyme residues, including Asn722. In
the present case, the closer of the two nitro group oxygens is 2.6 Å away from the side
chain nitrogen on Asn722. A second role for the nitro group is to withdraw electron
density from the "A"-aromatic ring of the indenoisoquinoline, which may facilitate the
formation of stabilizing π-stacking interactions between the flanking base pairs and the
indenoisoquinoline.
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Figure 15. Energy-minimized hypothetical binding pose of 116 (green) within the X-ray
crystal structure of a stalled Top1-DNA cleavage complex co-crystallized with MJ-2-38
(PDB ID 1SC7).21 Potential hydrogen bonding interactions are indicated by dashed lines.
Heavy atom distances appear next to the dashed lines. The stereoview is programmed for
wall-eyed (relaxed) viewing.

The ß-glucopyranosylmethyl moiety present in 94 and 119 is structurally and
stereochemically identical to the sugar appended to edotecarin, except for the addition of
a single methylene spacer between the glycosyl group and the nitrogen in 94 and 119.
Potent Top1 inhibition and growth inhibition activities were anticipated with this most
accurate ß-glucopyranosyl translation.

In a previous study seeking to optimize the

carbohydrate moiety of indolocarbazole NB-506, ß-glucopyranosyl was found to
outperform most other furanose and pyranose sugars in terms of in vitro cytotoxicity,
Top1 inhibition, and safety margin in a tumor xenograft experiment.72 However,
compounds 94 and 119 displayed poor Top1 and growth inhibitory activities. Both
compounds scored ++ for Top1 inhibition, and neither inhibited TDP1 at an IC 50 under
12 M. Mean growth percent at 10 M was 97.65% and 77.36% for 94 and 119,
respectively, and therefore neither met the threshold for MGM GI50 determination in a

55
five-dose assay. Each of the two compounds was the least active in their respective series
for growth inhibition and Top1 inhibition (Table 4).
A docking study was carried out to investigate whether indenoisoquinoline 94 is
predicted to assume a similar binding pose to indolocarbazole glycoside SA315F in the
Top1-DNA cleavage complex. In the highest-ranked docking pose of 94, its polycyclic
core overlaps with that of SA315F, and their carbohydrate moieties project into the major
groove (Figure 16). However, a significant difference is that the ß-glucopyranosylmethyl
group of 94 projects toward Asp352, while the ß-glucopyransoyl group of SA315F points
in the opposite direction, away from Asp352.
It is unclear why the cyclic carbohydrate moiety confers less Top1 inhibitory
activity than linear carbohydrates. The entropy penalty that must be paid upon ligand
binding would be less for the rigid ß-glucopyranose versus a linear chain. On the other
hand, conformational freedom of five- and six-carbon linear sugar side chains may allow
them to reach and interact with far-away residues in the binding site better than a rigid ßglucopyranose; although, three-carbon side chains also confer excellent Top1 inhibitory
activity.
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Figure 16. Overlay of SA315F (green) and 94 (purple) within the X-ray crystal structure
of a stalled Top1-DNA cleavage complex co-crystallized with MJ-2-38 (PDB ID
1SC7).21 The stereoview is programmed for wall-eyed (relaxed) viewing.

A rank-order comparison of three series of indenoisoquinoline glycosides [ringunsubstituted (Figure 17), 2,3-dimethoxy-8,9-methylenedioxy (Scheme 19), and 3-nitro
(Figure 21)] was carried out to elucidate structure-activity relationships, using Top1
inhibition (Table 5) or the mean growth percent (Table 6) as criteria.
In terms of Top1 inhibition, no clear S.A.R. trends for the tested glycosides
emerge (Table 5). Three-, five-, and six- carbon linear sugars are all among the best
Top1 inhibitors within each series. One conclusion from the rank-order comparison is
that 3-nitro substitution enhances or maintains Top1 inhibitory activity relative to
analogous compounds in the 2,3-dimethoxy-8,9-methylenedioxy or unsubstituted series.
This is true in nearly all cases, with propanediols 111 and 112 being the sole exceptions.
The ribityl side chain was enigmatic. While ring-unsubstituted 136 received a 0 score for
Top1 inhibition, the 3-nitro analogue 114 scored an exceptional ++++(+). Meanwhile,
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the 2,3-dimethoxy-8,9-methylenedioxy analogue 88 earned +++. For some reason, the
effect of ribityl substitution is particularly sensitive to its context.

Figure 17. Previously reported ring-unsubstituted indenoisoquinoline glycosides.31
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Table 5. Rank-Order for Top1-Mediated DNA Cleavage Assay Score vs Side Chain for Three Carbohydrate-Substituted
Indenoisoquinoline Series
Unsubstituteda
lyxityl
S-propanediol
arabityl
racemic
propanediol
140 glucosyl
138 xylityl
141 mannityl
137
133
135
132

139 galactityl
134 R-propanediol
136 ribityl

Top1
Cleavage
+++
+++
++
++

85
84
86
89

2,3-Dimethoxy-8,9methylenedioxy
S-propanediol
racemic propanediol
R-propanediol
lyxityl

++
++
+

93
90
92

+

88

0/+
0

Top1
Cleavage
++++
++++
++++
++++

116
114
117
113

Xylityl
Ribityl
Galactityl
arabityl

Top1
Cleavage
++++(+)
++++(+)
++++
++++

mannityl
xylityl
glucosyl

++++
++++
+++

115
118
131

lyxityl
mannityl
glucosyl

++++
++++
++++

ribityl

+++

130

S-propanediol

++++

+++
++
++

111
112
119

racemic propanediol
R-propanediol
glucopyranosylmethyl

+++
+++
++

87 arabityl
91 galactityl
94 glucopyranosylmethyl
a
Data for compounds 130–141 from Peterson et al.31

3-Nitro
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On the other hand, rank-ordering the compounds within each series using mean
growth percent as the criterion reveals a clear dependence of biological activity on the
number of carbons in the side chain (Table 6). Consistently, the worst growth inhibitors
in each series bear a linear, six-carbon or ß-glucopyranosylmethyl side chain, and none of
those compounds expressed a mean growth percent above 50% when tested at 10 µM.
Standout side chains in this regard include ribityl, xylityl, and S-, R-, and racemic
propanediols, and they were distinguished by their consistent presence near the top of the
rank-order within each series.

As seen with the rank-order comparison by Top1

inhibitory activity, 3-nitro substitution is present on the best growth inhibitors. With only
one exception, 3-nitro substitution conferred a better inhibition of mean growth percent to
a compound with a given side chain than 2,3-dimethoxy-8,9-methylenedioxy substitution
or non-substitution. No such trend is detected when comparing the unsubstituted series
compounds with a given side chain to their analogue in the 2,3-dimethoxy-8,9methylenedioxy series. In that case, aromatic substitution conferred better activity to
compounds with xylityl, lyxityl, arabityl, and glucosyl side chains, while worse activity
resulted when ribityl, galactityl, and mannityl chains were attached.
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Table 6. Rank-Order for Mean Growth Percent vs Side Chain for Three Carbohydrate-Substituted Indenoisoquinoline Series
2,3-Dimethoxy-8,9methylenedioxy
90 xylityl
136 ribityl
85 S-propanediol
138 xylityl
84 racemic propanediol
137 lyxityl
86 R-propanediol
135 arabityl
89 lyxityl
139 galactityl
88 ribityl
141 mannityl
87 arabityl
140 glucosyl
93 mannityl
91 galactityl
92 glucosyl
94 glucopyranosylmethyl
a
Data for compounds 131 and 135–141 from Peterson et al.31
Unsubstituteda

Mean
Growth %
17.28
34.91
50.62
58.44
67.99
69.35
97.16

Mean
Growth %
5.32
7.10
27.11
31.56
34.68
46.90
52.80
79.47
82.29
87.53
97.65

3-Nitro
114
112
111
115
116
113
117
131
118
119

ribityl
R-propanediol
racemic propanediol
lyxityl
xylityl
arabityl
galactityl
glucosyl
mannityl
glucopyranosylmethyl

Mean
Growth %
-27.46
-26.99
-17.51
-16.07
-14.59
-9.21
51.53
58.05
73.17
77.36
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Comparisons between side chains on the basis of stereochemistry are considerably
more complicated than when using length or shape as the basis. Only in cases in which
the side chain length was held constant, and a single stereocenter inverted, have
comparisons been made. Several interesting stereochemical effects were observed in the
2,3-dimethoxy-8,9-methylenedioxy series.

While all three propanediol side chains

conferred ++++ Top1 activity, wide variance was seen between R- (86) and Spropanediols (85) for growth inhibition, which achieved mean growth percentages of
31.56% and 7.10%, respectively.

Among the five-carbon side chains, 2’S

stereochemistry appeared optimal for growth inhibition (e.g. 90, 5.32%; 89, 34.68%),
although it did not appear to influence Top1 inhibition scores. 3’R Stereochemistry
appeared to confer improved growth inhibition and Top1 inhibition (e.g. 90, 5.32%,
++++; 88, 46.90%, +++). Finally, two separate comparisons were made within the sixcarbon side chain trio. While 2’ and 4’ stereochemistry had a slight effect on growth
inhibition, 2’R 93 (++++) outperformed 2’S 92 (+++), and 4’R 92 (+++) bested 4’S 91
(++) in Top1 inhibition scores.
Similar comparisons within the 3-nitro series show that its stereochemical
preferences do not necessarily follow those seen above, complicating the development of
a comprehensive S.A.R. for the carbohydrate-substituted indenoisoquinolines. While 2'R
stereochemistry confers better growth inhibition than 2'R,S to the propanediol side chain
(112, -26.99%; 111, -17.51%), Top1 inhibition is best with 2'S vs 2'R (130, ++++; 112,
+++). A preference for S vs R stereochemistry on the propanediol side chain was also
found for the ring-unsubstituted series (133, +++; 134, 0/+). When five-carbon side
chains are being considered, 2'R is best for Top1 inhibition [113, ++++; 114, ++++(+)].
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2'R Stereochemistry on six-carbon side chains appears to hold a slight edge over 2'S for
growth inhibition (131, 58.05%; 118, 73.17%).
Molecular models of compounds 112 and 130 bound to the Top1-DNA cleavage
complex were constructed in an effort to explain the apparent preference for 2’S over R
stereochemistry (Figure 18). The calculated binding poses revealed the potential for a
network of intra- and intermolecular hydrogen bonding interactions that could stabilize
130 in the Top1-DNA cleavage complex to a greater extent than 112. The isoquinoline
carbonyl oxygen of 130 is predicted to engage in an intramolecular hydrogen bond with
the side chain 2’S hydroxyl. Such an interaction is not possible in the case of 112, where
the 2’R hydroxyl is oriented away and at a further distance from the carbonyl oxygen.
Alternatively, or in concert, the stereochemistry at the 2’ hydroxyl may influence the
positioning of the indenoisoquinoline fused-ring system relative to the flanking
nucleobases, and thus modulate the π-stacking interactions.

Figure 18. Energy-minimized hypothetical top-ranked binding pose of 112 (top, green)
and 130 (bottom, green) within the X-ray crystal structure of a stalled Top1-DNA
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cleavage complex co-crystallized with MJ-2-38 (PDB ID 1SC7).21 Potential hydrogen
bonding interactions are indicated by dashed lines. Heavy atom distances appear next to
the dashed lines. The stereoview is programmed for wall-eyed (relaxed) viewing.

Exceptionally potent antiproliferative Top1 inhibitors from the present work were
compared to analogues bearing 3-morpholinopropyl or 3-imidazolylpropyl side chains
(Figure 19).

2,3-Dimethoxy-8,9-methylenedioxy-substituted indenoisoquinoline 85,

bearing an S-propanediol side chain, displays more potent antiproliferative activity
(MGM 0.049 ± 0.003 µM) than indotecan (20) or indimitecan (21), while maintaining
equivalent Top1 inhibitory activity. 3-Nitro-substituted indenoisoquinoline 116, bearing
a xylityl side chain, is as potent or more potent in the antiproliferative (MGM 0.372 ±
0.024 µM) and the Top1 inhibition [++++(+)] assays than its analogues 142 and 143 in
either respect.

These findings contradict the “conventional wisdom” that nitrogen

heterocycles and amine moieties ought to be attached to indenoisoquinolines for maximal
growth and Top1 inhibitory activity potencies.
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Figure 19. Indenoisoquinolines bearing 3-imidazolyl- and 3-morpholinopropyl side
chains for comparison to indenoisoquinoline glycosides.

3.4
New

indenoisoquinoline

Conclusion

glycosides

featuring

carbohydrate-derived

or

carbohyhdrate-mimetic moieties attached at the lactam nitrogen were produced through
efficient synthetic routes that permit late-stage divergence from a common intermediate
(e.g., 9 or 57) , and thus avoid costly linear routes to each compound or use of protecting
groups. Twelve new compounds achieved Top1 inhibition assay scores of ++++ or better.
Several compounds achieved this level of Top1 inhibition activity along with a double- or
triple-digit nanomolar MGM GI50.

These highly active carbohydrate-substituted

indenoisoquinolines provide a set of new lead compounds for further optimization studies.
TDP1 inhibition assay scores were very weak, with 12 compounds scoring 0, six
compounds scoring +, and only two compounds scoring ++.

Incorporation of a

carbohydrate therefore offers a way to ensure low TDP1 inhibitory activity while
maintaining Top1 inhibition. If required, maximum TDP1 inhibition can be ensured by
installation of lactam substituents containing primary amines at the end of the chain, and
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by formation of bis(indenoisoquinolines) linked through their lactam nitrogens with
polyaminoalkyl chains.37, 38
In addition to the twenty indenoisoquinoline glycosides with sugar-derived side
chains, eight new 2,3-dimethoxy-8,9-methylenedioxy-substituted indenoisoquinolines
with carbohydrate-mimetic side chains, and four novel aza A-ring indenoisoquinoline
glycosides were prepared. These latter compounds had not undergone biological testing
as of the writing of this thesis, but will be evaluated in the near future.
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CHAPTER 4. DISCOVERY OF POTENT INDENOISOQUINOLINE
TOPOISOMERASE I POISONS LACKING THE 3-NITRO TOXICOPHORE

4.1

Introduction

Numerous 3-nitroindenoisoquinolines have been identified that display potent Top1
inhibitory activities along with mean-graph midpoint (MGM) GI50 values in the doubledigit nanomolar range. 3-Position nitration also contributes to inhibitory activity against
tyrosyl DNA phosphodiesterase 1 (TDP1), an enzyme involved in the repair of DNA
damage caused by Top1 inhibitors. Predictably, several 3-nitroindenoisoquinolines have
undergone preclinical development.34
Although an aromatic nitro group may be acceptable if a drug is selectively
delivered to cancer cells, systemic therapy with a non-targeted molecule would expose
healthy cells to the nitro toxicophore. Metabolic reduction of aryl nitro groups converts
them to potentially toxic aryl nitroso and hydroxylamine species that can covalently
modify the DNA and proteins of healthy cells.73 The NCI-60 screening service has
instituted a new policy wherein submission of molecules containing “problematic”
functionalities,

including

nitro

groups,

is

discouraged.74

For

these

reasons,

indenoisoquinolines were sought that lack this potential metabolic and toxicological
liability, but maintain similar pharmacological activities.
Two generations of bioisosterically modified indenoisoquinolines have been
designed, prepared, and tested. The following two sections (4.2–4.3) detail the design,
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synthesis, and biological evaluation of first-generation bioisosteric indenoisoquinolines.
In nearly all cases, the analogues were outperformed by their 3-nitro counterparts in
cytotoxicity and Top1 poisoning activity—although there were some important
exceptions.75 The second generation (Sections 4.4–4.5) made use of the information
learned from the first generation.

It combined the new bioisosteres with optimal

substitutions at both the D-ring and lactam nitrogen. The ultimate goal of this study was
to generate new lead structures with greater potential for safety when administered for
systemic chemotherapy.

4.2

Synthesis of the First Generation

The first generation consists of simplified indenoisoquinolines that have a nitro
group replacement in the 3-position and a side chain attached to the lactam nitrogen, but
no other A- or D-ring substitution. These compounds were rapidly prepared using
synthetic routes that diverge at a late stage from common intermediates: tetracyclic
lactones, such as compound 149 (Scheme 25).
Fluorinated lactone 149 was synthesized following the route shown in Scheme 26.
Benzaldehyde 144 was reduced with NaBH4 to provide the bromobenzylic alcohol 145.
Rosenmund-von Braun reaction with CuCN and in situ hydrolysis and lactonization of
the intermediate yielded compound 146 in 59% yield. Alternatively, 145 was subjected
to a halogen-lithium exchange reaction, followed by a dry ice quench and treatment with
acid to yield 146. This latter method was inferior because it gave phthalide 146 in only
14% yield. Phthalide 146 was next subjected to radical bromination, and the obtained 3bromophthalide intermediate 147 was hydrolyzed to produce 3-hydroxyphthalide 148.
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Compound 148 was condensed with phthalide (52) in refluxing MeOH-EtOAc with
NaOMe, and then dehydratively cyclized in refluxing Ac2O to afford lactone 149.

Scheme 26. Synthesis of Fluorinated Lactone 149a

a

Reagents and conditions: (a) NaBH4, MeOH, 0 °C to room temp.; (b) i. CuCN, DMF,

reflux, ii. H2O, reflux; (c) NBS, AIBN, CCl4, reflux; (d) KOH, H2O, reflux; (e) i. NaOMe,
MeOH, EtOAc, reflux, ii. Ac2O, reflux.

Lactones 163–166 were synthesized following nearly identical synthetic routes,
whose only point of difference was in step c (Scheme 27). 6-Aminophthalide (150) was
prepared in two steps from phthalide (52) following known procedures.76, 77 Sandmeyer
chemistry was employed to introduce halogens or a nitrile group. Fluorination of 150
was accomplished using the Sandmeyer reaction (not shown), although 6-fluorophthalide
(146) could only be obtained in 10% yield. Radical bromination and hydrolysis of each
3-bromophthalide 155–158 gave 3-hydroxyphthalides 159–162, which were used to make
lactones 163–166.
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Scheme 27. Synthesis of Halogenated and Cyanated Lactones 163–166a

a

Reagents and conditions: (a) KNO3, H2SO4, 0 °C to room temp.; (b) H2, Pd/C, EtOAc;

(c) i. NaNO2, 37% HCl, 0 °C, ii. CuCl, 37% HCl, 0 °C to reflux (151); or i. NaNO2, 48%
HBr, 0 °C, ii. CuBr, 48% HBr, 0 °C to 80 °C (152); or i. NaNO2, 37% HCl, 0 °C, ii. KI,
0 °C to room temp. (153); or i. NaNO2, 37% HCl, 0 °C, ii. NaCN, CuCN, 0 °C to room
temp. (154); (d) NBS, AIBN, CCl4, reflux; (e) KOH, H2O, reflux; (f) i. NaOMe, MeOH,
EtOAc, reflux, ii. Ac2O, reflux.

Several routes to the 3-trifluoromethyl-substituted lactone 176 were evaluated,
owing to difficulties with material throughput.

One of these routes made use of

intermediate 153 (Scheme 28). Trifluoromethylation was attempted with CF3CO2Na and
CuI in DMF or NMP. No product 167 was isolated, and starting material was recovered
in each case. Substitution of methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (MDFA) for
CF3CO2Na was beneficial, and allowed for some reaction to occur. However, the product
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could not be fully separated from the starting material, even after advancing to the next
step with a crude mixture.

Scheme 28. Synthesis of Phthalide 167a

a

Reagents and conditions: (a) CF3CO2Na, CuI, DMF, reflux or NMP, 180 °C; (b) MDFA,

CuI, DMF, reflux.

Finally, a successful route to lactone 176 was found (Scheme 29). A fortuitous
byproduct of the synthetic route to lactone 175 permitted a comparison of the effect of
substituting either the 2- or 3-positions with a trifluoromethyl group. Phthalic acid 168
was converted to its anhydride 169 by refluxing in AcCl. Anhydride 169 was reduced
with NaBH4 in THF to give a 1:1 mixture of 5- and 6-(trifluoromethyl)phthalides 170 and
167, which were readily separated by silica gel column chromatography. The identity of
each isomer was confirmed by comparing 1H NMR spectral information to that reported
in the literature.78 Phthalides 170 and 167 were separately subjected to radical
bromination and subsequent hydrolysis to provide 3-hydroxyphthalides 173 and 174.
Lactones 175 and 176 were obtained by the condensation of 3-hydroxyphthalides 173 or
174 with phthalide (52), and dehydrative cyclization of the unisolated intermediates was
carried out as usual.

71
Scheme 29. Synthesis of Trifluoromethylated Lactones 175 and 176a

a

Reagents and conditions: (a) AcCl, reflux; (b) i. NaBH4, THF, 0 °C, ii. HCl; (c) NBS,

AIBN, CCl4, reflux; (d) KOH, H2O, reflux; (e) i. NaOMe, MeOH, EtOAc, reflux; ii.
Ac2O, reflux.

Three different routes were evaluated in the effort to produce a 3methylsulfonated lactone (i.e., 191 in Scheme 32). The first of these, shown in Scheme
30, failed due to difficulties with oxidation of the benzylic methylene present in 179 and
180.

In each case, only starting material was recovered from the product mixture.

Intermediate 179 was synthesized from phthalide (52) in three steps:

1. aromatic

chlorosulfonation at a carefully controlled temperature range (177); 2. reduction of the
chlorosulfone with PPh3 (178); and 3. thiol alkylation (179). Intermediate 180 was
produced by m-CPBA oxidation of 179.
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Scheme 30. Abandoned Route to Sulfonated Lactone 191a

a

Reagents and conditions: (a) ClSO3H, 125–135 °C; (b) PPh3, CHCl3, reflux; (c) MeI,

K2CO3, DMF, room temp.; (d) m-CPBA, CHCl3; (e) NBS, AIBN, CCl4, reflux.

The second route that was attempted also failed owing to difficulties with latestage benzylic carbon oxidation (Scheme 31).

Methyl ester 183 was first

chlorosulfonated at 100–110 °C to give a 1:4 mixture of carboxylic acid 184 and ester
185. The latter was treated with Na2SO3, and the unisolated intermediate 186 was
alkylated with MeI to give methyl sulfone 187. However, methyl sulfone 187 could not
be oxidized with NBS to give 188.
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Scheme 31. Second Abandoned Route to Sulfonated Lactone 191a

a

Reagents and conditions: (a) ClSO3H, 100–110 °C; (b) i. SOCl2, reflux; ii. MeOH, room

temp.; (c) i. Na2SO3, NaHCO3, EtOH, H2O, reflux; ii. MeI, K2CO3, DMF, room temp.; (e)
NBS, AIBN, CCl4, reflux.

Finally, a successful route to the sulfonated lactone was found (Scheme 32). 3Hydroxyphthalide 148 was subjected to a nucleophilic aromatic substitution with NaSMe
to deliver product 189. 3-Hydroxyphthalide 189 was condensed with phthalide (52) and
dehydratively cyclized as described before to provide lactone 190. Oxidation of lactone
190 with m-CPBA provided lactone 191.
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Scheme 32. Successful Synthesis of the Sulfonated Lactone 191a

a

Reagents and conditions: (a) NaSMe, DMF, 120 °C; (b) i. NaOMe, MeOH, EtOAc,

reflux; ii. Ac2O, reflux; (c) m-CPBA, CHCl3, room temp.

(S)-3-Amino-1,2-propanediol (82) was condensed with ten different lactones to
produce indenoisoquinolines (Scheme 33).

1-(3-Aminopropyl)imidazole (18) was

condensed with seven lactones to yield another series of indenoisoquinolines.
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Scheme 33. Synthesis of Indenoisoquinolines 193–209a

a

Reagents and conditions: (a) MeOH-CHCl3, reflux; (b) CHCl3, reflux.

3-Morpholinopropylamine (17) was condensed with lactones 149, 163, and 165 to
produce indenoisoquinolines 210–212 (Scheme 34).

Scheme 34. Synthesis of Indenoisoquinolines 210–212a

a

Reagents and conditions: (a) CHCl3, reflux.
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4.3

Rationale, Biological Results, and Discussion

The goal of this study was to discover a suitable bioisosteric replacement for the
3-nitro group on the indenoisoquinoline system that would maintain or improve Top1 and
growth inhibitory potencies.

Accordingly, the newly synthesized compounds were

subjected to the Top1-mediated DNA cleavage assay7 to assess Top1 inhibitory activity,
and the NCI-60 human tumor cell line screen61 to evaluate growth inhibitory activity. A
representative Top1 assay gel is shown in Figure 20.

Figure 20. Top1-mediated DNA cleavage assay gel. From left: lane 1, DNA alone; lane
2, DNA and Top1; lane 3, DNA and Top1 and 1 µM camptothecin (CPT); lane 4, DNA
and Top1 and 1 µM MJ-3-65; remaining lanes, DNA and Top1 and indicated
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concentration (µM) of test compound. The numbers and arrows at the left indicate
cleavage site positions (see Experimental Section). Gel-based assays are performed twice
for each active compound, and they are always run with positive controls, including
camptothecin and MJ-3-65.

The representative Top1 assay gel reveals additional information beyond Top1
poisoning activity. First, the intensities of the DNA cleavage bands in test agent lanes do
not increase in a simple dose-dependent manner. The intensities appear to subside at
high drug concentration, after increasing steadily at lower concentrations (e.g. compound
211, bands at positions 92 and 119). One possible cause is that high drug concentrations
produce a significant population of DNA with intercalated test agent, which is a poorer
enzyme substrate than non-intercalated DNA. Intercalation of drug molecules into DNA
suppresses Top1 nonspecifically and this mechanism is distinct from Top1 poisoning.79
Second, the DNA cleavage patterns induced by test agents indicate preferences for
different flanking base pairs at the binding site, or cleavage site specificities, versus the
control compounds. For example, the dark band at position 62 for MJ-3-65 (22), which
has a unique hydroxyethylaminopropyl side chain, is not observed for camptothecin or
the test agents. Different cleavage site specificities may translate into unique antitumor
activity profiles for Top1 poisons.
Recent investigations have focused on mapping out the structural features of
indenoisoquinolines that contribute to potent TDP1 inhibition.37, 38, 70, 80 TDP1 is a DNArepair enzyme that is specifically involved in the recognition and repair of DNA lesions
induced by Top1 poisons. Co-treatment with a TDP1 inhibitor and Top1 inhibitor may
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achieve a selective cytotoxic effect on cancer cells versus normal cells because cancer
cells often have a reduced capacity for DNA repair.81 Without exception, the compounds
prepared in the first generation did not display TDP1 inhibitory activity. This result was
not entirely unexpected: the most potent indenoisoquinoline TDP1 inhibitors typically
have small, sterically limited amine groups appended to a propyl lactam side chain. In
the present series, the side chains carried five- or six-membered nitrogen heterocycles
(i.e., imidazole or morpholine) or no amine at all [(S)-2,3-dihydroxypropyl].
Molecular modeling studies performed by Morrell et al. suggest two explanations
for

the

marked

enhancement

in

biological

activity observed

with

nitrated

indenoisoquinolines.26, 27 The first possibility is that a 3-nitro is appropriately positioned
to engage the side chain carboxamide of the nearby residue Asn722 in a direct hydrogen
bond. Replacement substituents CN, SO2Me, CO2Me, and 3-aza were investigated here
because they too could function as hydrogen bond acceptors. A second possibility is that
the electronegative 3-nitro group creates favorable polar interactions between the ligand
and surrounding DNA. All of the atoms and groups selected for study exert an electronwithdrawing effect. A comparison of the electronegativities of several of these chemical
groups, obtained from ab initio calculations performed by de Proft et al. 82, is displayed in
Table 7.
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Table 7. Electronegativities of Bioisosteres from the Present Study
Group

Electronegativity (eV)a

NO2

7.84

F

10.01

Cl

7.65

CN

8.63

CF3

6.30

CO2Me

5.48

SMe

4.99

a

Calculated at the CISD level.82

Biological testing data are organized in Table 8. Compounds 130 and 213–220
were previously studied and are included in the table for easy referencing. Among the
bioisosteric compounds, 203, 204, 210, and 218 display the best Top1 inhibitory
activities.

The Top1-mediated DNA cleavage induced by these four compounds is

between 75 and 95% that of 1 µM CPT (i.e. +++). MGM GI50 values were calculated to
be 0.692 µM for 203, 0.229 µM for 204, and 2.75 µM for 210. Compound 218 was not
advanced to five-dose testing for determination of MGM GI50 because it failed to
significantly reduce the mean growth of the same cancer cell lines at 10 µM. Compounds
203, 204, 210, and 218 are substituted with the halogens F, Cl, and Br. It was not
immediately clear why “smaller” halogens were better replacements for nitro than other
atoms and functional groups. For this reason, several model systems were studied using
molecular mechanics and quantum mechanics calculations (vide infra).

It is not
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unprecedented that F should act as a bioisostere of nitro.83 In the course of optimizing
adrenoceptor antagonists, a p-nitrophenyl ring was replaced by a 3,4-difluorophenyl one
with retention or improvement of Ki. This exchange provided additional value by sidestepping toxicity concerns about the nitro group.84
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Table 8. Antiproliferative and Top1 Poisoning Activities of Indenoisoquinolines in the First Generation
Cytotoxicity (GI50 in µM)
Top1
Cleavagea
++++

Mean Growth
Percentb
N.D.

Lung,
HOP-62
0.01

Colon,
HCT-116
0.03

CNS,
SF-539
0.01

Melanoma,
UACC-62
0.01

Ovarian,
OVCAR-3
0.22

Renal,
SN12C
0.02

Prostate,
DU-145
0.01

Breast,
MCF7
0.01

0.0405 ± 0.0187

130

++++

N.D.

0.089

0.025

0.157

0.098

0.309

0.241

0.040

0.016

0.156 ± 0.061

213

++++

N.D.

0.19

0.274

0.016

0.012

0.864

0.015

0.017

2.17

0.370 ± 0.28

217

+++

N.D.

0.021

0.038

0.095

0.380

0.309

0.085

193

++

61.14

203

+++

-8.15

0.490

0.309

0.417

0.245

1.29

0.437

0.575

0.135

0.692

210

+++

30.31

2.09

1.29

2.95

1.38

4.27

2.34

2.95

0.347

2.75

194

++

14.53

0.692

0.437

0.417

0.398

2.24

0.977

2.09

0.257

1.12

204

+++

0.06

0.186

0.107

0.204

0.074

0.407

0.110

0.309

0.031

0.229

211

++

44.73

2.14

1.62

2.40

3.31

6.03

5.01

4.07

0.372

4.17

195

++

46.84

214

++

27.33

218

+++

84.03

196

++

39.73

N.T.e

0.631

3.02

2.14

5.27

4.27

3.02

0.331

3.16

205

++

43.54

0.437

0.200

0.550

2.29

3.89

0.708

0.603

0.074

1.62

212

+

96.00

N.S.

197

+(+)

42.65

N.S.

215

++

41.11

compd
camptothecin

3-NO2

3-F

3-Cl

3-Br

3-I

MGMc

0.632 ± 0.029
N.S.d

N.S.
0.513

0.251

0.676

0.427

3.31

0.468

0.676

0.191

1.26
N.S.

3-CN
0.537

0.112

0.501

0.407

4.68

0.575

0.562

0.033

0.944 ± 0.015
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219

++

101.69

N.S.

198

+

82.67

N.S.

206

0/+

49.34

N.S.

199

+

52.24

N.S.

207

0/+

6.57

0.407

0.646

1.29

0.537

1.51

1.78

1.10

0.257

1.07

200

+

39.68

1.82

0.741

2.34

1.38

4.37

1.95

2.51

0.427

2.51

208

+

42.65

N.S.

3-

201

++

96.74

N.S.

SO2Me

209

++

59.38

N.S.

202

+

N.A.f

N.A.

216

++

62.13

220

+

87.47

N.S.

A

+

47.53

N.S.

B

++

N.A.

N.A.

125

++

-9.25

2-CF3

3-CF3

3-SMe

30.589

0.398

0.490

100

100

0.525

0.692

0.316

5.37

CO2Me

3-aza

a

0.871

0.380

0.708

1.23

2.00

0.955

0.977

0.331

0.977

Compound-induced DNA cleavage due to Top1 poisoning, with scores given according to the following system based on the activity

of 1 µM camptothecin: 0, no activity; +, between 20 and 50% activity; ++, between 50 and 75% activity; +++, between 75 and 95%
activity; ++++, equal activity; bGrowth percent of cultured cells of ~60 cancer cell lines treated with 10 µM compound relative to
vehicle-treated control; cMean graph midpoint of growth inhibition from 5 dose assay, ranging from 10-8–10-4 M; dN.S. = not selected
82

for 5 dose assay; eN.T. = cell line not tested; fN.A. = not accepted by the National Cancer Institute for screening in the NCI-60.
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Figure 21. Structures of previously (numbered compounds, 130 and 213–220) and
contemporaneously (A, B, and 125) synthesized indenoisoquinolines for comparison of
biological activities. All of the compounds were prepared by other Cushman laboratory
members.

Indenoisoquinoline lactam side chains are known to exert a significant influence
on Top1 poisoning and growth inhibitory activities.29, 34 Unexpectedly, dihydroxy side
chain analogues 193 and 194 displayed worse Top1 poisoning activity and cytotoxicity
than imidazolylpropyl side chain analogues 203 and 204. This trend held generally true
for all of the other potential bioisosteres. The S-2,3-dihydroxypropyl lactam side chain
was recently reported to impart equivalent or greater Top1 poisoning activity, and
improved MGM GI50 values, compared to imidazolylpropyl and morpholinopropyl
lactam side chains.54 This trend is applicable to 2,3-dimethoxy-8,9-methylenedioxy- and

84
3-nitro-substituted indenoisoquinolines, but clearly not for all aromatic ring substitution
patterns.
There are several reports in the literature of successful nitro aryl replacement with
a pyridine ring,83 and it might therefore be expected that the 3-azaindenoisoquinolines A,
B, and 125 would display Top1 poisoning and growth inhibitory activities comparable to
3-nitroindenoisoquinolines 130, 213, and 217. Two possibilities to explain why this
‘swap’ has turned out to be successful in other studies include (1) the pyridine nitrogen,
like nitro group oxygens, can function as a hydrogen bond acceptor, and (2) the
electronegative nitrogen within the pyridine ring mimics the electron-withdrawing effect
of nitro. On the contrary, the 3-azaindenoisoquinolines’ Top1 poisoning scores were
mediocre to poor (++ or +). A single compound, 125, progressed to the five-dose growth
inhibition assay, and its MGM GI50 was 0.977 µM. None of the other 3-aza compounds
displayed sub-micromolar MGM GI50 values or Top1 poisoning scores above ++.
The other potential bioisosteres (i.e., I, CN, CF3, SMe, SO2Me, and CO2Me) did
not display Top1-mediated DNA cleavage assay scores above ++. Although all of the
new compounds had some activity, the majority were clustered with “+” and “++” Top1
assay scores. Only four of these compounds, 196, 205, 206, and 215, were advanced to
the five-dose assay for MGM GI50 determination. However, none of these four displayed
MGM GI50 values better than 0.944 µM.
In an effort to rationalize the observed biological activities on the basis of
molecular mechanics, several ligands were docked into the X-ray crystal structure of the
indenoisoquinoline MJ-2-38 bound to the Top1-DNA ternary complex.21 The ligands,
Top1-DNA cleavage complex, and resulting ligand-Top1-DNA ternary complexes were
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energy minimized as described in the experimental section. The graphics in Figures 22–
24 were prepared in Pymol.85 The ligand binding poses are the same as that observed for
MJ-2-38 in the 1SC7 X-ray crystal structure, except for some minor deviations. The Cring carbonyl oxygen is within hydrogen-bonding distance of Arg364 in each case.
The binding mode of 203 may provide insight into its relatively potent Top1
poisoning activity (Figure 22).

The 3-fluoro substituent is calculated to be within

hydrogen bonding distance (2.98 Å) of the carboxamide nitrogen of Asn722. The angle
defined by the fluorine of 203 and the carboxamide hydrogen and nitrogen of Asn722
would ideally be >150° for hydrogen bonding,86 but the measured angle in the docking
pose is 116°. The fluorine atom occupies a pocket defined by two deoxyribose sugars
and Top1 residues Asn722 and Thr718 (not shown). Its close contacts (≤ 3.5 Å) with
heavy atoms from each of these four structures favorably impact the van der Waals
contribution to the ligand’s binding energy.

Figure 22. Energy-minimized hypothetical binding pose of 203 (green) within the X-ray
crystal structure of a stalled Top1−DNA cleavage complex co-crystallized with
indenoisoquinoline MJ-2-38 (PDB code 1SC7).21 A potential interaction is indicated by
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the dashed line. The distance between heavy atoms appears next to the dashed line. The
stereoview is programmed for wall-eyed (relaxed) viewing.

Compound 204 was also studied by molecular mechanics molecular modeling
(Figure 23). The binding mode of 204, which is highly similar to that obtained for 203,
does not suggest a halogen bonding interaction between the chlorine and Asn722. In
halogen bonding, chlorine, bromine, or iodine interacts as a Lewis acid with a Lewis
basic atom such as oxygen or nitrogen.87 The electron density surrounding the halogen
atom is unevenly distributed, such that a small region of electropositivity exists at one
face.86 This type of bonding seems unlikely for 204, given that the distance between the
chlorine and the carboxamide oxygen of Asn722 is calculated to be 4.19 Å. The carbonyl
does not align with the C-Cl bond on the ligand. Furthermore, its 3-bromo and 3-iodo
analogs do not show the marked enhancement in activity relative to 3-fluoro observed
with some halogen-bonding ligands.86,
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Another possibility is that the 3-chloro

substituent has appropriate shape complementarity for its surroundings. Significantly
larger monatomic bioisosteres (i.e., bromine and iodine) and multi-atom groups (e.g.
CO2Me and SO2Me) were unable to confer similar Top1 poisoning and growth inhibitory
activities.
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Figure 23. Energy-minimized hypothetical binding pose of 204 (orange) within the X-ray
crystal structure of a stalled Top1−DNA cleavage complex co-crystallized with
indenoisoquinoline MJ-2-38 (PDB code 1SC7).21 A potential interaction is indicated by
the dashed line. The distances between heavy atoms appear next to the dashed lines. The
stereoview is programmed for wall-eyed (relaxed) viewing.

Trifluoromethylated indenoisoquinoline 207 exhibits poor Top1 poisoning
activity. In its molecular model (Figure 24), the CF3 group packs closely with the
Asn722 residue. The same attractive intermolecular interactions that could stabilize the
binding of 203 and 204 seem plausible. As can be observed from the ligand overlay of
203 and 207, the latter is rotated relative to 203 so as to maximize its interaction with
Asn722, an effect that may consequently weaken other important interactions for ligand
binding. The trifluoromethyl group is unusual among the bioisosteres selected for this
study because of its tetrahedral geometry (the only other being SO2Me). Its geometry
may help to explain why the 3-CF3 compounds exhibit very poor Top1 poisoning
activities (0/+ or +).
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Figure 24. Overlay of energy-minimized hypothetical binding poses of 207 (blue) and
203 (green) within the X-ray crystal structure of a stalled Top1−DNA cleavage complex
co-crystallized with indenoisoquinoline MJ-2-38 (PDB code 1SC7).21

Previous quantum mechanics studies suggest that the interactions between an
indenoisoquinoline and its flanking base pairs within the cleavage complex are predictive
of ligand binding orientation.89 Electrostatic potential surfaces calculated using quantum
mechanics showed that the electron withdrawing effect of 3-nitro pulls electron density
away from the lactam carbonyl.

This polar effect serves to minimize poor charge

complementarity at the lactam carbonyl and to maximize the charge complementarity just
outside of the A-ring 3-position with the flanking base pairs.89 The theoretical binding
energy, including its charge transfer and dispersion force components, of the
azaindenoisoquinolines in their binding site are sensitive to both incorporation and
position of the nitrogen atom in the D-ring.90 In the present study, it was predicted that
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the quantum mechanics-calculated binding energies of bioisosterically modified
indenoisoquinolines would be similar to those for nitrated indenoisoquinolines.
The binding energies of five model indenoisoquinolines 222–226 in a simplified
version of a Top1-DNA cleavage complex (Figure 25) were calculated by quantum
mechanics at the MP2/6-31G* level of theory. The quantum mechanics calculations
were performed with a model Top1-DNA cleavage complex containing only the
heterocyclic bases shown in Figure 25, and simplified indenoisoquinolines in which the
lactam side chains were replaced by a methyl group. These approximations were made
because (1) previous theoretical studies have demonstrated that the experimentally
observed indenoisoquinoline binding orientation can be predicted using this simplified
binding site model89 and (2) the lactam side chain of the indenoisoquinolines projects out
of the cleavage site and into the DNA major groove.21
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Figure 25. Two- and three-dimensional depictions of the model complex used for
quantum mechanics calculations.

The three-dimensional depiction is shown in

stereoview and is programmed for wall-eyed (relaxed) viewing.

The quantum mechanics-derived binding energies (Table 9) display a correlation
with Top1 assay scores. The two nitro bioisosteres that result in +++ Top1 assay scores,
F and Cl (i.e. compounds 203 and 204), also have the most favorable theoretical binding
energies, at -17.36 and -18.60 kcal/mol, respectively. In line with Top1 assay scores,
neither fluorinated 224 nor chlorinated 225 were calculated to bind as favorably as 222,
the nitrated analogue. The negative control ligand 223 is substituted with 3-H and it has
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the least favorable calculated binding energy. Ligand 226 is substituted with a CF3 group
in the 3-position. Its calculated binding energy was slightly better than negative control
223’s, although considerably worse than those of 222, 224, or 225.

Table 9. Calculated Binding Energies of Hypothetical Indenoisoquinolines 222–226 in
the Model Binding Site.

a

Ligand

R

Einter, kcal/mola

Electronegativity
of R (eV)b

222

NO2

-21.34

7.84

223

H

-15.87

224

F

-17.36

10.01

225

Cl

-18.60

7.65

226

CF3

-16.09

6.30

Binding energies were calculated at the MP2/6-31G* level and include the basis set

superposition error; b Calculated at CISD level by de Proft et al.82

The calculated binding energies of the ligands also show a correlation with group
electronegativity. The substituents on ligands 222 and 225, NO2 and Cl respectively,
have similar electronegativities, and their theoretical binding energies are the most
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favorable of all five systems studied. With its substantially greater electronegativity,
fluorinated analogue 224 could be anticipated to have a more favorable theoretical
binding energy than 222 and 225, but it does not. The CF3 group present on ligand 226
has the lowest electronegativity among the nitro bioisosteres, and this may factor into its
unfavorable calculated binding energy and low Top1 assay scores. It is possible that both,
or either, direct substituent-substituent interactions and polarized aromatic system
interactions dominate the calculated theoretical binding energies.

4.4

Design of the Second Generation

In the preceding section, an effort to identify safer bioisosteric replacements for a
nitro group on the indenoisoquinoline system was detailed. Although numerous 3-nitrosubstituted compounds have been identified that exhibit double-digit nanomolar mean
graph midpoint (MGM) GI50 values and potent Top1 poison activities, we were
concerned by potential conversion of the aryl nitro group to nitroso or hydroxylamine
functional groups, which have general protein reactivity. In terms of biological activity,
fluorine and chlorine proved to be the best replacements for nitro among the potential
bioisosteres investigated. Furthermore, each of these halogens is metabolically stable.
Although the fluorinated and chlorinated compounds retained Top1 poison and cytotoxic
activities, performance was lessened in nearly all cases.
In the second generation, new bioisosteric Top1 poisons were designed that
combine the S.A.R. data obtained for the first generation with observations made from a
molecular modeling study. It was anticipated that the resulting compounds would have
improved activities over the first generation. Models of 203 and 204 in the Top1-DNA
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cleavage complex (Figures 22 and 23) showed a region of unfilled space between the
indenoisoquinoline D-ring and the surrounding structure.

Previous studies of

indenoisoquinolines and camptothecins have shown that some alkoxy groups in the 8and/or 9-positions of the indenoisoquinoline system, and their analogous positions on the
camptothecin system, have a beneficial impact on Top1 inhibitory activity. The alkoxy
groups that can be installed have steric constraints, however, as this location in the
binding site abuts the intact DNA strand.22, 91 Finally, various side chains were installed
at the lactam nitrogen. Linear carbohydrate-derived side chains derived from D-xylose
and D-ribose, as well as the side chain present on potential future clinical trial drug 22
were investigated in the second-generation as lactam side chains, in addition to those
studied in the first generation.
A second motivation for our continued studies of bioisosteric indenoisoquinolines
was to discover common points between the indenoisoquinoline Top1 poison S.A.R. and
tyrosyl DNA phosphodiesterase 1 (TDP1) S.A.R. TDP1 is a DNA repair enzyme that
removes irreversible Top1-DNA cleavage complexes. Because many cancer cells have
compromised DNA repair pathways, inhibition of TDP1 may eliminate these cells’
ability to execute this repair and overcome Top1 poison cytotoxic effects. A growing
collection of indenoisoquinolines has been identified that have dual Top1-TDP1
inhibitory activities.37,

38, 70, 80

Information that is learned about the effects of

indenoisoquinoline ring substituents and lactam side chains on both activities can be used
to design more potent dual-acting agents.
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4.5

Synthesis of the Second Generation

3-Position fluorinated and chlorinated lactones 231 and 232 were synthesized by
the route shown below (Scheme 35). 3-Fluoro- and 3-chlorobenzoic acids (227 and 228)
were converted to the desired intermediates 146 and 151 in good yields (21% and 43%,
respectively), and in a single step, using C-H bond activation methodology.47 Each of the
phthalides 146 and 151 was converted to its corresponding 3-hydroxyphthalide as before
(see Schemes 26 and 27).

3-Hydroxyphthalides 148 or 159 were condensed with

phthalide 7 under basic conditions, and the unisolated indanedione intermediates 229 and
230 were each cyclized in Ac2O with heating to provide lactones 231 and 232.

Scheme 35. Synthesis of Lactones 231 and 232a

a

Reagents and conditions: (a) CH2Br2, Pd(OAc)2, KHCO3, 140 °C, 2 d; (b) i. NaOMe,

MeOH, EtOAc, reflux; ii. Ac2O, reflux.
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Lactones bearing a 3-position halogen along with other D-ring substitutions were
desired.

The synthesis of 8,9-ethylenedioxy-substituted lactones 234 or 235 was

attempted, but neither was isolated (Scheme 36).

Scheme 36. Attempted Synthesis of Lactones 234 and 235a

a

Reagents and conditions: (a) BrCH2CH2Br, Cs2CO3, DMF, 70 °C; (b) i. NaOMe, MeOH,

EtOAc, reflux, ii. Ac2O, reflux.

Previous indenoisoquinoline S.A.R. studies conducted by Morrell et al.
determined that 9-methoxy D-ring substitution generally enhances the Top1 poisoning
activities and antiproliferative effects of 3-position nitrated indenoisoquinolines.25 The
syntheses, and isolations, of lactones 241 and 242 were thus attempted (Scheme 37). It
was possible to isolate one of the two regioisomeric intermediates 239 or 240, although
not both. The identity of the isolated lactone (i.e., 239 or 240) was not assigned. When
the single lactone was condensed with amine 18, a 1:1 mixture of indenoisoquinolines
241 and 242 was obtained, as expected. Similar to step b, where an intermediate with
free rotation about the bond connecting the A-ring to the indanedione portion (indicated
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for 238) is produced, step d also scrambles the regiochemistry of the 8- and 9-positions.
The latter step includes a ring-opened intermediate similar to 238. Neither of the two
indenoisoquinolines could be isolated, in spite of the numerous, varied attempts
(chromatography on silica gel or alumina; solvent washes and precipitations) made to
isolate them.

Scheme 37. Attempted Synthesis of Indenoisoquinolines 241 and 242a

a

Reagents and conditions: (a) 37% HCHO, 37% HCl, AcOH, 90–110 °C; (b) i. NaOMe,

MeOH, EtOAc, reflux; ii. Ac2O, reflux; (c) CHCl3, reflux.
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Lactones 231 and 232 were condensed with primary amines 17–19, 63, 69, and 82
to yield new indenoisoquinolines 243–252 (Scheme 38). Carbohydrate-derived primary
amines 63 and 69 were prepared according to published procedures.31

Scheme 38. Synthesis of Indenoisoquinolines 243–252a

a

Reagents and conditions: (a) CHCl3, (MeOH or MeOH-H2O), reflux.

2,3-Difluoroindenoisoquinolines 259 and 260 were synthesized beginning from obromobenzoic acid 253 (Scheme 39).

Reduction of the carboxylic acid with BH3

provided benzylic alcohol 254. The latter was subjected to a Rosenmund-von Braun
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reaction followed by hydrolysis and lactonization to yield phthalide 255. Oxidation of
255 was carried out using NBS, and the resulting 3-bromophthalide 256 was hydrolyzed
immediately

following

column

chromatography

purification

to

provide

3-

hydroxyphthalide 257. Condensation of 257 and 7 under basic conditions and treatment
of the unisolated indanedione intermediate in Ac2O delivered lactone 258 in acceptable
yield for derivatization. Lactone 258 was condensed with primary amines 82 and 18 to
yield indenoisoquinolines 259 and 260, respectively.
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Scheme 39. Synthesis of Indenoisoquinolines 259 and 260a

a

Reagents and conditions: (a) BH3, THF, reflux; (b) CuCN, DMF, H2O, reflux; (c) NBS,

AIBN, CCl4, reflux; (d) H2O, reflux; (e) i. NaOMe, MeOH, EtOAc, reflux; ii. Ac2O,
90 °C; (f) CHCl3, (MeOH), reflux.

3,4-Dichloroindenoisoquinolines were synthesized in six steps, as shown in
Scheme 40. Diacid 261 was converted to its anhydride 262 in refluxing AcCl. The
anhydride 262 was reduced with NaBH4 and then treated with catalytic pTSA in
refluxing PhMe to deliver phthalide 263. Oxidation of 263 with NBS and hydrolysis of
3-bromophthalide 264 gave 3-hydroxypthalide 265.

3-Hydroxyphthalide 265 and

phthalide 7 were condensed and then cyclized to produce lactone 266 by the two-step
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sequence described before. Derivatization of lactone 266 with primary amines 82 and 18
provided 267 and 268, respectively.

Scheme 40. Synthesis of Indenoisoquinolines 267 and 268a

a

Reagents and conditions: (a) AcCl, reflux; (b) NaBH4, THF, 0 °C to room temp.; (c)

NBS, AIBN, CCl4, reflux; (d) H2O, reflux; (e) i. NaOMe, MeOH, EtOAc, reflux; ii. Ac2O,
90 °C; (f) CHCl3, (MeOH), reflux.

4.6

Rationale, Biological Results, and Discussion

Bioisosteric replacements for a 3-nitro group on the indenoisoquinoline system
were sought in order to limit potential genotoxicity (Sections 4.2 and 4.3).75 Although
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numerous 3-nitro-substituted compounds have been identified that have double-digit
nanomolar MGM GI50 values and Top1 poison activities equal to or greater than
camptothecin,25-28,

31, 54, 70

the nitro group has the potential to be converted to toxic

metabolites with general reactivity toward biological nucleophiles.73 Fluorine and
chlorine atoms proved to be the optimal replacements for nitro among the eleven
potential bioisosteres investigated. Although the fluorinated and chlorinated compounds
retained Top1 poison and cytotoxic activities, they were less potent than the
corresponding nitro compounds in nearly all cases.75
Several structural modifications were made to the 3-position fluorinated and
chlorinated indenoisoquinolines that were expected to enhance their activities.

As

mentioned in Section 4.4, a region of unoccupied space in the binding site, between the
indenoisoquinoline D-ring and the intact DNA strand, could be substituted with sterically
limited alkoxy groups in the 8- and/or 9-positions. S.A.R. knowledge for both the
camptothecins and the indenoisoquinolines could be used here, since it is known that
each of these chemotypes binds to the Top1-DNA cleavage complex in a similar
orientation (Figure 26).

The 10,11-ethylenedioxy substitution of formerly clinically

studied camptothecin analog lurtotecan (Figure 27) could not be successfully transferred
to the indenoisoquinoline system using the chemistry shown in Scheme 35; neither could
an 8- or 9-methoxy group be installed.
substitution could be installed successfully.

In the end, only the 8,9-methylenedioxy
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Figure 26. (Above) Chemical structures of MJ-2-38 and topotecan. (Below) Overlay of
the X-ray crystal structures of the ternary Top1-DNA-drug cleavage complexes
containing MJ-2-38 (PDB ID 1SC7, turquoise)21 or topotecan (PDB ID 1K4T, green).92
The stereoview is programmed for wall-eyed (relaxed) viewing.

Figure 27. Structure of camptothecin analog lurtotecan.

The location of the

ethylenedioxy substitution is described according to the camptothecin numbering system.
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The lactam nitrogen and the 2-position were also substituted to modulate biological
activity. Various side chains, either derived from carbohydrates or containing the 3aminopropyl motif, were introduced at the lactam nitrogen. A third modification was
made to the 2-position. The molecular model of compound 250 (Figure 28) shows that a
single remaining aromatic ring position on the indenoisoquinoline scaffold (the 2-position)
could be substituted to target a direct interaction with the Top1-DNA cleavage complex.
Nearby Top1 residue Thr718 extends its methyl group toward the 2-position. It was
hypothesized that a small halogen atom like fluorine or chlorine at this position could
favorably interact with the methyl group through van der Waals interactions.
Simultaneously, the electron-withdrawing nature of the halogen could favorably impact
the interaction between the ligand and the flanking base pairs.

Figure 28. Energy-minimized hypothetical binding pose of 250 (purple) within the X-ray
crystal structure of a stalled Top1-DNA cleavage complex co-crystallized with
indenoisoquinoline MJ-2-38 (PDB ID 1SC7).21 A heavy atom distance (in Å) appears
next to the dashed line. The stereoview is programmed for wall-eyed (relaxed) viewing.
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The objectives of this study were to optimize 3-fluoro- and 3-chloro-substituted
indenoisoquinolines for Top1 poisoning and growth inhibitory activities. The Top1mediated DNA cleavage assay7 was used to evaluate the compounds’ Top1 poisoning
activities. A representative gel is shown in Figure 29.

Figure 29. Top1-mediated DNA cleavage assay gel. From left: lane 1, DNA alone; lane
2, DNA and Top1; lane 3, DNA and Top1 and 1 µM camptothecin (CPT); lane 4, DNA
and Top1 and 1 µM indenoisoquinoline MJ-3-65; remaining lanes, DNA and Top1 and
indicated concentration (µM) of test compound. The numbers and arrows at the left
indicate cleavage site positions (see Experimental Section). The image was cropped to
remove irrelevant compounds that also appeared on this gel.
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The NCI-60 human tumor cell line screen was used to evaluate the cytotoxicity of
the new compounds. Cytotoxicity data, as well as Top1-mediated DNA cleavage assay
scores for the tested compounds are displayed in Table 10. Compound 269 (Figure 30)
and camptothecin are included in the table for easy referencing.
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Table 10. Antiproliferative and Top1 Inhibitory Activities of Indenoisoquinolines in the Second Generation
Cytotoxicity (GI50, µM)

camptothecin

Top1
Cleavagea
++++

Mean Growth
Percentb
N.D.

Lung,
HOP-62
0.01

Colon,
HCT-116
0.03

CNS,
SF-539
0.01

Melanoma,
UACC-62
0.01

Ovarian,
OVCAR-3
0.22

Renal,
SN12C
0.02

Prostate,
DU-145
0.01

Breast,
MCF7
0.01

269

++++

N.D.

< 0.010

< 0.010

< 0.010

0.017

0.302

< 0.010

< 0.010

0.025

0.0405 ±
0.0187
0.090 ± 0.04

243

++++

-23.51

0.049

0.079

0.051

0.045

0.182

0.076

0.102

0.032

0.105

246

++

-13.19

0.032

0.035

0.029

0.025

0.100

0.079

0.051

0.012

0.078

247

+++

-23.26

< 0.010

< 0.010

< 0.010

< 0.010

0.019

< 0.010

< 0.010

< 0.010

0.011

249

+

46.13

251

++

-47.12

0.036

0.019

0.041

0.028

0.076

0.107

0.033

< 0.010

0.055

244

++

-8.57

0.022

0.020

0.025

0.012

0.062

0.027

0.032

< 0.010

0.042

245

+

N.T.e

248

++

-16.85

250

+

55.96

252

+++

-72.73

0.071

0.105

0.240

0.043

1.32

1.07

0.059

0.018

0.229

259

++

-14.01

0.022

0.037

0.029

0.015

0.224

0.033

0.041

< 0.010

0.068

260

+

-5.77

< 0.010

< 0.010

< 0.010

< 0.010

0.115

< 0.010

< 0.010

< 0.010

0.030

267

++

-27.96

< 0.010

< 0.010

< 0.010

< 0.010

0.016

< 0.010

< 0.010

< 0.010

0.013

268

+

5.28

< 0.010

< 0.010

< 0.010

< 0.010

0.043

< 0.010

< 0.010

< 0.010

0.017

2,3-Cl

2,3-F

3-Cl

3-F

compd

MGMc

N.S.d

N.T.
< 0.010

< 0.010

< 0.010

< 0.010

0.040

< 0.010

< 0.010

< 0.010

0.024
N.S.
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Table 10 footnote
a

Compound-induced DNA cleavage due to Top1 poisoning, with scores given according

to the following system based on the activity of 1 µM camptothecin: 0, no activity; +,
between 20 and 50% activity; ++, between 50 and 75% activity; +++, between 75 and 95%
activity; ++++, equal activity; ++++(+), greater activity;

b

Mean growth percent of

cultured cells of ~60 cancer cell lines treated with 10 µM compound relative to vehicletreated control; c Mean graph midpoint of growth inhibition from 5 dose assay, ranging
from 10-8–10-4 M; d N.S. = not selected for 5 dose assay; e N.T. = compound not tested.

Figure 30. Indenoisoquinolines used in comparisons of biological activities.

The second generation of bioisosteric indenoisoquinolines was not enriched in
++++ or +++ Top1 poisons, contrary to expectation. Of the fourteen new compounds,
one achieved a ++++ score, and two achieved a +++ score.

Although all of the

compounds displayed some Top1 poisoning activity, most were clustered at + or ++
scores. In contrast, the six fluorinated and chlorinated compounds in the first generation
(Table 8) either achieved a +++ score (three compounds) or a ++ score (three
compounds). The major structural difference between these two generations was at the
D-ring, where an 8,9-methylenedioxy substitution was added in the second generation.
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The effect of installation of this group on indenoisoquinoline Top1 poisoning activity was
not well-characterized prior to this investigation. It was known that installation of a 9methoxy group onto 3-nitroindenoisoquinolines could slightly improve Top1 poisoning
activity.27
On the other hand, the second generation compounds generally have much
improved cytotoxicity versus the first generation. Twelve of the fourteen compounds
have MGM GI50 values below 100 nM. The remaining two compounds also have low
MGM GI50 values (105 nM and 229 nM). It was previously established that various
alkoxy substituents at the 8- and/or 9-positions could enhance antiproliferative potency of
indenoisoquinolines. For example, compound 269 has an MGM GI50 value of 90 nM,
while its analog 270, which lacks the 8,9-methylenedioxy group, has an MGM GI50 value
of 245 nM.26
The second generation indenoisoquinolines substituted with a 2,3-difluoro- or 2,3dichloro-pattern were expected to have improved Top1 poisoning activity relative to 3fluoro- or 3-chloro-substituted analogues.

The halogen atom in the 2-position was

predicted to interact with nearby Top1 residue Thr718. Instead, these four compounds
displayed low Top1 scores (+ or ++), but, their MGM GI50 values were 68 nM or below.
Each of the new compounds was tested in biochemical assays of TDP1 and
tyrosyl DNA phosphodiesterase 2 (TDP2) activities.

TDP2 is another DNA repair

enzyme and is involved in the removal of stalled topoisomerase II (Top2) cleavage
complexes.

Similar to the idea with dual Top1-TDP1 inhibition, dual Top2-TDP2

inhibition may produce a synergistic effect that selectively targets cancer cells. TDP1
and TDP2 inhibitors would be useful not just for augmenting DNA-damaging cancer
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chemotherapy, but also radiation and antiviral therapies, where DNA damage is induced
to create a therapeutic effect.
Two compounds prepared in the current study were found to be highly active in
the TDP1 inhibition assay (Figure 31). Indenoisoquinolines 251 and 252 each received a
score of +++, which indicates an IC50 value between 1 and 12 µM against purified
recombinant TDP1 enzyme.

These two compounds are highly similar structurally,

possessing a fluorine (251) or chlorine (252) substitution in the 3-position, along with the
hydroxyethylaminopropyl side chain. This side chain was not previously known to
confer TDP1 inhibitory activity to the indenoisoquinolines.

This observation is

significant, because the same side chain is known to confer Top1 inhibitory activity.12, 20
Compound 251 achieved a ++ score, while compound 252 achieved a +++ score in the
Top1 assay.
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Figure 31. TDP1 inhibition assay gel. The concentrations of positive control AM-8-3
(271, Figure 32) and test compounds were 0.46, 1.4, 4.1, 12.3, 37, 111 µM (left to right).
N14Y is 5′-end labeled DNA oligonucleotide with 3′ phosphotyrosyl, and N14P is 5′-end
labeled DNA oligonucleotide (see Experimental Section).

Gel-based assays are

commonly acquired twice for each compound. The “+”-based scoring system rubric is as
follows: 0, IC50 > 111 µM; +, IC50 37–111 µM; ++, IC50 12–37 µM; +++, IC50 > 1–12
µM; ++++, IC50 ≤ 1 µM.

Figure 32. Structure of positive control AM-8-3.
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The same two compounds (251 and 252) displayed potent inhibitory activity
versus TDP2, as well. Here, too, their scores were +++, which indicates IC50 values
between 1 and 12 µM versus purified recombinant TDP2 enzyme (Figure 33).

Figure 33. TDP2 inhibition assay gel. The concentrations of positive control SV-5-153
(272, Figure 34) were 0.005, 0.017, 0.05, 0.15, 0.46, 1.4 µM, and the concentrations for
the test compounds were 0.46, 1.4, 4.1, 12.3, 37, 111 µM (left to right). The TDP2
substrate Y19 corresponds to a 3′-end labeled DNA oligonucleotide with a 5′
phosphotyrosyl, and the TDP2 product p19 corresponds to a 3′-end labeled DNA
oligonucleotide with a 5’ phosphate group (see Experimental Section). The “+”-based
scoring system rubric is the same as that for the TDP1 assay (see Figure 2 caption).

Figure 34. Structure of positive control SV-5-153.
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Accurate IC50 determinations were made for each compound versus both TDP1
and TDP2, and these are displayed in Table 11.

Table 11. Accurate IC50 Determinations for Indenoisoquinolines 251 and 252 versus
TDP1 and TDP2
Compound

TDP1 IC50, µM

TDP2 IC50, µM

251

8.9 (n = 1)

14.1 (n = 1)

252

6.3 ± 1.4 (n = 3)

6.2, 11.2 (n = 2)

Molecular modeling studies were carried out to examine the potential interactions
between 247 or 248 with their binding site in the Top1-DNA cleavage complex. The
fluorine atom of indenoisoquinoline 247 is calculated to engage Asn722 in a hydrogenbonding interaction (Figure 35). The binding mode of the ligand is nearly identical to
that observed for indenoisoquinoline MJ-2-38 in its co-crystal structure with the Top1DNA cleavage complex.21

Figure 35. Energy-minimized hypothetical binding pose of 247 (green) within the X-ray
crystal structure of a stalled Top1-DNA cleavage complex co-crystallized with an
indenoisoquinoline ligand (PDB ID 1SC7).21 Potential hydrogen-bonding interactions are
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indicated by dashed lines. Heavy atom distances appear next to the dashed lines. The
stereoview is programmed for wall-eyed (relaxed) viewing.

In the case of analog 248, the chlorine atom does not have appropriate positioning
to engage the side chain oxygen of Asn722 in a halogen bond (Figure 36). Instead, it is
more likely to engage only in weak van der Waals interactions with Asn722. The binding
mode of the ligand is nearly identical to that observed for indenoisoquinoline MJ-2-38 in
its co-crystal structure with the Top1-DNA cleavage complex.21

Figure 36. Energy-minimized hypothetical binding pose of 248 (purple) within the X-ray
crystal structure of a stalled Top1-DNA cleavage complex co-crystallized with an
indenoisoquinoline ligand (PDB ID 1SC7)21. Potential hydrogen-bonding interactions
are indicated by dashed lines. Heavy atom distances appear next to the dashed lines. The
stereoview is programmed for wall-eyed (relaxed) viewing.

The effect of A-ring substitution pattern on the intermolecular interactions
between an indenoisoquinoline and its flanking base pairs was investigated using
quantum mechanics calculations. The protocol that was followed for these calculations is
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identical to the one used prior (Section 4.3), facilitating comparisons between the
substitution patterns. Briefly, the Top1-DNA cleavage complex was reduced to two sets
of flanking base pairs above and below the indenoisoquinoline MJ-2-38 in its X-ray
crystal structure. Model indenoisoquinolines were constructed by truncating the side
chain of MJ-2-38 to a single methyl group and modifying the 2- and 3-positions of the
ligand to produce one of four halogenation patterns: 3-fluoro; 3-chloro; 2,3-difluoro; and
2,3-dichloro. Two- and three-dimensional representations of the model complex are
shown in Figure 25.
Quantum

mechanics-calculated

binding

energies

of

the

hypothetical

indenoisoquinolines 223–225 and 273–274 in the model cleavage site were not predictive
of average Top1 scores (Table 12).

The average Top1 scores in Table 12 were

exclusively calculated from data for 8,9-methylenedioxy-substituted indenoisoquinolines
prepared in this study or in previous ones.22, 30 Model ligands 225, 273, and 274 exhibited
the most favorable predicted binding energies, but their average Top1 scores were below
++. On the other hand, model ligands 223 and 224, with the least favorable predicted
binding energies, had marginally better average Top1 scores, which were 2.2 or 2.4,
respectively.
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Table 12. Calculated Binding Energies of Simplified, Hypothetical Indenoisoquinolines
in the Model Binding Site.

Ligand

Substitution

223

a

Einter, kcal/mola

Average Top1 Score

-15.87

2.2b

224

3-F

-17.36

2.4c

225

3-Cl

-18.60

1.8c

273

2,3-diF

-18.22

1.5c

274

2,3-diCl

-18.83

1.5c

Binding energies were calculated at the MP2/6-31G* level and include the basis set

superposition error; b Data from previous publications22, 30; c Data from Table 10.

There are several items to keep in mind when rationalizing the data in Table 12.
One possible explanation for the poor agreement between theoretical calculations and
experimental observations is that the surrounding cleavage complex structures, such as
enzyme side chains and DNA backbone, play a larger role in ligand stabilization than
previously suspected. There had been ample evidence to suggest a highly significant
contribution of base pair-indenoisoquinoline interactions to cleavage complex binding:
(1) 57% of the solvent accessible surface area of MJ-2-38 is covered by DNA in its cocrystal structure with the Top1-DNA cleavage complex21; (2) only one polar interaction
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between the ligand and its binding site is present in the latter crystal structure—a
hydrogen bond between Arg364 and the 11-keto oxygen21; and (3) quantum mechanics
calculations are predictive of the binding orientation of indenoisoquinolines89. A second
possible explanation for the marked discrepancy is that our calculations do not factor in
several of the contributions to the energetics of ligand binding, such as solvationdesolvation, ligand and/or cleavage complex reorganization, and entropy. One potential
implication for future studies is that additional components of the Top1-DNA cleavage
complex, such as Asp722, may need to be included in quantum mechanics calculations to
achieve predictive results.

4.7

Conclusion

In the first generation, twenty new 3-substituted indenoisoquinolines were
synthesized to investigate the effects of bioisosteric replacements for the nitro group in
the

3-nitroindenoisoquinoline

Top1

poison

family.

Although

many

3-

nitroindenoisoquinolines display potent activity in the Top1-mediated DNA cleavage
assay and growth inhibitory effect in the NCI-60 antiproliferative assay, it would be
advantageous to identify bioisosteres that mitigate potential toxicity risks associated with
aryl nitro groups. Fluorine and chlorine were identified as bioisosteres on the basis of
their Top1 poisoning activities and growth inhibitory potencies. Molecular mechanics
modeling and quantum mechanics calculations indicate that hydrogen-bonding, van der
Waals forces, and interactions between the flanking base pairs and the indenoisoquinoline
could stabilize bioisosterically modified indenoisoquinolines within their binding site in
the Top1-DNA cleavage complex.
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Information learned from the first-generation aided the design of the second
generation.

Installation of the 8,9-methylenedioxy substitution on the D-ring, and

exploration of varied lactam side chains resulted in compounds with extremely potent
growth inhibition activity.

Attachment of a fluorine or chlorine in the 2-position,

resulting in novel 2,3-dihalo substitution patterns, was attempted because of observations
made from molecular modeling.
inhibitory

activity.

However, these compounds displayed weak Top1

Altogether,

the

second

generation

produced

two

3-

fluoroindenoisoquinolines which show potent growth inhibitory and Top1 poisoning
activities that are on par with the best 3-nitroindenoisoquinolines. These two molecules
can serve as lead structures for future studies. The triple enzyme inhibitory activities of
251 and 252 increase the attractiveness of these indenoisoquinolines for continued
development as cancer chemotherapeutic agents. At present, there are few reported
TDP1 and TDP2 inhibitors, and none that inhibit both of these enzymes and Top1.
The findings from this study are also valuable because they can aid the design of
novel Top1 poisons.

3,9-Difluorinated indolocarbazole glycosides (Figure 37) have

demonstrated efficacy in preclinical models and advanced to human clinical trials.93, 94
The 3-position substituents on the indenoisoquinoline and indolocarbazole scaffolds
project toward Asn722 (Figure 38). This observation provides support for a universal
structure-activity relationship for the Top1 poisons, and may therefore aid in the
structure-based design and optimization of new and different Top1 poisons.95
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Figure 37. General structure of a 3,9-difluorinated indolocarbazole glycoside Top1
poison.

Figure 38. Overlay of the X-ray crystal structures of the ternary Top1-DNA-drug
cleavage complexes containing MJ-2-38 (PDB ID 1SC7, purple)21 or SA315F (PDB ID
1SEU, green),21 showing the distances (in Å) of their respective 3-positions to Top1
residue Asn722.

119

CHAPTER 5. BIS(INDENOISOQUINOLINES) WITH DUAL TOPOISOMERASE ITYROSYL-DNA PHOSPHODIESTERASE 1 ACTIVITIES

5.1

Introduction

One limitation of current cytotoxic chemotherapy and radiation treatments is that
beneficial therapy-induced DNA damage can be repaired by cancer cells. For example,
Top1 poisons induce two types of DNA damage after a replication fork “collides” with
the trapped Top1-DNA cleavage complex. One is a “replication runoff” product, which
is a DNA double-strand break, and it is repaired by homologous recombination. The
second is an irreversible Top1-DNA adduct. At least two different DNA repair pathways
can mend these adducts: (1) a pathway that uses TDP1 to hydrolyze the Top1-DNA
phosphotyrosyl linkage; and (2) a pathway that cuts the DNA with a 3’-flap
endonuclease, such as the XPF-ERCC1 enzyme.36
Recent work suggests that it may be possible to target both Top1 and TDP1 in
cancer cells with an indenoisoquinoline to conceivably achieve a more pronounced
cytotoxic effect.37, 38, 54, 69, 70, 75 The S.A.R. of indenoisoquinolines as Top1 inhibitors are
especially well developed. Our laboratory has reported several indenoisoquinoline TDP1
inhibitors that exhibit IC50 values between 1–12 µM while retaining Top1 poisoning
activity.37, 38, 69 Bis(indenoisoquinoline) 27138, 96 is a potent dual inhibitor of Top1 and
TDP1, with IC50 values of 1.54 µM and 1.9 µM against purified recombinant and whole
cell extract TDP1, respectively.38 Analogues of compound 271 tethered by all-carbon
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linker chains are essentially inactive against TDP1 (IC50 values greater than 111 µM).38
The low-micromolar IC50 value of 271 against TDP1 compares favorably to other known
TDP1 inhibitors.64-67
It was hypothesized that new dual Top1-TDP1 inhibitor indenoisoquinolines
could be engineered by combining the current S.A.R. knowledge. Lead molecule 271
was modified by installation of the 2,3-dimethoxy-8,9-methylenedioxy aromatic ring
substitution pattern, and modulation of its polyaminoalkyl linker chain. The first of these
changes was anticipated to enhance Top1 inhibitory activity. The second was expected to
be important for potent TDP1 inhibitory activity. The compounds were evaluated in the
NCI-60 cytotoxicity assay and in Top1 and TDP1 enzyme inhibition assays to evaluate
their cytotoxic effects.

5.2

Synthesis of Bis(Indenoisoquinolines)

Bis(indenoisoquinolines) 281–286 were synthesized by the condensation of two
equivalents of lactone 9 with one equivalent of a polyamine 275–280 (Scheme 41).
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Scheme 41. Syntheses of Bis(Indenoisoquinolines) 281–286a

a

Reagents and conditions: (a) i. CHCl3, MeOH, reflux; ii. TFA (282 and 286).

Triazole-linked-bis(indenoisoquinoline) was synthesized via copper-catalyzed
1,3-dipolar cycloaddition of 288 and 289 (Scheme 42). Alkyne 288 was synthesized by
condensation of amine 287 with lactone 9. Azide 289 was prepared by substitution of 29
with NaN3.22 The conditions employed are known to exclusively afford the 1,4-product,
and not the 1,5-regioisomer.97 Compound 290 was insoluble in all solvents tested except
for neat TFA, and consequently, it was not submitted for biological testing.
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Scheme 42. Synthesis of Bis(Indenoisoquinoline) 290a

a

Reagents and conditions: (a) CHCl3, reflux; (b) NaN3, DMF, reflux; (c) CuSO4·5H2O,

sodium ascorbate, NEt3, DMF, room temp.
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5.3

Biological Results and Discussion

The new bis(indenoisoquinolines) were evaluated for cancer cell growth
inhibitory activities in the National Cancer Institute’s NCI-60 cytotoxicity assay,61 and
the Top1-mediated DNA cleavage assay7 was used to measure Top1 inhibitory activity.
A representative gel is shown in Figure 39.

Figure 39. Top1-mediated DNA cleavage assay gel. From left: lane 1, DNA alone; lane
2, DNA and Top1; lane 3, DNA and Top1 and 1 µM camptothecin (CPT); lane 4, DNA
and Top1 and 1 µM MJ-III-65 (22); remaining lanes, DNA and Top1 and indicated
concentration (µM) of test compound. The numbers and arrows at the left indicate
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cleavage site positions (see Experimental Section). The image was cropped to remove
irrelevant compounds that also appeared on this gel.

The compounds were also tested in a TDP1 inhibition assay.65 A representative
gel is shown in Figure 40.

Figure 40. TDP1 inhibition assay gel.

The concentrations of test compounds are

indicated above each lane. N14Y is 5’-end labeled DNA oligonucleotide with a terminal
3’-phosphotyrosyl substituent, and N14P is 5’-end labeled DNA oligonucleotide (see
Experimental Section).

Of the bis(indenoisoquinolines) submitted for testing, only two, 281 and 285,
exerted Top1 inhibitory activity at 50–75% of an equivalent dose of camptothecin (i.e.,
++).

This result was somewhat surprising, given that the 2,3-dimethoxy-8,9-

methylenedioxy substitution pattern enhances Top1 inhibitory activity of monomeric
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indenoisoquinolines. An especially illustrative comparison is that between 271 (++++)
and 285 (++), which are identical in all respects except for aromatic ring substitution
(Table 13).
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Table 13. Antiproliferative and Top1 and TDP1 Inhibitory Activities of Bis(Indenoisoquinolines)
Cytotoxicity (GI50 in µM)
linker
chain

compd

TDP1
inhibitiona

Top1
cleavageb

Mean
growth %c

Lung,
HOP-62

Colon,
HCT-116

CNS,
SF-539

Melanoma,
UACC-62

Ovarian,
OVCAR-3

Renal,
SN12C

Prostate,
DU-145

Breast,
MCF7

MGMd

3-3-3

271

+++

++++

< 0.010

< 0.010

0.011

0.042

0.074

< 0.010

N.T.e

0.107

0.394 ± 0.33

2-2

281

++

++

107.07

N.D.f

2-2-2

282

+++

+

74.84

N.D.

2-3-2

283

++

+

44.60

3-2-3

284

+++

0

69.07

3-3-3

285

++

++

64.42

3-pip-3g

286

0

0

97.33

0.331

1.12

2.69

2.82

5.01

1.91

3.39

0.389

3.11 ± 0.85
N.D.

6.61

0.525

7.76

17.4

12.3

6.31

4.90

1.48

7.59
N.D.
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Table 13 footnote
a

TDP1 inhibition scores are given according to IC50: 0, > 111 µM; +, 37–111 µM; ++,

12–37 µM; +++, 1–12 µM; ++++, < 1 µM; b Compound-induced DNA cleavage due to
Top1 inhibition, with scores given according to the following system based on the
activity of 1 µM camptothecin: 0, no inhibition; +, between 20 and 50% activity; ++,
between 50 and 75% activity; +++, between 75 and 95% activity; ++++, equal activity; c
Growth percent of cultured cells of ~60 cancer cell lines treated with 10 µM compound
relative to vehicle-treated control; d Mean growth midpoint of growth inhibition from 5
dose assay, ranging from 10-8–10-4 M;

e

cell line not tested;

f

not determined;

g

pip =

piperazine.

The

comparison

of

2,3-dimethoxy-8,9-methylenedioxy-substituted

bis(indenoisoquinolines) and their unsubstituted counterparts 291–296 (Figure 41 and
Table 14), shows that the dramatic improvement of Top1 scores seen in the latter series
with 2-3-2, 3-2-3, and 3-3-3 linker chains does not carry over to the new series. In fact,
no preference was observed in the new series for linker chains of a certain length or
number of secondary amines. For example, the two best Top1 inhibitors prepared in this
study, 281 and 285, contained the shortest (2-2) and the longest (3-3-3) linker chains
examined.
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Figure 41. Previously reported ring-unsubstituted bis(indenoisoquinolines).96

Table 14. Top1-Mediated DNA Cleavage Assay Score vs Linker Chain for the
Symmetrical Ring-Unsubstituted Bis(indenoisoquinoline) Seriesa

a

Compd

Linker

Top1 Inhibition

291

2-2

+

292

2-2-2

+

293

2-3-2

++++

294

3-2-3

++++

271

3-3-3

++++

295

3-piperazine-3

0

Data for compounds 271 and 291–295 from Nagarajan et al.96

Although the Top1 inhibitory scores were weak, TDP1 scores were generally
strong, especially in comparison to the limited list of known organic TDP1 inhibitors.37, 38,
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66, 80

Two bis(indenoisoquinolines) received a “+++” score for TDP1 inhibition,

indicating that their IC50 values are between 1–12 µM.
Bis(indenoisoquinolines) 283 and 285 were selected for 5 dose cytotoxicity
testing in the NCI’s 60 cell line assay following acceptable performance in the single
dose initial screen at 10 µM. The MGM GI50 value for 283 was 3.11 ± 0.85 µM (n = 2),
and for 285 it was 7.59 µM (n = 1). The remaining compounds exhibited poor growth
inhibitory activity at 10 µM. Among these are 286 and 284, which achieved “0” and
“+++” TDP1 inhibition scores, respectively. Neither 286 or 284 showed detectable Top1
inhibitory activity at 1 µM in the Top1-mediated DNA cleavage assay.

One

interpretation of this result is that inhibition of TDP1 alone is insufficient to arrest cell
proliferation.

5.4

Conclusion

New dimeric indenoisoquinolines were designed and synthesized to investigate
their Top1 and TDP1 inhibitory activities. Substitution of the bis(indenoisoquinolines’)
aromatic rings with the 2,3-dimethoxy-8,9-methylenedioxy pattern weakened Top1
inhibitory activity and cytotoxic potency, relative to ring-unsubstituted analogues.
Modifications to the aminoalkyl linker chain were key to maximizing TDP1 inhibitory
potency.

These results were contrary to the expectation of achieving potent dual

inhibition of both enzymes, but can educate future design efforts.
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CHAPTER 6. EXPERIMENTAL

General. Reactions were monitored by silica gel analytical TLC, and 254 nm UV
light was used for visualization.

All yields refer to isolated compounds.

Unless

otherwise stated, chemicals and solvents were used as obtained from commercial sources
without further purification. Melting points were determined using capillary tubes and
are uncorrected. 1H Nuclear magnetic resonance (NMR) spectroscopy was performed
using a 300 or 500 MHz spectrometer, and

13

C NMR was performed using a 125 MHz

spectrometer. Dr. Huaping Mo (Purdue University Interdepartmental NMR Facility) is
acknowledged for his assistance with collecting NMR data.

Infrared spectra were

obtained using an FTIR spectrometer. Dr. Karl Wood and his staff (Purdue University
Campus-Wide Mass Spectrometry Center) are thanked for collecting mass spectrometry
data.

Compound purities were estimated by reversed phase C18 HPLC, with UV

detection at 254 nm. The major peak area of each tested compound was ≥ 95% of the
combined total peak area.
5,6-Dimethoxyphthalide (2).39 Veratric acid (1, 5.0 g, 27 mmol) was added to a
solution of aqueous solution of 37% formaldehyde (15 mL) and 37% HCl (75 mL). The
reaction mixture was stirred at 90 ºC for 4 h, and then at room temperature overnight. 28%
NH4OH was carefully added to the mixture until it was neutralized. The mixture was
stirred until it cooled to room temperature, and the precipitated solids were filtered off.
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The residue was recrystallized from 95% EtOH to yield 2 (4.0 g, 75%) as an off-white
solid: Rf (SiO2, 50:50 hexanes-EtOAc) 0.50, mp 153–155 °C. 1H NMR (300 MHz,
DMSO) δ 7.26 (s, 1 H), 7.23 (s, 1 H), 5.27 (s, 2 H), 3.86 (s, 3 H), 3.83 (s, 3 H).
Alternative Method. An oven-dried 15 mL pressure tube with a stir-bar was
cooled to room temperature under an argon atmosphere. The tube was charged with
veratric acid (1, 100 mg, 0.549 mmol), KHCO3 (138 mg, 1.38 mmol), Pd(OAc)2 (19 mg,
15 mol%), and CH2Br2 (6 mL). The vessel was submerged in a silicone oil bath to the
top level of the reaction mixture and heated to 140 ºC with stirring for 2 d. The black
suspension was concentrated in vacuo. The residue was purified by silica gel column
chromatography (CHCl3 then 50:50 hexanes-EtOAc).
fractions were concentrated in vacuo.

The pure product-containing

The solid was dried under vacuum to yield

phthalide 2 (34 mg, 32%) as a white solid: mp 145–149 °C. 1H NMR (300 MHz, CDCl3)
 7.32 (s, 1 H), 6.91 (s, 1 H), 5.23 (s, 2 H), 3.98 (s, 3 H), 3.95 (s, 3 H).
3-Hydroxy-5,6-dimethoxyphthalide (4).40 Phthalide 2 (12.1 g, 62.3 mmol), NBS
(11.1 g, 62.4 mmol), benzoyl peroxide (10 mg) and anhydrous CCl4 (100 mL) were
added to an oven-dried dry round-bottomed flask. The reaction mixture was heated to
reflux with stirring under an Ar atmosphere while being exposed to the light of a 250 W
light bulb for 3 h. The mixture was filtered, and the filtrate was concentrated to obtain
crude 3-bromo-5,6-dimethoxyphthalide (3) as an oil. The oil was heated at reflux for 2 h
in H2O (200 mL), by which time a white precipitate formed. The solution was basified to
pH 14 with solid KOH and subsequently washed with EtOAc (3 x 40 mL). The solution
was then acidified to pH 1 with aqueous HCl (37%) and concentrated to remove ~70% of
the solvent. The suspension was filtered to provide 4 as a white solid (11.0 g, 84%): mp
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181–182 °C. 1H NMR (300 MHz, acetone-d6) δ 10.60 (s, 0.25 H), 7.99 (s, 0.25 H), 7.53
(s, 0.25 H), 7.41 (s, 0.25 H), 7.19 (s, 0.75 H), 7.16 (s, 0.75 H), 6.87 (d, J = 8.3 Hz, 0.75
H), 6.51 (d, J = 8.2 Hz, 0.75 H), 3.93 (s, 3 H), 3.90 (s, 3 H); negative ESIMS m/z (rel
intensity) 209 (M - H+, 100).
6-Bromopiperonol (6).98 Piperonol (5, 21.40 g, 140.7 mmol) was dissolved in
CH2Cl2 (200 mL) with stirring.

The solution was cooled to 0–5 °C under an Ar

atmosphere and NBS (25.03 g, 140.6 mmol) was added in several portions over 30 min.
The mixture was stirred at 0–5 °C for 2 h and then 10% Na2SO3 solution (100 mL) was
added. The mixture was stirred for 5 min. The organic layer was removed and set aside.
The aqueous layer was extracted with CH2Cl2 (2 x 100 mL). The combined organic
layers were washed with brine (100 mL) and dried over Na2SO4 and concentrated in
vacuo. The product was recrystallized from Et2O to provide 6 (27.58 g, 85%) as a white
solid: mp 71–77 °C. 1H NMR (300 MHz, CDCl3)  6.99 (s, 1 H), 6.97 (s, 1 H), 5.97 (s, 2
H), 4.63 (d, J = 6.10 Hz, 2 H).
Alternative Method.44 6-Bromopiperonal (11, 6.5 g, 28 mmol) was dissolved in
absolute EtOH (100 mL), and the reaction mixture was cooled to 5 ºC under an Ar
atmosphere. NaBH4 (1.5 g, 40 mmol) was added in three portions over the next 30 min
while maintaining the reaction temperature at 5 ºC. The reaction mixture was allowed to
warm to room temperature with stirring for 18 h, and concentrated to one-third its
original volume, and diluted with H2O (30 mL). The product was extracted with CHCl3
(3 x 50 mL), and the combined organic layers were washed with H2O (3 x 30 mL) and
brine (1 x 30 mL), dried over Na2SO4, and concentrated. The residue was recrystallized
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from EtOAc-hexanes to provide 6 (5.6 g, 85%) as a white solid: mp 87–88 ºC. 1H NMR
is identical.
5,6-Methylenedioxyphthalide (7). 6-Bromopiperonol (6, 7.7 g, 33 mmol) was
dissolved in freshly distilled THF (70 mL) with stirring. The solution was cooled to -78
˚C, and then a 1.6 M solution of n-BuLi in hexanes (63 mL, 100 mmol) was added
dropwise via addition funnel. The solution was allowed to stir 30 min at -78 ˚C after the
addition of n-BuLi was complete, and slowly poured into a large beaker containing Et2O
(80 mL) and an excess (> 15 g) of solid CO2. The mixture was allowed to stir for 30 min,
over which time small chunks of solid CO2 were added periodically to maintain the
constant presence of solid CO2. Aqueous HCl (37%, 25 mL) was added slowly, and the
mixture was allowed to stir for 16 h at room temperature. H2O (80 mL) was added to the
mixture, the ether layer of the mixture was removed, and the aqueous layer extracted with
CH2Cl2 (3 x 20 mL).

The combined organic layers were dried over Na2SO4, and

concentrated. The oil that was obtained was triturated with hexanes (10 mL), filtered,
and washed with hexanes (10 mL) to provide 7 as a white-yellow solid (4.5 g, 76%): mp
188–189 ºC. IR (film) 1748, 1282, 1013 cm-1; 1H NMR (300 MHz, CDCl3)  7.23 (s, 1
H), 6.84 (s, 1 H), 6.12 (s, 2 H), 5.19 (s, 2 H); CIMS m/z (rel intensity) 179 (MH+, 100).
Alternative Method 1.46 CuCN (8.856 g, 98.88 mmol) was suspended in DMF (65
mL) and H2O (2 mL). The mixture was heated to 120 ºC, and intermediate 6 (11.40 g,
49.34 mmol) was added in four portions over 15 min while holding the temperature
steady. The mixture was then heated with stirring to 160 C for 2.5 h, cooled to 110 C,
and a solution of NaCN (14.5 g, 296 mmol) in H2O (10 mL) was added. The resultant
mixture was stirred overnight with cooling to room temperature. CHCl3 (20 mL) was
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added to the mixture, which was then filtered through Celite, eluting with CHCl 3 (200
mL). The organic phase was removed and the aqueous phase was extracted with CHCl3
(2 x 50 mL). The combined organic extracts were dried over MgSO4, and silica (2 g) was
added. After stirring for 5 min, the mixture was filtered through a sintered glass funnel,
and the filter cake was washed with boiling CHCl3 (20 mL).

The solution was

concentrated in vacuo to yield compound 7 as a tan solid (2.58 g, 29%). 1H NMR is
identical.
Alternative Method 2.46 CuCN (0.773 g, 8.63 mmol) was stirred in a solution of
formamide (6 mL) and H2O (0.1 mL).

The mixture was heated to 120 ºC, and

intermediate 6 (1.046 g, 4.53 mmol) was added in four portions over 15 min while
holding the temperature steady. The mixture was then heated with stirring to 160 C for
2 h, cooled to 110 C, and a solution of NaCN (1.348 g, 27.5 mmol) in H2O (10 mL) was
added. The resultant mixture was stirred overnight with cooling to room temperature.
CH2Cl2 (20 mL) was added to the mixture, which was then filtered through Celite, eluting
with additional CH2Cl2 (100 mL). The organic phase was removed and the aqueous
phase was extracted with CH2Cl2 (1 x 10 mL). The combined organic extracts were dried
over MgSO4, and silica (0.2 g) was added. After stirring for 5 min, the mixture was
filtered through a sintered glass funnel, and the filter cake was washed with boiling
CH2Cl2 (20 mL). The solution was concentrated to yield compound 7 as orange crystals
(0.65 g, 81%): mp 188–189 ºC. 1H NMR is identical.
Alternative Method 3. Phthalide 12 (1.77 g, 10.7 mmol) was suspended in DMF
(15 mL) with stirring, and Cs2CO3 (5.25 g, 16.1 mmol) was added. After allowing the
mixture to stir at room temperature for 15 min, CH2Br2 (1.12 mL, 16.1 mmol) was added
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dropwise. The mixture was heated to 95–100 °C for 16.5 h, and then cooled to room
temperature. H2O (50 mL) was added and the product was extracted into EtOAc (10 x 50
mL). The combined EtOAc layers were washed with brine (1 x 50 mL), dried over
MgSO4, and concentrated in vacuo. The sticky, semi-solid residue was stirred in 50:50
hexanes-EtOAc (~10 mL) and filtered to provide product 7 (0.71 g, 37%) as a beige solid.
1

H NMR is identical.
Alternative Method 4. An oven-dried 48 mL pressure tube with a stir-bar was

cooled to room temperature under an argon atmosphere. The tube was charged with
piperonylic acid (13, 203 mg, 1.22 mmol), K2HPO4 (646 mg, 3.71 mmol), Pd(OAc)2 (43
mg, 15 mol%), and CH2Br2 (12 mL, 170 mmol). The vessel was submerged in a silicone
oil bath to the top level of the reaction mixture and heated to 140 ºC with stirring for 4 d.
The black suspension was concentrated in vacuo. The residue was purified by silica gel
column chromatography (CHCl3, 4 cm x 6 cm, 25 mL fractions) to yield phthalide 7 (136
mg, 62%) as a yellow-white solid: Rf (SiO2, 50:50 hexanes-EtOAc) 0.25, Rf (SiO2,
CHCl3) 0.11, mp 180–185 °C. 1H NMR is identical.
Methylene Bis(3,4-methylenedioxycarboxylate) (7a).

When conducting the

Alternative Method 4 reaction using the conditions specified for Entry 7 (Table 1,
Scheme 7) on a two gram scale (e.g., 2.01 g of 13 used), 7a (70 mg, 3%) was isolated as a
white solid: Rf (SiO2, CHCl3) 0.20, mp 166–169 °C. 1H NMR (300 MHz, CDCl3) δ 7.71
(dd, J = 8.2, 1.7 Hz, 2 H), 7.50 (d, J = 1.7 Hz, 2 H), 6.84 (d, J = 8.2 Hz, 2 H), 6.17 (s, 2
H), 6.04 (s, 4 H); EIMS m/z (rel intensity) 344 (M+, 15), 149 (100).
2,2,2-Trifluoroethyl 3,4-Methylenedioxybenzoate (7c). When conducting the
Alternative Method 4 reaction using the conditions specified for Entry 4 (Table 1,
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Scheme 7) on a 200 mg scale (e.g., 205 mg of 13 used), 7c (76 mg, 25%) was isolated as
a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.69 (dd, J = 8.2, 1.7 Hz, 1 H), 7.47 (d, J =
1.7 Hz, 1 H), 6.85 (d, J = 8.2 Hz, 1 H), 6.05 (s, 2 H), 4.65 (q, J = 8.4 Hz, 2 H).
2,3-Dimethoxy-8,9-methylenedioxyindeno[1,2-e]benzopyran-6,11-dione

(9).

3-Hydroxyphthalide 4 (3.44 g, 16.4 mmol) and phthalide 7 (2.94 g, 16.5 mmol) were
suspended with stirring in EtOAc (40 mL). A NaOMe solution was prepared by carefully
dissolving Na (3.24 g, 141 mmol) in MeOH (anhydrous, 80 mL), and this solution was
added to the suspension. The reaction mixture was stirred and heated to reflux under an
Ar atmosphere for 24 h. The solution was cooled to room temperature, acidified to pH 1
with 37% HCl, and concentrated in vacuo to dryness. Ac2O (40 mL) was added to the
residue and the mixture was heated to reflux with stirring for 72 h under an Ar
atmosphere. After cooling to room temperature, hexanes (50 mL) were added, and the
mixture was filtered. The residue was washed with hexanes (100 mL), suspended in H2O
(75 mL) and extracted with CHCl3 (8 x 250 mL). The combined organic layers were
concentrated in vacuo and azeotroped once with PhMe (20 mL).

The residue was

purified by two precipitations from CHCl3-hexanes (30 mL:25 mL) and one from CHCl3Et2O (30 mL:25 mL) to yield 9 as a dark purple solid (2.92 g, 51%): mp 311–314 C. IR
(film) 1732, 1707, 1520, 1476, 1364, 1315, 1243 cm-1; 1H NMR (300 MHz, CDCl3) δ
7.69 (s, 1 H), 7.64 (s, 1 H), 7.08 (s, 1 H), 6.99 (s, 1 H), 6.09 (s, 2 H), 4.05 (s, 3 H), 3.98 (s,
3 H);

13

C NMR (125 MHz, CDCl3) δ 189.0, 168.8, 160.7, 156.1, 151.6, 149.6, 149.2,

132.4, 128.8, 127.4, 111.2, 110.5, 106.7, 105.5, 103.3, 102.5, 102.0, 56.5, 56.1; ESIMS
m/z (rel intensity) 353 (MH+, 100); HRESIMS m/z calcd for C19H13O7 353.0661 (MH+),
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found: 353.0664; HPLC purity: 100% (90% MeOH, 10% H2O), 100% (95% MeOH, 5%
H2O).
11-Hydroxy-2,3-dimethoxy-8,9-methylenedioxy-indeno[1,2-c]isochromen5(11H)-one (9-keto-metabolite). NaBH4 (226 mg, 5.97 mmol) was added in small
portions over 1 h to a stirring solution of lactone 9 (209 mg, 0.593 mmol) dissolved in
CHCl3 (10 mL) and MeOH (15 mL). The mixture was stirred at room temperature for 2
h and concentrated in vacuo. The residue was washed with H2O (10 mL) and MeOH (10
mL) and azeotroped with PhH in vacuo to provide 9-keto-metabolite (112 mg, 53%) as a
yellow solid: mp 240–243 ºC. IR (film) 3456, 2945, 1691, 1616, 1519, 1477, 1366, 1246
cm-1; 1H NMR (300 MHz, DMSO-d6) δ 7.54 (s, 1 H), 7.29 (s, 1 H), 7.19 (s, 1 H), 7.08 (s,
1 H), 6.10 (d, J = 4.9 Hz, 2 H), 6.05 (d, J = 8.3 Hz, 1 H), 5.48 (d, J = 7.8 Hz, 1 H), 3.94 (s,
3 H), 3.88 (s, 3 H); negative ESIMS m/z (rel intensity) 353 (M - H+, 100); HRESIMS m/z
calcd for C19H14O7Na 377.0637 (M + Na+), found 377.0643; HPLC purity: 100% (100%
MeOH).
6-Bromopiperonal (11). Iron powder (5.98 g, 110 mmol) was suspended in
glacial AcOH (160 mL) with vigorous stirring. After cooling the mixture to 15 C, Br2
(8.8 mL, 170 mmol) was added dropwise. After 20 min a solution of piperonal (10,
15.38 g, 100 mmol) in AcOH (140 mL) was added dropwise via an addition funnel. The
mixture was allowed to stir for 5 min following this addition, and an additional portion of
Br2 (5.7 mL, 110 mmol) was added dropwise. The mixture was allowed to stir at room
temperature for 5 d, with additional portions of Br2 (10 x 0.3 mL, 10 x 6 mmol) being
added every 12 h. The reaction mixture was then diluted with CHCl3 (400 mL), filtered
through a pad of Celite, and washed with aqueous Na2S2O3 (saturated, 5 x 150 mL),
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aqueous NaHCO3 (saturated, 3 x 100 mL), and brine (3 x 100 mL). The organic layer
was dried over Na2SO4, concentrated, and the product was recrystallized from 95% EtOH
to provide 11 as a white solid (19.05 g, 82%): mp 127–128 ºC. 1H NMR (300 MHz,
CDCl3)  9.88 (s, 1 H), 7.37 (s, 1 H), 7.07 (s, 1 H), 6.09 (s, 2 H).
5,6-Dihydroxyphthalide (12). Phthalide 2 (2.5 g, 13 mmol) was dissolved with
stirring in CH2Cl2 (100 mL) and then cooled to -78 °C under Ar. A solution of 1.0 M
BBr3 in CH2Cl2 (30 mL, 30 mmol) was added dropwise by syringe. After the addition of
reagent was complete, the reaction mixture was removed from the cooling bath and
stirred with warming to room temperature for 19 h. The reaction was quenched by
careful addition of MeOH (30 mL) and allowed to stir 15 min.

The mixture was

concentrated in vacuo. Aqueous Na2SO3 solution (10%, 30 mL) and brine (30 mL) were
added to the residue, and the mixture was stirred for 15 min and filtered. The solids were
washed with Et2O (10 mL), air-dried, and dried under high-vacuum to provide 12 (1.9 g,
87%) as a beige solid: Rf (SiO2, 50:50 hexanes-EtOAc) 0.22, mp 250–257 °C. 1H NMR
(300 MHz, DMSO-d6) δ 10.31 (s, 1 H), 9.76 (s, 1 H), 7.09 (s, 1 H), 6.96 (s, 1 H), 5.16 (s,
2 H); CIMS m/z 167 (MH+, 100).
5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-6-(3-morpholinopropyl)5,11-dioxo-11H-indeno[1,2-c]isoquinoline (20). 3-Morpholinopropylamine (17, 0.081
g, 0.56 mmol) was added to a stirring solution of lactone 9 (0.069 g, 0.20 mmol) in
CHCl3 (20 mL). The solution was stirred and heated to reflux under Ar for 16 h. The
cooled reaction mixture was washed with water (2 x 15 mL) and brine (1 x 15 mL) and
then dried over Na2SO4 and concentrated to provide 20 (0.092 g, 96%) as a dark purple
solid: Rf (SiO2, 95:5 CHCl3-MeOH) 0.55, mp 294–296 ºC. 1H NMR (300 MHz, CDCl3) δ
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8.04 (s, 1 H), 7.64 (s, 1 H), 7.43 (s, 1 H), 7.08 (s, 1 H), 6.10 (s, 2 H), 4.51 (m, 2 H), 4.05
(s, 3 H), 3.99 (s, 3 H), 3.75 (m, 4 H), 2.58-2.43 (m, 6 H), 2.02, (m, 2 H); HPLC purity:
99.52% (90% MeOH, 10% H2O).
5,6-Dihydro-6-(3-(1H-imidazol-1-yl)propyl)-2,3-dimethoxy-8,9methylendioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline

(21).

3-

Imidazolylpropylamine (18, 0.078 g, 0.62 mmol) was added to a stirring solution of
lactone 9 (0.079 g, 0.22 mmol) in CHCl3 (20 mL). The solution was stirred and heated to
reflux under Ar for 16 h. Additional amine 18 (0.071 g, 0.57 mmol) was added, and
stirring and heating at reflux was continued for 24 h. The cooled reaction mixture was
washed with H2O (20 mL), and the aqueous layer containing emulsified product was
extracted with 95:5 CHCl3-MeOH (4 x 100 mL). The combined organic layers were
washed with H2O (4 x 50 mL) and brine (1 x 50 mL), dried over Na2SO4, and
concentrated. The residue was washed with H2O (5 mL) to provide 21 (0.083, 82%) as a
dull purple solid: Rf (SiO2, 95:5 CHCl3-MeOH) 0.25, mp 320–322 ºC. 1H NMR (300
MHz, CDCl3) δ 8.02 (s, 1 H), 7.64 (s, 1 H), 7.62 (s, 1 H), 7.16 (s, 1 H), 7.06 (s, 1 H), 7.05
(s, 1 H), 6.41 (s, 1 H), 6.09 (s, 2 H), 4.46 (t, J = 7.2 Hz, 2 H), 4.22 (t, J = 6.7 Hz, 2 H),
4.05 (s, 3 H), 4.00 (s, 3 H), 2.46 – 2.27 (m, 2 H); HPLC purity: 97.54% (90% MeOH, 10%
H2O).
5,6-Dihydro-6-[3-(2-hydroxyethyl)amino-1-propyl]-2,3-dimethoxy-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline

(22).

2-(3-

Aminopropylamino)ethanol (19, 0.060 g, 0.51 mmol) was dissolved in CHCl3 (1 mL) and
added to a stirring solution of lactone 9 (0.060 g, 0.17 mmol) in CHCl3 (20 mL). The
solution was stirred and heated to reflux under Ar for 18 h. The cooled reaction mixture
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was concentrated until ~5 mL of solvent remained, hexanes (1 mL) were added, and the
suspension filtered. The solids were washed with 4:1 CHCl3-hexanes (1 mL) and H2O (2
mL) to provide 22 (0.058 g, 75%) as a dark purple solid: mp 241–242 ºC. 1H NMR (300
MHz, CDCl3 + 5 drops CD3OD) δ 7.92 (s, 1 H), 7.54 (s, 1 H), 7.12 (s, 1 H), 6.98 (s, 1 H),
6.04 (s, 2 H), 4.46 (t, J = 7.2 Hz, 2 H), 3.98 (s, 3 H), 3.93 (s, 3 H), 3.72 – 3.56 (m, 2 H),
2.79 – 2.66 (m, 5 H), 2.01 (p, J = 6.6 Hz, 2 H).
ß-Alanine Methyl Ester Hydrochloride (31). SOCl2 (1.35 mL, 18.6 mmol) was
added to a stirring mixture of MeOH (7 mL) and β-alanine (30, 0.547 g, 6.14 mmol)
under an Ar atmosphere at 0 ºC. The mixture was heated to reflux overnight. The
resulting yellow solution was concentrated to dryness to obtain 31 (0.826 g, 96%) as a
colorless oil that solidified upon standing at room temperature: mp 86–88 ºC. 1H NMR
(300 MHz, D2O) δ 3.71 (s, 3 H), 3.25 (t, J = 6.4 Hz, 2 H), 2.78 (t, J = 6.5 Hz, 2 H).
3-[Bis(2-hydroxyethyl)amino]propanenitrile (34). Diethanolamine (33, 2.789 g,
27.38 mmol) was stirred and cooled to -5 ºC under an Ar atmosphere. Acrylonitrile (32,
1.8 mL, 27 mmol) was added dropwise through a rubber septum. The mixture was stirred
at room temperature overnight, and then concentrated in vacuo to yield 34 (5.604 g,
100%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 3.66 (t, J = 5.1 Hz, 4 H), 2.90 (t,
J = 6.6 Hz, 2 H), 2.71 (t, J = 5.1 Hz, 4 H), 2.53 (t, J = 6.6 Hz, 2 H).
2,2'-[(3-Aminopropyl)azanediyl]diethanol (35). LiAlH4 in THF (1 M, 16.8 mL,
16.8 mmol) was stirred and cooled to -5 ºC under an Ar atmosphere. Concentrated
H2SO4 (18.4 M, 0.35 mL, 6.32 mmol) was added dropwise to the solution through a
septum, and the mixture was allowed to stir at -5 ºC for 2 h.

3-(Bis(2-

hydroxyethyl)amino)propanenitrile (34, 0.501 g, 3.16 mmol) dissolved in THF (5 mL)
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was added dropwise through the septum while the temperature of the reaction mixture
was maintained at 5 ºC. The mixture was allowed to stir overnight at room temperature.
The reaction was then quenched at 0 ºC by addition of H2O (1 mL). The mixture was
filtered by gravity and the residue in the filter paper was placed inside a Soxhlet extractor,
where it was continuously extracted with MeOH (300 mL) for 4 d. The resulting yellow
solution was dried over Na2SO4, concentrated, resuspended in CH2Cl2, dried over Na2SO4,
filtered through Celite, and concentrated, to yield 35 (0.478 g, 93%) as a yellow-orange
syrup: 1H NMR (300 MHz, CD3OD) δ 3.59 (t, J = 5.7 Hz, 4 H), 3.27 (p, J = 3.2, 1.6 Hz,
4 H), 2.77 (t, J = 6.6 Hz, 2 H), 2.63-2.50 (m, 6 H), 1.66 (p, J = 6.7 Hz, 2 H).
3-((2-(2-Hydroxyethoxy)ethyl)amino)propanenitrile (37). Amine 36 (1.38 g,
13.1 mmol) was stirred and cooled to -5 ºC under an Ar atmosphere. Acrylonitrile (32,
0.9 mL, 14 mmol) and EtOH (absolute, 4 mL) were added dropwise through a rubber
septum. The mixture was stirred at room temperature overnight, and then concentrated in
vacuo to yield 37 (2.11 g, 100%) as an oil. 1H NMR (300 MHz, CDCl3) δ 3.69 – 3.64 (m,
2 H), 3.58 – 3.49 (m, 4 H), 2.90 (t, J = 6.7 Hz, 2 H), 2.82 – 2.75 (m, 2 H), 2.50 (t, J = 6.7
Hz, 2 H).
2-(2-((3-Aminopropyl)amino)ethoxy)ethan-1-ol (38).

LiAlH4 (2.61 g, 68.8

mmol) in freshly distilled THF (80 mL) was stirred and cooled to -5 ºC under an Ar
atmosphere. Concentrated H2SO4 (18.4 M, 1.4 mL, 26 mmol) was added dropwise to the
solution through a septum, and the mixture was allowed to stir at -5 ºC for 2 h. Nitrile 37
(2.03 g, 12.8 mmol) dissolved in THF (25 mL) was added dropwise through the septum
while the temperature of the reaction mixture was maintained at 5 ºC. The mixture was
allowed to stir overnight at room temperature. The reaction was then quenched at 0 ºC by
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addition of H2O (4 mL). The mixture was filtered by gravity and the residue in the filter
paper was placed inside a Soxhlet extractor, where it was continuously extracted with
MeOH (300 mL) for 24 h. The resulting solution was dried over Na2SO4, concentrated,
resuspended in CH2Cl2, dried over Na2SO4, filtered through Celite, and concentrated to
yield 38 (1.2 g, 57%) as a syrup: 1H NMR (300 MHz, CDCl3) δ 3.71 – 3.62 (m, 2 H),
3.60 – 3.49 (m, 4 H), 2.78 – 2.67 (m, 4 H), 2.63 (t, J = 6.5 Hz, 2 H), 1.58 (p, J = 6.5 Hz, 2
H).
6-(3-Methoxy-3-oxopropyl)-2,3-dimethoxy-8,9-methylendioxy-5,11-dioxo11H-indeno[1,2-c]isoquinoline (43). Triethylamine (0.119 g, 1.18 mmol) was added to
a stirring solution of ß-alanine methyl ester hydrochloride (31, 0.100 g, 0.716 mmol) in
CHCl3 (25 mL) under an Ar atmosphere at room temp. The mixture was allowed to stir
for 1 h, and then a solution of lactone 9 (0.098 g, 0.28 mmol) in CHCl3 (25 mL) was
added. The reaction mixture was heated to reflux for 3 d. CHCl3 (100 mL) was added to
the cooled reaction mixture, and the organic layer was washed with water (3 x 50 mL)
and brine (1 x 50 mL), dried over MgSO4, concentrated, precipitated from 3:1 CHCl3MeOH, and concentrated to yield 43 (0.058 g, 48%) as a purple solid: mp 294–296 ºC. IR
(film) 1731, 1699, 1655, 1482, 1391, 1252 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.04 (s, 1
H), 7.65 (s, 1 H), 7.19 (s, 1 H), 7.09 (s, 1 H), 6.10 (s, 2 H), 4.73 (t, J = 8.7 Hz, 2 H), 4.06
(s, 3 H), 3.99 (s, 3 H), 3.79 (s, 3 H), 2.93 (t, J = 7.7 Hz, 2 H); ESIMS m/z (rel. intensity)
438 (MH+, 100); HRESIMS m/z calcd for C23H20NO8 438.1189 (MH+), found 438.1186;
HPLC purity: 97.86% (90% MeOH, 10% H2O).
6-(2-Carboxyethyl)-2,3-dimethoxy-8,9-methylendioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (44).

Indenoisoquinoline 43 (0.030 g, 0.069 mmol) was

143
diluted in a solution of LiOH·H2O (2.5 g) in H2O (25 mL). The mixture was heated to
reflux with stirring for 4 h, cooled, acidified to pH 1 with concd HCl, and filtered. The
residue was washed with CHCl3 (5 mL) and diethyl ether (5 mL) to yield 44 (0.010 g,
34%) as a purple solid: mp > 350 ºC. IR (film) 3326, 1733, 1691, 1662, 1460, 1164 cm-1;
1

H NMR (300 MHz, CDCl3) δ 7.93 (s, 1 H), 7.54 (s, 1 H), 7.13 (s, 1 H), 6.99 (s, 1 H),

6.00 (s, 2 H), 4.61 (m, 2 H), 3.95 (s, 3 H), 3.89 (s, 3 H), 2.80 (m, 2 H); ESI-MS m/z (rel.
intensity) 424 (MH+, 100); HRESIMS m/z calcd for C22H18NO8 424.1032 (MH+), found
424.1026; HPLC purity: 99.26% (85% MeOH, 15% H2O).
6-(3-(Bis(2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-8,9-methylendioxy5,11-dioxo-11H-indeno[1,2-c]isoquinoline (45). A solution of amine 35 (0.091 g, 0.56
mmol) in MeOH (3 mL) was added to a stirring solution of lactone 9 (0.101 g, 0.287
mmol) in CHCl3 (50 mL). The mixture was stirred and heated to reflux overnight under
an Ar atmosphere. After cooling to room temperature, the product was precipitated with
the addition of EtOAc (10 mL) and filtered. The product was absorbed onto silica gel
and purified by column chromatography (100% CHCl3 to 85:15 CHCl3-MeOH) and
concentrated to yield 45 (0.025 g, 18%) as a purple solid: mp 265–268 ºC. IR (film) 3434,
1694, 1638, 1557, 1486, 1396 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1 H), 7.61 (s,
1 H), 7.05 (s, 1 H), 7.03 (s, 1 H), 6.10 (s, 2 H), 4.54 (m, 2 H), 4.04 (s, 3 H), 3.98 (s, 3 H),
3.70 (t, J = 5.0 Hz, 4 H), 2.71 (m, 6 H), 2.02 (m, 2 H); ESIMS m/z (rel. intensity) 497
(MH+, 100); HRESIMS m/z calcd for C26H29N2O8 497.1924 (MH+), found 497.1917;
HPLC purity: 96.80% (100% MeOH).
6-(3-((2-(2-Hydroxyethoxy)ethyl)amino)propyl)-2,3-dimethoxy-8,9methylendioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (46). A solution of amine 38
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(0.129 g, 0.80 mmol) was added to a stirring solution of lactone 9 (0.94 g, 0.27 mmol) in
CHCl3 (35 mL). The mixture was stirred and heated to reflux for 16 h under an Ar
atmosphere. After cooling to room temperature, the crude mixture was washed with H2O
(3 x 10 mL) and brine (10 mL). The organic solution was dried over Na2SO4 and
concentrated in vacuo to yield 46 (0.087 g, 65%) as a purple solid: mp 203–205 ºC. 1H
NMR (300 MHz, CDCl3) δ 7.94 (s, 1 H), 7.62 (s, 1 H), 7.20 (s, 1 H), 6.98 (s, 1 H), 6.06 (s,
2 H), 4.52 (t, J = 7.1 Hz, 2 H), 4.03 (s, 3 H), 3.98 (s, 3 H), 3.81 – 3.74 (m, 2 H), 3.72 –
3.66 (m, 2 H), 3.66 – 3.61 (m, 2 H), 3.14 (s, 2 H), 2.87 (t, J = 4.9 Hz, 2 H), 2.80 (t, J =
6.2 Hz, 2 H), 2.13 – 1.99 (m, 2 H); ESIMS m/z (rel. intensity) 497 (MH+, 100);
HRESIMS m/z calcd for C26H29N2O8 497.1924 (MH+), found 497.1926; HPLC purity:
99.63% (90% MeOH, 10% H2O).
6-(3,3-Diethoxypropyl)-2,3-dimethoxy-8,9-methylendioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (47). A solution of amine 39 (0.091 g, 0.62 mmol) in CHCl3
(3 mL) was added to a stirring solution of lactone 9 (0.100 g, 0.284 mmol) in CHCl3 (47
mL). The mixture was stirred and heated to reflux overnight under an Ar atmosphere.
The solution was concentrated to one half its original volume, cooled, and EtOAc (5 mL)
was added to precipitate the product, which was filtered and washed with diethyl ether (5
mL) to yield 47 (0.063 g, 46%) as a dull purple solid: mp 224–227 ºC. IR (film) 1690,
1649, 1614, 1393, 1309, 1032 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.04 (s, 1 H), 7.65 (s,
2 H), 7.06 (s, 1 H), 6.08 (s, 2 H), 4.72 (t, J = 4.5 Hz, 1 H), 4.56 (m, 2 H), 4.05 (s, 3 H),
3.98 (s, 3 H), 3.78 (m, 2 H), 3.60 (m, 2 H), 2.22 (m, 2 H), 1.29 (t, J = 7.0 Hz, 6 H);
ESIMS m/z (rel intensity) 504 (MNa+, 100); HRESIMS m/z calcd for C26H27NO8Na
504.1634 (MNa+), found 504.1636.
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2,3-Dimethoxy-8,9-methylendioxy-5,11-dioxo-6-(3-oxopropyl)-11Hindeno[1,2-c]isoquinoline (48).

Indenoisoquinoline 47 (0.063 g, 0.13 mmol) was

dissolved with stirring in a solution of CHCl3 (45 mL) and TFA (5 mL) was added. The
reaction mixture was stirred and heated to reflux for 15 h. The residue was absorbed onto
silica gel and purified by column chromatography (100% CHCl3 to 95:5 CHCl3-MeOH),
and precipitated from 3:1 CHCl3-hexanes to yield 48 (0.008 g, 15%) as a purple solid:
mp > 350 ºC. IR (film) 1700, 1639, 1552, 1391, 1308, 1253 cm-1; 1H NMR (300 MHz,
CDCl3) δ 9.95 (s, 1 H), 8.04 (s, 1 H), 7.63 (s, 1 H), 7.10 (s, 1 H), 6.95 (s, 1 H), 6.09 (s, 2
H), 4.75 (m, 2 H), 4.05 (s, 3 H), 3.99 (s, 3 H), 3.11 (s, 2 H); ESI-MS m/z (rel intensity)
408 (MH+, 100); HRESIMS m/z calcd for C22H18NO7 408.1083 (MH+), found 408.1089;
HPLC purity: 100% (95% MeOH, 5% H2O).
6-(3-Hydroxypropyl)-2,3-dimethoxy-8,9-methylendioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (49). 3-Aminopropan-1-ol (40, 0.163 g, 2.17 mmol) was
added to a stirring solution of lactone 9 (0.203 g, 0.576 mmol) in CHCl3 (100 mL). The
mixture was stirred and heated to reflux overnight under an Ar atmosphere. The reaction
mixture was concentrated to dryness, absorbed onto silica gel, and purified by column
chromatography (100% CHCl3 to 95:5 CHCl3-MeOH), and precipitated from 3:1 CHCl3EtOAc to yield 49 (0.082 g, 35%) as a purple solid: mp 316–318 ºC. IR (film) 3477,
1701, 1640, 1497, 1306, 1254 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.74 (s, 1 H), 7.35 (s,
1 H), 6.90 (s, 1 H), 6.78 (s, 1 H), 5.79 (s, 2 H), 4.33 (m, 1 H), 3.75 (s, 3 H), 3.69 (s, 3 H),
3.38 (m, 2 H), 1.81 (m, 2 H); ESIMS m/z (rel. intensity) 432 (MNa+, 18); HRESIMS m/z
calcd for C22H19NO7Na 432.1059 (MNa+), found: 432.1064; HPLC purity: 98.29% (95%
MeOH, 5% H2O).
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2,3-Dimethoxy-8,9-methylendioxy-5,11-dioxo-6-(prop-2-enyl)-11Hindeno[1,2-c]isoquinoline (50).

Prop-2-en-1-amine (41, 0.05 mL, 0.66 mmol) was

dissolved in CHCl3 (2 mL) and added to a stirring solution of lactone 9 (78 mg, 0.22
mmol) in CHCl3 (50 mL). The mixture was stirred and heated to reflux for 4 d under an
Ar atmosphere. The reaction mixture was cooled to room temperature and washed with
dilute HCl (10 mL), H2O (3 x 10 mL), and brine (10 mL). The organic solution was
dried over Na2SO4 and concentrated in vacuo. The product was precipitated from 4:1
CHCl3-EtOAc to yield 50 (100 mg, 100%) as a purple solid: mp 298–300 °C. 1H NMR
(300 MHz, CDCl3) δ 8.02 (s, 1 H), 7.66 (s, 1 H), 7.04 (s, 1 H), 6.94 (s, 1 H), 6.20 – 6.02
(m, 1 H), 6.07 (s, 2 H), 5.31 (dt, J = 10.4, 1.6 Hz, 1 H), 5.16 (dt, J = 17.3, 1.9 Hz, 1 H),
5.11 – 5.05 (m, 2 H), 4.05 (s, 3 H), 3.98 (s, 3 H); HPLC purity: 100% (90% MeOH, 10%
H2O).
6-(3-Aminopropyl)-2,3-dimethoxy-8,9-methylendioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (51). Mono-Boc-protected propane-1,3-diamine (42, 65 mg,
0.37 mmol) was dissolved in MeOH (2 mL) and added to a stirring solution of lactone 9
(42 mg, 0.12 mmol) in CHCl3 (25 mL). The mixture was stirred and heated to reflux for
16 h under an Ar atmosphere. The reaction mixture was cooled to room temperature and
TFA (5 mL) was added. After stirring for 16 h, the mixture was concentrated in vacuo.
The residue was partitioned between saturated NaHCO3 solution and CHCl3 (25 mL
each), and the organic layer was removed and washed with dilute HCl (10 mL), H2O (3 x
10 mL), and brine (10 mL).

The organic solution was dried over Na2SO4 and

concentrated in vacuo to yield 51 (20 mg, 41%) as a purple solid: mp >180 °C. 1H NMR
(300 MHz, CDCl3) δ 7.88 (s, 1 H), 7.48 (s, 1 H), 6.99 (s, 1 H), 6.94 (s, 1 H), 5.98 (s, 2 H),
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4.43 (t, J = 6.7 Hz, 2 H), 3.92 (s, 3 H), 3.85 (s, 3 H), 2.71 (t, J = 6.6 Hz, 2 H), 1.93 (p, J =
6.5 Hz, 2 H).
6-Nitrophthalide (53).76 Phthalide (52, 30.0 g, 224 mmol) was dissolved in 98%
H2SO4 (48 mL) with stirring. A solution of KNO3 (28.0 g, 277 mmol) in 98% H2SO4 (65
mL) was added dropwise to the first solution at 0 °C. The mixture was allowed to stir
with warming to room temperature over 3 h. The the mixture was poured into ice-water
(400 mL). The solids that precipitated were collected by vacuum filtration and washed
with H2O (200 mL).

The solid was recrystallized from EtOAc-hexanes (10:1) and

azeotroped with PhMe (50 mL) to yield 53 (31.3 g, 78%) as a yellow solid. 1H NMR (300
MHz, CDCl3) δ 8.75 (dd, J = 2.0, 0.7 Hz, 1 H), 8.57 (dd, J = 8.4, 2.1 Hz, 1 H), 7.73 (dq, J
= 8.4, 0.8 Hz, 1 H), 5.46 (s, 2 H).
3-Hydroxy-6-nitrophthalide (55). Phthalide 53 (7.0 g, 39 mmol) and NBS (7.0
g, 39 mmol) were suspended in CCl4 (140 mL) with stirring and then benzoyl peroxide
(68 mg) was added. The mixture was heated to reflux with stirring under Argon, and
then it was exposed to the light of a 250 W, 125 V sunlamp located 4” from the flask.
After 2 h the reaction mixture was cooled to room temperature and filtered. The filtrate
was concentrated to yield a yellowish oil. Water (40 mL) was added to the oil and the
mixture was heated to reflux with stirring for 2 h, at which time the solution was nearly
colorless. The solution was then kept at 5 °C for 16 h and then gently shaken one time,
which appeared to initiate crystallization. The mixture was kept at 5 °C for 2 h more and
then filtered to provide 55 as a white crystalline solid intermixed with some yellowish
solid (2.3 g, 30%): mp 160–164 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.60 (dd, J = 8.3
Hz, J = 2.1 Hz, 1 H), 8.49 (d, J = 2.1 Hz, 1 H), 7.96 (d, J = 8.3 Hz, 1 H), 6.82 (s, 1 H).
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3-Nitroindeno[1,2-c]isochromene-5,11-dione (57).59 Phthalide (52, 0.9 g, 6.7
mmol) and 3-hydroxyphthalide 55 (1.3 g, 6.7 mmol) were stirred as a suspension in
EtOAc (25 mL) and a NaOMe in MeOH solution (0.8 g Na dissolved in 50 mL MeOH)
was added. The mixture was heated to reflux with stirring, and after 19 h an additional
portion of phthalide (52, 0.3 g, 2.2 mmol) was added. After 39 h the reaction mixture was
cooled to room temperature and acidified with 37% HCl (~2 mL) to pH 1. The mixture
was concentrated in vacuo and azeotroped once with PhMe (30 mL). Acetic anhydride
(60 mL) was added to the residue, and the mixture was heated to reflux for 29 h. The
mixture was filtered and concentrated, and the residue was dissolved in CHCl3 (80 mL)
and washed with saturated NaHCO3 solution (1 x 40 mL) and H2O (2 x 40 mL). The
organic solution was concentrated to ~5 mL, loaded onto a silica gel column and purified
by flash chromatography (CHCl3, 13 cm x 2 cm, 25 mL fractions). The impure, productcontaining fractions were concentrated to ~5 mL, hexanes (1 mL) were added, and the
mixture was filtered. The residue was resuspended in EtOAc (20 mL) and filtered to
provide 57 as a bright orange solid (224 mg, 11%): mp 271–274 °C. 1H NMR (300 MHz,
DMSO-d6) δ 8.81 (d, J = 2.4, 1 H), 8.69 (dd, J = 8.8 Hz, 2.5 Hz, 1 H), 8.40 (d, J = 2.4 Hz,
1 H), 7.73 – 7.55 (m, 4 H); EIMS m/z (rel intensity) 293 (MH+, 100).
ß-D-Glucopyranosyl Methylamine (80). PtO2·H2O (36 mg) was added to a
stirring solution of ß-D-glucopyranosyl nitromethane (79, 309 mg, 1.38 mmol) in MeOH
(20 mL) and H2O (5 mL) in a 50 mL oven-dried flask, which was then stoppered by a
rubber septum. The system was flushed with argon and evacuated using a high-vacuum
pump, and this cycle was repeated twice more. A balloon containing H2 gas was affixed
and the mixture was allowed to stir at room temperature under the H2 atmosphere for 18 h.
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The mixture was filtered and the residue washed with MeOH (5 mL). The filtrate was
concentrated in vacuo to provide 80 as a colorless oil that solidified upon standing as a
white solid (225 mg, 84%): mp 157–160 °C. 1H NMR (300 MHz, CD3OD) δ 3.86 (dd, J
= 11.9 Hz, 2.0 Hz, 1 H), 3.60 (dd, J = 11.9 Hz, 6.1 Hz, 1 H), 3.38 – 2.96 (m, 7 H), 2.66
(dd, J = 13.3 Hz, 7.4 Hz, 1 H); ESIMS m/z (rel intensity) 192 [(M-H+)-, 92].
(2'RS)-5,6-Dihydro-6-(2',3'-dihydroxypropyl)-2,3-dimethoxy-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline

(84).

Racemic

3-

aminopropane-1,2-diol (81, 43 mg, 0.47 mmol) was dissolved in MeOH (1 mL) and the
obtained solution was added to a stirring solution of lactone 9 (66 mg, 0.19 mmol) in
CHCl3 (25 mL). The reaction mixture was heated at reflux with stirring for 18 h. The
product precipitated and was collected by filtration of the cooled reaction mixture. The
residue was dried by evaporation of solvents in vacuo to provide compound 84 as a
purple solid (56 mg, 69%): mp 323 C (dec). IR 3588, 2980, 1657, 1647, 1530, 1501,
1421, 1053 cm-1; 1H NMR (DMSO-d6) δ 7.89 (s, 1 H), 7.63 (s, 1 H), 7.46 (s, 1 H), 7.03 (s,
1 H), 6.14 (d, J = 1.5 Hz, 2 H), 5.11 (d, J = 5.0 Hz, 1 H), 5.00 (t, J = 5.3 Hz, 1 H), 4.54–
4.27 (m, 2 H), 3.97–3.88 (m, 1 H), 3.88 (s, 3 H), 3.83 (s, 3 H), 3.53 (t, J = 5.1 Hz, 2 H),
MALDI m/z (rel intensity) 426 (MH+, 27); HREIMS m/z calcd for C22H19NO8 425.1111
(M+), found 425.1108; HPLC purity: 99.16% (90% MeOH, 10% H2O).
(2'S)-5,6-Dihydro-6-(2',3'-dihydroxypropyl)-2,3-dimethoxy-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (85). (S)-3-Aminopropane1,2-diol (82, 35 mg, 0.38 mmol) was dissolved in MeOH (1 mL), and the obtained
solution was added to a stirring solution of lactone 9 (55 mg, 0.16 mmol) in CHCl3 (25
mL). The reaction mixture was heated at reflux with stirring for 18 h. The product
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precipitated and was collected by filtration of the cooled reaction mixture. The residue
was dried by evaporation of solvents in vacuo to yield compound 85 as a purple solid (50
mg, 73%): mp 315–318 C (dec). IR 3369, 2926, 1696, 1655, 1628, 1560, 1497, 1396,
1305 cm-1; 1H NMR (DMSO-d6) δ 7.90 (s, 1 H), 7.65 (s, 1 H), 7.48 (s, 1 H), 7.04 (s, 1 H),
6.16 (d, J = 1.8 Hz, 2 H), 5.12 (d, J = 5.1 Hz, 1 H), 5.00 (t, J = 5.2 Hz, 1 H), 4.56-4.29 (m,
2 H), 3.99-3.90 (m, 1 H), 3.90 (s, 3 H), 3.85 (s, 3 H), 3.55 (t, J = 5.1 Hz, 2 H), MALDI
m/z (rel intensity) 426 (MH+, 100); HRESIMS m/z calcd for C22H20NO8 426.1189 (MH+),
found 426.1202; HPLC purity: 98.51% (90% MeOH, 10% H2O).
(2'R)-5,6-Dihydro-6-(2',3'-dihydroxypropyl)-2,3-dimethoxy-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (86). (R)-3-Aminopropane1,2-diol (83, 54 mg, 0.59 mmol) was dissolved in MeOH (1 mL), and the obtained
solution was added to a stirring solution of lactone 9 (64 mg, 0.18 mmol) in CHCl3 (25
mL). The reaction mixture was heated at reflux with stirring for 26 h. The product
precipitated and was collected by filtration of the cooled reaction mixture. The residue
was dried by evaporation of solvents in vacuo to furnish compound 86 as a purple solid
(58 mg, 76%): mp 321 C (dec). IR 3463, 2925, 1694, 1629, 1555, 1509, 1389, 1205,
1046 cm-1; 1H NMR (DMSO-d6) δ 7.88 (s, 1 H), 7.62 (s, 1 H), 7.46 (s, 1 H), 7.02 (s, 1 H),
6.15 (d, J = 1.7 Hz, 2 H), 5.11 (d, J = 5.1 Hz, 1 H), 5.00 (t, J = 5.4 Hz, 1 H), 4.53–4.27
(m, 2 H), 3.96–3.89 (m, 1 H), 3.89 (s, 3 H), 3.84 (s, 3 H), 3.54 (t, J = 5.1 Hz, 2 H),
MALDI m/z (rel intensity) 426 (MH+, 71); HREIMS m/z calcd for C22H19NO8 425.1111
(M+), found 425.1119; HPLC purity: 99.39% (90% MeOH, 10% H2O).
(2'R,3'S,4'R)-5,6-Dihydro-6-(2',3',4',5'-tetrahydroxypentyl)-2,3-dimethoxy8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (87). D-Arabitylamine
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(60, 69 mg, 0.46 mmol) was dissolved in MeOH (15 mL) and H2O (0.5 mL) and the
obtained solution was added to a stirring solution of lactone 9 (51 mg, 0.14 mmol) in
CHCl3 (20 mL). The reaction mixture was heated at reflux with stirring for 48 h. The
product precipitated and was collected by filtration of the cooled reaction mixture. The
residue was washed with MeOH (10 mL) and CHCl3 (10 mL), and dried in vacuo.
Compound 87 was obtained as a purple solid (54 mg, 79%): mp 318–319 C (dec). IR
3365, 2912, 1697, 1656, 1646, 1575, 1554, 1462, 1050 cm-1; 1H NMR (DMSO-d6) δ 7.93
(s, 1 H), 7.80 (s, 1 H), 7.50 (s, 1 H), 7.05 (s, 1 H), 6.16 (d, J = 3.5 Hz, 2 H), 4.99 (d, J =
6.7 Hz, 1 H), 4.83 (d, J = 5.8 Hz, 1 H), 4.50 (d, J = 5.7 Hz, 1 H), 4.47-4.36 (m, 3 H), 3.91
(s, 3 H), 3.85 (s, 3 H), APCIMS m/z (rel intensity) 486 (MH+, 64); HRESIMS m/z calcd
for C24H24NO10 486.1400 (MH+), found 486.1396; HPLC purity: 98.43% (90% MeOH,
10% H2O).
(2'S,3'S,4'R)-5,6-Dihydro-6-(2',3',4',5'-tetrahydroxypentyl)-2,3-dimethoxy8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (88). D-Ribitylamine
(63, 74 mg, 0.49 mmol) was dissolved in MeOH (15 mL) and H2O (0.5 mL), and the
obtained solution was added to a stirring solution of lactone 9 (76 mg, 0.22 mmol) in
CHCl3 (20 mL). The reaction mixture was heated at reflux with stirring for 18 h, at
which time additional D-ribitylamine (39 mg, 0.26 mmol) dissolved in MeOH (1 mL)
and H2O (3 drops) was added. After 48 h, the product precipitated and was collected by
filtration of the cooled reaction mixture. The residue was washed with MeOH (10 mL)
and CHCl3 (10 mL), and dried in vacuo. Compound 88 was obtained as a purple solid
(74 mg, 69%): mp 307–310 C (dec). IR 3312, 1746, 1676, 1581, 1500, 1409, 1221, 969
cm-1; 1H NMR (DMSO-d6) δ 7.93 (s, 1 H), 7.80 (s, 1 H), 7.50 (s, 1 H), 7.05 (s, 1 H), 6.16
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(d, J = 3.5 Hz, 2 H), 4.99 (d, J = 6.7 Hz, 1 H), 4.83 (d, J = 5.8 Hz, 1 H), 4.50 (d, J = 5.7
Hz, 1 H), 4.47-4.36 (m, 3 H), 3.91 (s, 3 H), 3.85 (s, 3 H), MALDI m/z (rel intensity) 486
(MH+, 100); HREIMS m/z calcd for C24H23NO10 485.1322 (M+), found 485.1330; HPLC
purity: 97.39% (90% MeOH, 10% H2O).
(2'R,3'R,4'R)-5,6-Dihydro-6-(2’,3’,4’,5’-tetrahydroxypentyl)-2,3-dimethoxy8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (89). D-Lyxitylamine
(66, 72 mg, 0.48 mmol) was dissolved in MeOH (15 mL) and H2O (1 mL) and the
obtained solution was added to a stirring solution of lactone 9 (68 mg, 0.19 mmol) in
CHCl3 (20 mL). The reaction mixture was heated at reflux with stirring for 40 h. The
product precipitated and was collected by filtration of the cooled reaction mixture. The
residue was washed with MeOH (10 mL) and CHCl3 (10 mL), and dried in vacuo.
Compound 89 was obtained as a purple solid (64 mg, 69%): mp 305–309 C (dec). IR
3212, 2899, 1701, 1632, 1552, 1530, 1499, 1261, 1087 cm-1; 1H NMR (DMSO-d6) δ 7.91
(s, 1 H), 7.65 (s, 1 H), 7.48 (s, 1 H), 7.04 (s, 1 H), 6.16 (d, J = 6.1 Hz, 2 H), 5.05 (d, J =
5.5 Hz, 1 H), 4.85 (d, J = 6.1 Hz, 1 H), 4.74-4.35 (m, 2 H), 4.33 (d, J = 6.4 Hz, 1 H), 4.00
(s, 1 H), 3.90 (s, 3 H), 3.85 (s, 3 H), 3.71-3.57 (m, 2 H), 3.54-3.42 (m, 1 H), MALDI m/z
(rel intensity) 486 (MH+, 100); HRESIMS m/z calcd for C24H24NO10 486.1400 (MH+),
found 486.1401; HPLC purity: 96.04% (90% MeOH, 10% H2O).
(2'S,3'R,4'R)-5,6-Dihydro-6-(2',3',4',5'-tetrahydroxyhexyl)-2,3-dimethoxy8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinolone (90). D-Xylitylamine
(69, 65 mg, 0.43 mmol) was dissolved in MeOH (15 mL) and H2O (3 mL) and the
obtained solution was added to a stirring solution of lactone 9 (70 mg, 0.20 mmol) in
CHCl3 (20 mL). The reaction mixture was heated at reflux with stirring for 16 h, at
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which time additional D-xylitylamine (93 mg, 0.62 mmol) was added as a solution in
MeOH (2 mL) and H2O (5 drops). After stirring and heating the reaction at reflux for 16
h, the product precipitated from the product solution and was collected by filtration of the
cooled reaction mixture. The residue was washed with MeOH (10 mL) and CHCl3 (10
mL), and dried in vacuo. Compound 90 was obtained as a dark purple solid (68 mg,
70%): mp 310 C (dec). IR 3272, 2967, 1700, 1651, 1608, 1476, 1430, 1030 cm-1; 1H
NMR (DMSO-d6) δ 7.87 (s, 1 H), 7.76 (s, 1 H), 7.45 (s, 1 H), 7.02 (s, 1 H), 6.14 (s, 2 H),
5.00 (d, J = 5.0 Hz, 1 H), 4.90 (d, J = 5.4 Hz, 1 H), 4.64-4.46 (m, 4 H), 3.89 (s, 3 H), 3.83
(s, 3 H), 3.66-3.51 (m, 5 H), MALDI m/z (rel intensity) 486 (MH+, 100); HRESIMS m/z
calcd for C24H24NO10 486.1400 (MH+), found 486.1409; HPLC purity: 98.33% (90%
MeOH, 10% H2O).
(2'S,3'R,4'S,5'R)-5,6-Dihydro-6-(2',3',4',5',6'-pentahydroxyhexyl)-2,3dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (91). DGalactitylamine (72, 84 mg, 0.46 mmol) was dissolved in MeOH (15 mL) and H2O (0.25
mL) and the obtained solution was added to a stirring solution of lactone 9 (74 mg, 0.21
mmol) in CHCl3 (20 mL). The reaction mixture was heated at reflux with stirring for 72
h. The product precipitated and was collected by filtration of the cooled reaction mixture.
The residue was washed with MeOH (10 mL) and CHCl3 (10 mL), and dried in vacuo.
Compound 91 was obtained as a purple solid (84 mg, 78%): mp 300 C (dec). IR 3315,
2938, 1605, 1506, 1551, 1535, 1511, 1386, 1084 cm-1; 1H NMR (300 MHz, DMSO-d6) δ
7.91 (s, 1 H), 7.80 (s, 1 H), 7.48 (s, 1 H), 7.03 (s, 1 H), 6.15 (d, J = 4.0 Hz, 2 H), 4.95 (d,
J = 4.0 Hz, 1 H), 4.75 (d, J = 5.8 Hz, 1 H), 4.54-4.24 (m, 4 H), 4.20 (d, J = 6.6 Hz, 1 H),
4.14-4.06 (m, 1 H), 3.90 (s, 3 H), 3.84 (s, 3 H), 3.77 (d, J = 6.6 Hz, 1 H), 3.59-3.37 (m, 2
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H), MALDI m/z (rel intensity) 516 (MH+, 100); HRCIMS m/z calcd for C25H26NO11
516.1506 (MH+), found 516.1501; HPLC purity: 100% (90% MeOH, 10% H2O).
(2'S,3'R,4'R,5'R)-5,6-Dihydro-6-(2',3',4',5',6'-pentahydroxyhexyl)-2,3dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinolone (92). DGlucamine (75, 130 mg, 0.72 mmol) was dissolved in MeOH (15 mL) and H2O (0.5 mL)
and the obtained solution was added to a stirring solution of lactone 9 (87 mg, 0.25 mmol)
in CHCl3 (20 mL). The reaction mixture was heated at reflux with stirring for 72 h. The
product precipitated and was collected by filtration of the cooled reaction mixture. The
residue was washed with MeOH (10 mL) and CHCl3 (10 mL), and dried in vacuo.
Compound 92 was obtained as a dark purple solid (135 mg, 100%): mp 289 C (dec). IR
3274, 2903, 1706, 1618, 1514, 1468, 1390, 1350, 1262, 1098 cm-1; 1H NMR (DMSO-d6)
δ 7.89 (s, 1 H), 7.75 (s, 1 H), 7.46 (s, 1 H), 7.02 (s, 1 H), 6.15 (s, 2 H), 5.11 (m, 1 H),
4.91 (m, 1 H), 4.59-4.47 (m, 6 H), 4.10 (m, 2 H), 3.89 (s, 3 H), 3.84 (s, 3 H), 3.57 (m, 4
H), APCIMS m/z (rel intensity) 516 (MH+, 100); HRESIMS m/z calcd for C25H26NO11
516.1506 (MH+), found 516.1508; HPLC purity: 99.33% (90% MeOH, 10% H2O).
(2'R,3'R,4'R,5'R)-5,6-Dihydro-6-(2',3',4',5',6’-pentahydroxyhexyl)-2,3dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (93).

D-

Mannitylamine (78, 92 mg, 0.51 mmol) was added as a solution in MeOH (5 mL) to a
stirring solution of lactone 9 (112 mg, 0.318 mmol) in CHCl3 (20 mL) and MeOH (10
mL). The reaction mixture was heated at reflux with stirring for 48 h. The product
precipitated from the product solution and was collected by filtration of the cooled
reaction mixture. The residue was washed with MeOH (10 mL) and CHCl3 (10 mL), and
dried in vacuo. Compound 93 was obtained as a dark purple solid (159 mg, 97%): mp
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285 C (dec). IR 3525, 2975, 1703, 1570, 1512, 1465, 1398, 1346, 1250, 1066 cm-1; 1H
NMR (DMSO-d6) δ 7.88 (s, 1 H), 7.80 (s, 1 H), 7.46 (s, 1 H), 7.00 (s, 1 H), 6.15 (d, J =
2.8 Hz, 2 H), 5.23 (d, J = 4.2 Hz, 1 H), 4.94 (d, J = 5.2 Hz, 1 H), 4.67 (d, J = 4.6, 1 H),
4.57-4.44 (m, 3 H), 4.13 (m, 1 H), 3.89 (s, 3 H), 3.84 (s, 3 H), 3.60 (m, 3 H), 3.47 (m, 1
H); MALDI m/z (rel intensity) 516 (MH+, 100); HRESIMS m/z calcd for C25H26NO11
516.1506 (MH+), found 516.1508; HPLC purity: 99.28% (90% MeOH, 10% H2O).
(2'S,3'R,4'R,5'S,6'R)-5,6-Dihydro-6-[(3',4',5'-trihydroxy-6'(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)]-2,3-dimethoxy-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (94). ß-D-Glucopyranosyl
methylamine (80, 59 mg, 0.31 mmol) was added to a stirring solution of lactone 9 (75
mg, 0.21 mmol) in CHCl3 (20 mL) and MeOH (10 mL). The reaction mixture was stirred
and heated at reflux for 20 h, cooled to room temperature, and concentrated in vacuo.
The residue was suspended in CHCl3 (20 mL) and filtered, and then suspended in MeOH
(20 mL), filtered, and dried by evaporation of solvents in vacuo to provide 94 as a purple
solid (70 mg, 63%): mp 324 C (dec). IR 3374, 2913, 1686, 1527, 1495, 1420, 1384,
1245, 1109 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 7.88 (s, 1 H), 7.58 (s, 1 H), 7.46 (s, 1
H), 7.01 (s, 1 H), 6.15 (s, 2 H), 5.44 – 5.37 (m, 1 H), 5.05 (d, J = 4.2 Hz, 1 H), 4.89 (d, J
= 5.1 Hz, 1 H), 4.78 – 4.67 (m, 1 H), 4.53 (s, 1 H), 4.00 – 3.93 (m, 1 H), 3.89 (s, 3 H),
3.84 (s, 3 H); MALDI m/z (rel intensity) 528 (MH+, 100); HRCIMS m/z calcd for
C26H26NO11 528.1506 (MH+), found 528.1484; HPLC purity: 98.80% (90% MeOH, 10%
H2O).
5,6-Dihydro-6-(2-(2-hydroxyethoxy)ethyl)-2,3-dimethoxy-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (103). Lactone 9 (90 mg,
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0.26 mmol) was dissolved with stirring in CHCl3 (35 mL). Amine 95 (81 mg, 0.77 mmol)
was added to the stirring solution, which was then heated to reflux with stirring for 16 h.
The resulting suspension was cooled to room temperature, and the crude mixture was
washed with H2O (3 x 15 mL) and brine (15 mL). The organic layer was dried over
Na2SO4 and concentrated in vacuo. The residue was washed with Et2O (5 mL) to yield
103 (64 mg, 56%) as a purple solid: mp 291–293 °C. 1H NMR [300 MHz, CDCl3 +
CD3OD (5:1)] δ 7.84 (s, 1 H), 7.44 (s, 1 H), 7.12 (s, 1 H), 6.88 (s, 1 H), 5.92 (s, 2 H),
4.49 (t, J = 6.2 Hz, 2 H), 3.86 (s, 3 H), 3.80 (s, 3 H), 3.75 (t, J = 6.3 Hz, 2 H), 3.53 – 3.44
(m, 2 H), 3.46 – 3.38 (m, 2 H); ESIMS m/z (rel intensity) 462 (MNa+, 100); HRESIMS
m/z calcd for C23H21NO8Na 462.1165 (MNa+), found 462.1160; HPLC purity: 99.70%
(90% MeOH, 10% H2O).
5,6-Dihydro-6-(trans-4-hydroxycyclohexyl)-2,3-dimethoxy-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (104). Amine 96 (42 mg,
0.36 mmol) and lactone 9 (62 mg, 0.18 mmol) were suspended in DMF (15 mL). The
mixture was stirred and heated to 120 °C for 2 h and then cooled to room temperature.
H2O (50 mL) was added and product was extracted with CHCl3 (3 x 25 mL). The
combined organic layers were washed with saturated LiCl solution (2 x 25 mL) and brine
(25 mL), dried over Na2SO4, and concentrated in vacuo to yield 104 (13 mg, 16%) as a
purple solid: mp > 400 °C. 1H NMR (300 MHz, CDCl3) δ 8.02 (s, 1 H), 7.60 (s, 1 H),
7.10 (s, 1 H), 6.90 (s, 1 H), 6.11 (s, 2 H), 4.53 – 4.36 (m, 1 H), 4.05 (s, 3 H), 3.98 (s, 3
H), 3.93 – 3.82 (m, 1 H), 3.04 (q, J = 13.3 Hz, 2 H), 2.23 (d, J = 12.7 Hz, 2 H), 1.93 (d, J
= 13.2 Hz, 2 H), 1.51 – 1.40 (m, partially obscured by solvent, 2 H); MALDI m/z (rel
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intensity) 449 (M+, 100); HRESIMS m/z calcd for C25H24NO7 450.1553 (MH+), found
450.1540; HPLC purity: 100% (MeOH, 100).
5,6-Dihydro-6-(tetrahydro-2H-pyran-4-yl)-2,3-dimethoxy-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (105). Amine 97 (19 mg,
0.19 mmol) was dissolved in DMF (1 mL) and added to a stirring suspension of lactone 9
(45 mg, 0.13 mmol) in DMF (5 mL). The mixture was stirred and heated to 100 °C for
24 h and then cooled to room temperature. H2O (20 mL) was added to precipitate the
product and the suspension was filtered. The collected solids were washed with H2O (20
mL) to yield 105 (28 mg, 50%) as a red-violet solid: mp 354 °C (dec). 1H NMR (300
MHz, CDCl3) δ 8.04 (s, 1 H), 7.63 (s, 1 H), 7.11 (s, 1 H), 6.95 (s, 1 H), 6.11 (s, 2 H), 4.76
– 4.64 (m, 1 H), 4.22 (dd, J = 11.4, 3.7 Hz, 2 H), 4.05 (s, 3 H), 3.99 (s, 3 H), 3.56 (t, J =
12.0 Hz, 2 H), 3.26 (dd, J = 12.1, 3.8 Hz, 2 H), 1.81 (d, J = 13.2 Hz, 2 H); MALDI m/z
(rel intensity) 436 (MH+, 100); HPLC purity: 96.98% (MeOH, 100).
(R)-5,6-Dihydro-6-(tetrahydrofuran-3-yl)-2,3-dimethoxy-8,9-methylenedioxy5,11-dioxo-11H-indeno[1,2-c]isoquinoline (106). Amine 98 (21 mg, 0.24 mmol) was
dissolved in DMF (1 mL) and added to a stirring suspension of lactone 9 (55 mg, 0.16
mmol) in DMF (5 mL). The mixture was stirred and heated to 100 °C for 24 h and then
cooled to room temperature. H2O (20 mL) was added to precipitate the product and the
suspension was filtered. The collected solids were washed with H2O (20 mL) to yield
106 (15 mg, 23%) as a blue-violet solid: mp 343–346 °C. 1H NMR (300 MHz, CDCl3) δ
8.04 (s, 1 H), 7.62 (s, 1 H), 7.10 (s, 1 H), 7.07 (s, 1 H), 6.11 (s, 2 H), 5.39 – 5.25 (m, 1
H), 4.48 (q, J = 7.9 Hz, 1 H), 4.31 (t, J = 8.2 Hz, 1 H), 4.27 – 4.10 (m, 2 H), 4.05 (s, 3 H),
3.99 (s, 3 H), 2.75 – 2.64 (m, 1 H), 2.40 – 2.27 (m, 1 H); ESIMS m/z (rel intensity) 422
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(MH+, 18); HRESIMS m/z calcd for C23H20NO7 422.1240 (MH+), found 422.1229;
HPLC purity: 100% (MeOH, 100).
(S)-5,6-Dihydro-6-(tetrahydrofuran-3-yl)-2,3-dimethoxy-8,9-methylenedioxy5,11-dioxo-11H-indeno[1,2-c]isoquinoline (107). Amine 99 (21 mg, 0.24 mmol) was
dissolved in DMF (1 mL) and added to a stirring suspension of lactone 9 (48 mg, 0.14
mmol) in DMF (5 mL). The mixture was stirred and heated to 100 °C for 24 h and then
cooled to room temperature. H2O (20 mL) was added to precipitate the product and the
suspension was filtered. The collected solids were washed with H2O (20 mL) to yield
107 (12 mg, 21%) as a blue-violet solid: mp 343–346 °C. 1H NMR (300 MHz, CDCl3) δ
8.04 (s, 1 H), 7.62 (s, 1 H), 7.10 (s, 1 H), 7.07 (s, 1 H), 6.10 (s, 2 H), 5.40 – 5.24 (m, 1
H), 4.48 (q, J = 8.0 Hz, 1 H), 4.31 (t, J = 8.2 Hz, 1 H), 4.25 – 4.10 (m, 2 H), 4.05 (s, 3 H),
3.98 (s, 3 H), 2.76 – 2.62 (m, 1 H), 2.39 – 2.26 (m, 1 H); ESIMS m/z (rel intensity) 422
(MH+, 100); HRESIMS m/z calcd for C23H20NO7 422.1240 (MH+), found 422.1246;
HPLC purity: 95.73% (MeOH, 100).
5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-6-(oxetan-3-yl)-5,11-dioxo11H-indeno[1,2-c]isoquinoline (108). Amine 100 (15 mg, 0.21 mmol) was dissolved in
DMF (1 mL) and added to a stirring suspension of lactone 9 (43 mg, 0.12 mmol) in DMF
(5 mL). The mixture was stirred and heated to 100 °C for 24 h and then cooled to room
temperature. H2O (20 mL) was added to precipitate the product and the suspension was
filtered. The collected solids were washed with H2O (20 mL) to yield 104 (20 mg, 40%)
as a brownish-purple solid: mp 316–320 °C. 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1 H),
7.61 (s, 1 H), 7.07 (s, 1 H), 6.65 (s, 1 H), 6.09 (s, 2 H), 5.67 (p, J = 7.0 Hz, 1 H), 5.10 (t, J
= 7.3 Hz, 2 H), 4.97 (t, J = 7.4 Hz, 2 H), 4.06 (s, 3 H), 3.99 (s, 3 H); ESIMS m/z (rel
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intensity) 408 (MH+, 31); HRESIMS m/z calcd for C22H18NO7 408.1084 (MH+), found
408.1067; HPLC purity: 97.67% (MeOH, 100).
5,6-Dihydro-6-(piperidin-4-yl)-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo11H-indeno[1,2-c]isoquinoline (109). Amine 101 (32 mg, 0.32 mmol) was dissolved in
DMF (1 mL) and added to a stirring suspension of lactone 9 (76 mg, 0.22 mmol) in DMF
(5 mL). The mixture was stirred and heated to 100 °C for 24 h and then cooled to room
temperature. H2O (20 mL) was added to precipitate the product and the suspension was
filtered. The collected solids were washed with H2O (20 mL) to yield 109 (33 mg, 35%)
as a purple solid: mp 289 °C (dec). 1H NMR (300 MHz, CDCl3) δ 8.02 (s, 1 H), 7.61 (s, 1
H), 7.09 (s, 1 H), 7.02-6.92 (m, 1 H), 6.10 (s, 2 H), 4.67-4.47 (m, 1 H), 4.04 (s, 3 H), 3.98
(s, 3 H), 3.35 (d, J = 12.6 Hz, 2 H), 3.13 – 2.92 (m, 2 H), 2.77 (t, J = 12.3 Hz, 2 H), 1.88
(d, J = 12.5 Hz, 2 H); MALDI m/z (rel intensity) 435 (MH+, 100); HRESIMS m/z calcd
for C24H23N2O6 435.1557 (MH+), found 435.1567; HPLC purity: 95.24% (0.1% TFA in
MeOH, 100).
5,6-Dihydro-6-(1-methylpiperidin-4-yl)-2,3-dimethoxy-8,9-methylenedioxy5,11-dioxo-11H-indeno[1,2-c]isoquinoline (110). Amine 102 (34 mg, 0.30 mmol) was
dissolved in DMF (1 mL) and added to a stirring suspension of lactone 9 (69 mg, 0.20
mmol) in DMF (5 mL). The mixture was stirred and heated to 100 °C for 24 h and then
cooled to room temperature. H2O (20 mL) was added to precipitate the product and the
suspension was filtered. The collected solids were washed with H2O (20 mL) to yield
110 (39 mg, 44%) as a light red-violet solid: mp 305–308 °C (dec). 1H NMR (300 MHz,
CDCl3) δ 8.03 (s, 1 H), 7.62 (s, 1 H), 7.10 (s, 1 H), 7.01 – 6.91 (m, 1 H), 6.11 (s, 2 H),
4.60 – 4.38 (m, 1 H), 4.04 (s, 3 H), 3.98 (s, 3 H), 3.43 – 3.00 (m, 4 H), 2.80 – 1.96 (m, 4
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H), 1.97 – 1.67 (m, 2 H); MALDI m/z (rel intensity) 449 (MH+, 100); HRESIMS m/z
calcd for C25H25N2O6 449.1713 (MH+), found 449.1723; HPLC purity: 95.39% (0.1%
TFA in MeOH, 100).
(2'RS)-5,6-Dihydro-6-(2',3'-dihydroxypropyl)-3-nitro-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (111). Lactone 57 (71 mg, 0.24 mmol) was suspended with
stirring in MeOH (20 mL) at room temperature. A solution of racemic 3-aminopropane1,2-diol (81, 56 mg, 0.62 mmol) in MeOH (2 mL) was added to the stirring suspension,
which was then heated at reflux with stirring for 23 h. The suspension was cooled to
room temperature, filtered, and dried in vacuo to provide 111 as a red solid (55 mg,
63%): mp 272–273 °C. IR 3419, 2923, 1751, 1701, 1648, 1609, 1541, 1420, 1041 cm-1;
1

H NMR (300 MHz, DMSO-d6) δ 8.87 (d, J = 2.5 Hz, 1 H), 8.73 (d, J = 9.0 Hz, 1 H),

8.56 (dd, J = 9.0 Hz, 2.5 Hz, 1 H), 8.15 (d, J = 7.3 Hz, 1 H), 7.66 – 7.49 (m, 4 H), 5.16
(d, J = 5.0 Hz, 1 H), 5.02 (t, J = 5.5 Hz, 1 H), 4.63 – 4.53 (m, 2 H), 4.05 – 3.96 (m, 1 H),
3.61 (t, J = 5.3 Hz, 2 H); negative ion ESIMS m/z (rel intensity) 401/403 (M + Cl-,
100/30); negative ion HRESIMS m/z calcd for C19H13N2O6 365.0774 [(M - H+)-], found
365.0777; HPLC purity: 99.71% (MeOH–H2O, 90:10).
(2'R)-5,6-Dihydro-6-(2',3'-dihydroxypropyl)-3-nitro-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (112). Lactone 57 (71 mg, 0.24 mmol) was suspended with
stirring in MeOH (20 mL) at room temperature. (R)-3-Aminopropane-1,2-diol (83, 52
mg, 0.57 mmol) was added to the stirring suspension, which was then heated at reflux
with stirring for 23 h. The product mixture was absorbed onto silica gel (2 g) and
purified by flash chromatography (SiO2, 100% CHCl3 to 95:5 CHCl3-MeOH, 11 cm x 2
cm, 10 mL fractions).

The impure, product-containing fractions were pooled and
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concentrated. The residue was suspended in CHCl3 (15 mL), filtered, and dried in vacuo
to provide 112 as a yellow-orange solid (31 mg, 35%): mp 226–229 °C (dec). IR 3303,
2929, 1707, 1657, 1624, 1583, 1542, 1497, 1456, 1328, 1034 cm-1; 1H NMR (300 MHz,
DMSO-d6) δ 8.89 (d, J = 2.5 Hz, 1 H), 8.76 (d, J = 9.0 Hz, 1 H), 8.58 (dd, J = 8.9, 2.5 Hz,
1 H), 8.17 (d, J = 7.3 Hz, 1 H), 7.67 – 7.52 (m, 3 H), 5.17 (d, J = 5.0 Hz, 1 H), 5.02 (t, J =
5.5 Hz, 1H), 4.62 – 4.56 (m, 2 H), 4.05 – 3.99 (m, 1 H), 3.61 (t, J = 5.3 Hz, 2 H);
negative ion ESIMS m/z (rel intensity) 401/403 (M + Cl-, 100/33); negative ion
HRESIMS m/z calcd for C19H13N2O6 365.0774 [(M - H+)-], found 365.0777; HPLC
purity: 99.71% (MeOH–H2O, 90:10).
(2'R,3'S,4'R)-5,6-Dihydro-6-(2',3',4',5'-tetrahydroxypentyl)-3-nitro-5,11dioxo-11H-indeno[1,2-c]isoquinoline (113). Lactone 57 (77 mg, 0.26 mmol) was
suspended with stirring in CHCl3 (20 mL) and MeOH (15 mL) at room temperature. A
solution of D-arabitylamine (60, 97 mg, 0.64 mmol) in H2O (0.5 mL) was added to the
stirring suspension, which was then heated at reflux with stirring for 22 h.

The

suspension was cooled to room temperature, filtered, and the residue was washed with
CHCl3 (10 mL) and dried in vacuo to provide 113 as a yellow-brown solid (47 mg, 42%):
mp 252–254 °C (dec). IR 3282, 2928, 1710, 1671, 1648, 1547, 1322, 1203 cm-1; 1H
NMR (300 MHz, DMSO-d6) δ 8.85 (d, J = 2.5 Hz, 1 H), 8.71 (d, J = 8.9 Hz, 1 H), 8.54
(dd, J = 9.0, 2.5 Hz, 1 H), 8.28 (d, J = 7.1 Hz, 1 H), 7.63 – 7.47 (m, 3 H), 4.99 (d, J = 7.4
Hz, 1 H), 4.89 (d, J = 5.8 Hz, 1 H), 4.72 – 4.59 (m, 1 H), 4.55 (d, J = 5.4 Hz, 1 H), 4.50 –
4.38 (m, 2 H), 4.38 – 4.27 (m, 1 H), 3.71 – 3.62 (m, 1 H), 3.60 – 3.41 (m, 2 H); negative
ion ESIMS m/z (rel intensity) 461/463 (M + Cl¯, 69, 31); negative ion HRESIMS m/z
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calcd for C21H17N2O8 425.0985 [(M - H+)-], found 425.0991; HPLC purity: 98.85%
(MeOH–H2O, 90:10).
(2'S,3'S,4'R)-5,6-Dihydro-6-(2',3',4',5'-tetrahydroxypentyl)-3-nitro-5,11dioxo-11H-indeno[1,2-c]isoquinoline (114).

Lactone 57 (38 mg, 0.13 mmol) was

suspended with stirring in MeOH (25 mL) at room temperature. A solution of Dribitylamine (63, 56 mg, 0.37 mmol) in H2O (0.25 mL) was added to the stirring
suspension, which was then heated at reflux with stirring for 72 h. The suspension was
cooled to room temperature, filtered, and the residue was washed with MeOH (2 mL) and
dried in vacuo to provide 114 as a yellow-orange solid (16 mg, 29%): mp 260–262 °C
(dec). IR 3395, 2928, 1669, 1553, 1622, 1507, 1432, 1353, 1262 cm-1; 1H NMR (300
MHz, DMSO-d6) δ 8.93 – 8.86 (m, 2 H), 8.76 (d, J = 9.5 Hz, 1 H), 8.63 – 8.52 (m, 1 H),
8.93 – 8.81 (m, 1 H), 8.34 (d, J = 7.0 Hz, 1 H), 7.70 – 7.49 (m, 2 H), 5.25 (d, J = 4.8 Hz,
1 H), 5.05 (d, J = 5.2 Hz, 1 H), 4.80 (d, J = 5.1 Hz, 1 H), 4.74 – 4.58 (m, 2 H), 4.56 –
4.41 (m, 1 H), 4.29 – 4.15 (m, 1 H), 3.74 – 3.54 (m, 3 H); negative ion ESIMS m/z (rel
intensity) 425 [(M - H+)-, 100]; negative ion HRESIMS m/z calcd for C21H17N2O8
425.0985 [(M - H+)-], found 425.0991; HPLC purity: 99.83% (MeOH–H2O, 90:10).
(2'R,3'R,4'R)-5,6-Dihydro-6-(2',3',4',5'-tetrahydroxypentyl)-3-nitro-5,11dioxo-11H-indeno[1,2-c]isoquinoline (115).

Lactone 57 (70 mg, 0.24 mmol) was

suspended with stirring in MeOH (30 mL) at room temperature. A solution of Dlyxitylamine (66, 75 mg, 0.50 mmol) in H2O (1 mL) was added to the stirring suspension,
which was then heated at reflux with stirring for 21 h. The suspension was cooled to
room temperature, filtered, and dried in vacuo to provide 115 as an orange solid (38 mg,
37%): mp 245 °C (dec). IR 3282, 2929, 1697, 1612, 1561, 1507, 1344, 1121 cm-1; 1H
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NMR (300 MHz, DMSO-d6) δ 8.90 (d, J = 2.5 Hz, 1 H), 8.76 (d, J = 9.0 Hz, 1 H), 8.58
(dd, J = 9.0, 2.5 Hz, 1 H), 8.17 (d, J = 7.3 Hz, 1 H), 7.68 – 7.48 (m, 3 H), 4.84 – 4.55 (m,
2 H), 4.09 (s, 1 H), 3.67 (t, J = 6.3 Hz, 2 H); negative ion ESIMS m/z (rel intensity)
461/463 (M + Cl-, 100, 50); negative ion HRESIMS m/z calcd for C21H18N2O8Cl
461.0751 (M + Cl-), found 461.0761; HPLC purity: 99.65% (MeOH–H2O, 90:10).
(2'S,3'R,4'R)-5,6-Dihydro-6-(2',3',4',5'-tetrahydroxypentyl)-3-nitro-5,11dioxo-11H-indeno[1,2-c]isoquinoline (116).

Lactone 57 (71 mg, 0.24 mmol) was

suspended with stirring in CHCl3 (20 mL) and MeOH (15 mL) at room temperature. A
solution of D-xylitylamine (69, 116 mg, 0.77 mmol) in H2O (0.5 mL) was added to the
stirring suspension, which was then heated at reflux with stirring for 22 h.

The

suspension was cooled to room temperature, filtered, and the residue was washed with
CHCl3 (15 mL) until the filtrate that drained was nearly colorless. The residue was dried
in vacuo to provide 116 as a red-orange solid (48 mg, 47%): mp 205 °C (dec). IR 3467,
2942, 1717, 1655, 1638, 1541, 1329, 1106 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 8.90
(d, J = 2.5 Hz, 1 H), 8.77 (d, J = 9.0 Hz, 1 H), 8.59 (dd, J = 9.0, 2.5 Hz, 1 H), 8.32 (d, J =
7.4 Hz, 1 H), 7.68 – 7.52 (m, 3 H), 5.08 (d, J = 5.1 Hz, 1 H), 4.91 (d, J = 6.2 Hz, 1 H),
4.68 (d, J = 5.3 Hz, 1 H), 4.59 (s, 2 H), 4.14 (s, 1 H), 3.67 (s, 2 H); negative ion ESIMS
m/z (rel intensity) 461/463 (M + Cl-, 100/30); negative ion HRESIMS m/z calcd for
C21H18N2O8Cl 461.0751 (M + Cl-), found 461.0760; HPLC purity: 95.09% (MeOH–H2O,
90:10).
(2'S,3'R,4'S,5'R)-5,6-Dihydro-6-(2',3',4',5',6'-pentahydroxyhexyl)-3-nitro5,11-dioxo-11H-indeno[1,2-c]isoquinoline (117). Lactone 57 (70 mg, 0.24 mmol) was
suspended with stirring in CHCl3 (20 mL) and MeOH (15 mL) at room temperature. A
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solution of D-galactitylamine (72, 130 mg, 0.72 mmol) in H2O (0.5 mL) was added to the
stirring suspension, which was then heated at reflux with stirring for 39 h.

The

suspension was cooled to room temperature, filtered, and the residue was washed with
CHCl3, H2O, and MeOH (10 mL of each), and dried in vacuo to provide 117 as a dull
yellow solid (51 mg, 51%): mp 284–287 °C (dec). IR 3536, 2931, 1624, 1561, 1524,
1332, 1206, 1090 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 8.84 (d, J = 2.5 Hz, 1 H), 8.71
(d, J = 9.0 Hz, 1 H), 8.54 (dd, J = 9.0, 2.5 Hz, 1 H), 8.30 (d, J = 6.6 Hz, 1 H), 7.70 – 7.38
(m, 4 H), 4.95 (d, J = 6.9 Hz, 1 H), 4.83 (d, J = 5.9 Hz, 1 H), 4.65 (d, J = 12.0 Hz, 1 H),
4.55 – 4.40 (m, 3 H), 4.40 – 4.29 (m, 8 H), 4.25 (d, J = 6.5 Hz, 1 H), 4.15 (d, J = 7.2 Hz,
1 H), 3.80 (d, J = 6.4 Hz, 1 H), 3.58 (t, J = 7.1 Hz, 2 H), 3.41 (d, J = 6.1 Hz, 3 H);
negative ion ESIMS m/z (rel intensity) 491/493 (M + Cl-, 100, 42); negative ion
HRESIMS m/z calcd for C22H19N2O9 455.1090 [(M - H+)-], found 455.1094; HPLC
purity: 98.99% (MeOH–H2O, 90:10).
(2'R,3'R,4'R,5'R)-5,6-Dihydro-6-(2',3',4',5',6'-pentahydroxyhexyl)-3-nitro5,11-dioxo-11H-indeno[1,2-c]isoquinoline (118). Lactone 57 (78 mg, 0.27 mmol) was
suspended with stirring in MeOH (30 mL) at room temperature. A solution of Dmannitylamine (78, 108 mg, 0.60 mmol) in H2O (0.5 mL) was added to the stirring
suspension, which was then heated at reflux with stirring for 20 h. The suspension was
cooled to room temperature, filtered, and the residue was washed with CHCl3 (5 mL) and
dried in vacuo to provide 118 as a red-orange solid (66 mg, 54%): mp 279–282 °C (dec).
IR 3210, 2970, 1712, 1638, 1519, 1389, 1348, 1245, 1009 cm-1; 1H NMR (300 MHz,
DMSO-d6) δ 8.90 (d, J = 2.5 Hz, 1 H), 8.76 (d, J = 9.0 Hz, 1 H), 8.58 (dd, J = 8.9, 2.5 Hz,
1 H), 8.15 (d, J = 7.3 Hz, 1 H), 7.71 – 7.50 (m, 3 H), 5.08 (d, J = 5.5 Hz, 1 H), 4.85 (d, J
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= 7.0 Hz, 1 H), 4.80 – 4.77 (m, 1 H), 4.52 (d, J = 4.9 Hz, 1 H), 4.42 (t, J = 5.6 Hz, 1 H),
4.27 (d, J = 7.5 Hz, 1 H), 4.09 (s, 1 H), 3.87 (d, J = 7.5 Hz, 1 H), 3.67 – 3.50 (m, 1 H);
negative ion ESIMS m/z (rel intensity) 491/493 (M + Cl-, 100/30); negative ion
HRESIMS m/z calcd for C22H20N2O9Cl 491.0857 (M + Cl-), found 491.0868; HPLC
purity: 99.64% (MeOH–H2O, 90:10).
(2'S,3'R,4'R,5'S,6'R)-5,6-Dihydro-6-[(3,4,5-trihydroxy-6(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)]-3-nitro-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (119). ß-D-Glucopyranosyl methylamine (80, 95 mg, 0.49
mmol) was added to a stirring suspension of lactone 57 (93 mg, 0.32 mmol) in MeOH (30
mL). The reaction mixture was stirred and heated at reflux for 23 h, cooled to room
temperature, and filtered. The residue was washed with CHCl3 and MeOH (5 mL of
each) and dried in vacuo to provide 119 as a red-orange solid (91 mg, 61%): mp 297–300
C (dec). IR (KBr) 3312, 2944, 1698, 1649, 1622, 1501, 1349, 1210, 683 cm-1; 1H NMR
(300 MHz, DMSO-d6) δ 8.88 (d, J = 2.5 Hz, 1 H), 8.73 (d, J = 9.0 Hz, 1 H), 8.56 (dd, J =
9.0, 2.5 Hz, 1 H), 8.11 (d, J = 7.2 Hz, 1 H), 7.67 – 7.48 (m, 3 H), 5.38 (d, J = 5.4 Hz, 1
H), 5.06 (d, J = 4.5 Hz, 1 H), 4.98 – 4.85 (m, 2 H), 4.71 – 4.55 (m, 1 H), 3.94 (t, J = 5.4
Hz, 1 H), 3.65 – 3.56 (m, 1 H), 3.50 – 3.39 (m, 1 H), 3.20 – 2.91 (m, 3 H); negative ion
ESIMS m/z (rel intensity) 503/505 [(M + Cl-), 100/39]; HRESIMS m/z calcd for
C23H20N2O9Na 491.1067 (M + Na+), found 491.1067; HPLC purity: 99.83% (MeOH–
H2O, 90:10).
1-Azaindeno[1,2-c]isochromene-5,11-dione (121). 3-Hydroxyphthalide 120
(0.57 g, 3.8 mmol) and phthalide (52, 0.51 g, 3.8 mmol) were suspended with stirring in
EtOAc (15 mL).

A solution of freshly prepared methanolic NaOMe, produced by
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dissolving Na (0.45 g, 20 mmol) in MeOH (30 mL), was added to the stirring suspension
and it was heated to reflux for 24 h. After cooling to room temperature, 37% HCl (2 mL)
was added to acidify to pH 1. The mixture was concentrated in vacuo and azeotroped
with PhMe (20 mL). Ac2O (20 mL) was added to the residue and the mixture was heated
to 90–100 °C with stirring for 3 h. The mixture was cooled to room temperature and
Ac2O was removed by azeotroping with PhMe (2 x 10 mL). CHCl3 (100 mL) was added
to the residue and the organic layer was washed with saturated NaHCO3 (3 x 50 mL) and
brine (50 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The
residue was purified by silica gel column chromatography. After concentrating the
mostly pure product-containing fractions, the residue was washed with 50:50 EtOAchexanes (20 mL) to yield 121 (110 mg, 12%) as a yellow-orange solid: mp 296–298 °C.
1

H NMR (300 MHz, CDCl3) δ 9.11 (dd, J = 4.7, 1.9 Hz, 1 H), 8.55 (dd, J = 8.1, 1.8 Hz, 1

H), 7.78 – 7.67 (m, 1 H), 7.59 – 7.49 (m, 3 H), 7.45 (dd, J = 8.1, 4.8 Hz, 1 H).
(2'S)-1-Aza-5,6-dihydro-6-(2',3'-dihydroxypropyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (122). Lactone 121 (54 mg, 0.22 mmol) was suspended with
stirring in CHCl3 (10 mL) and MeOH (2.5 mL). Amine 82 (32 mg, 0.35 mmol) dissolved
in MeOH (0.5 mL) was added to the suspension and it was stirred with heating to reflux
for 17.5 h. The mixture was cooled to room temperature and concentrated in vacuo. H2O
(5 mL) was added and the suspension was filtered to collect solids. Compound 122 (27
mg, 39%) was obtained as a red-orange solid: mp 245–250 °C (dec). 1H NMR (300 MHz,
DMSO-d6) δ 9.00 (dd, J = 4.5, 1.9 Hz, 1 H), 8.50 (dd, J = 8.1, 1.9 Hz, 1 H), 8.14 (d, J =
7.3 Hz, 1 H), 7.67 – 7.42 (m, 4 H), 5.15 (d, J = 5.0 Hz, 1 H), 5.00 (t, J = 5.6 Hz, 1 H),
4.58 (d, J = 6.7 Hz, 2 H), 4.10 – 3.90 (m, 1 H), 3.60 (t, J = 5.4 Hz, 2 H); ESIMS m/z (rel
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intensity) 345 (M + Na+, 100); HRESIMS m/z calcd for C18H14N2O4Na 345.0852 (M +
Na+), found 345.0861; HPLC purity: 100% (MeOH, 100%).
(2'S)-2-Aza-5,6-dihydro-6-(2',3'-dihydroxypropyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (124). Lactone 123 (50 mg, 0.20 mmol) was suspended with
stirring in CHCl3 (10 mL) and MeOH (2.5 mL). Amine 82 (26 mg, 0.29 mmol) dissolved
in MeOH (0.5 mL) was added to the suspension and it was stirred at room temperature
for 2 h and with heating to reflux for 23 h. The mixture was cooled to room temperature
and concentrated in vacuo. H2O (1 mL) was added and the suspension was filtered to
collect solids. Compound 124 (27 mg, 42%) was obtained as a red-orange solid: mp
229–232 °C. 1H NMR (300 MHz, DMSO-d6) δ 9.82 (d, J = 1.0 Hz, 1 H), 8.66 (d, J = 5.3
Hz, 1 H), 8.07 (d, J = 7.4 Hz, 1 H), 8.01 (dd, J = 5.4, 1.0 Hz, 1 H), 7.61 – 7.46 (m, 3 H),
5.14 (d, J = 5.0 Hz, 1 H), 5.01 (t, J = 5.6 Hz, 1 H), 4.60 – 4.46 (m, 2 H), 4.05 – 3.92 (m, 1
H), 3.65 – 3.53 (m, 2 H); CIMS m/z (rel intensity) 323 (MH+, 100); HRESIMS m/z calcd
for C18H15N2O4 323.1032 (MH+), found 323.1045; HPLC purity: 100% (MeOH, 100%).
(2'S)-3-Aza-5,6-dihydro-6-(2',3'-dihydroxypropyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (127). Azaindenoisoquinoline 125 (25 mg, 0.075 mmol) was
suspended with stirring in a solution of KOH (0.3 g, 5 mmol) dissolved in H2O (3 mL)
and MeOH (3 mL). The mixture was heated to reflux with stirring for 15 h, cooled to
room temperature, and concentrated in vacuo. The residue was azeotroped with PhMe (5
mL) to yield an indanedione intermediate. 1H NMR (300 MHz, D2O) δ 8.71 – 8.29 (m, 2
H), 7.66 – 7.14 (m, 6 H). Ac2O (5 mL) was added to the crude intermediate. The mixture
was stirred at room temperature for 1 h, and then with warming to 70 °C for 1 h. After
cooling to room temperature, the mixture was azeotroped to dryness with PhMe (5 mL)
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and the residue was dissolved in CHCl3 (5 mL) and washed with H2O (3 x 1 mL). The
organic solution was dried over MgSO4 and concentrated in vacuo to yield crude lactone
126 (11 mg, 59%). 1H NMR (300 MHz, CDCl3) δ 9.47 – 9.43 (m, 1 H), 8.90 (d, J = 5.4
Hz, 1 H), 8.15 (dd, J = 5.4, 1.0 Hz, 1 H), 7.74 – 7.46 (m, 4 H). Lactone 126 was
suspended with stirring in CHCl3 (1 mL) and a solution of amine 82 (7 mg, 0.08 mmol)
dissolved in MeOH (1 mL) was added. The mixture was stirred at room temperature for
1 h and concentrated in vacuo.

The residue was purified by silica gel column

chromatography, eluting with 95:5 CHCl3-MeOH, to yield 127 (6 mg, 42%) as a yelloworange solid: mp 237–238 °C. 1H NMR (300 MHz, DMSO-d6) δ 9.32 (s, 1 H), 8.79 (d, J
= 5.5 Hz, 1 H), 8.32 (dd, J = 5.5, 0.9 Hz, 1 H), 8.17 (d, J = 7.3 Hz, 1 H), 7.68 – 7.48 (m,
3 H), 5.17 (d, J = 5.0 Hz, 1 H), 5.02 (t, J = 5.6 Hz, 1 H), 4.65 – 4.46 (m, 2 H), 4.07 – 3.93
(m, 1 H), 3.60 (t, J = 5.3 Hz, 2 H); HPLC purity: 100% (MeOH, 100).
(2'S)-4-Aza-5,6-dihydro-6-(2',3'-dihydroxypropyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (129). Lactone 128 (46 mg, 0.18 mmol) was suspended with
stirring in CHCl3 (10 mL) and MeOH (2.5 mL). Amine 82 (21 mg, 0.23 mmol) dissolved
in MeOH (0.5 mL) was added to the suspension and it was stirred at room temperature
for 2 h and with heating to reflux for 23 h. The mixture was cooled to room temperature
and concentrated in vacuo. H2O (1 mL) was added and the suspension was filtered to
collect solids. Compound 129 (27 mg, 45%) was obtained as a yellow-orange solid: mp
247–255 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.90 (dd, J = 8.3, 1.7 Hz, 1 H), 8.78 (dd, J
= 4.3, 1.7 Hz, 1 H), 8.09 (d, J = 7.5 Hz, 1 H), 7.77 (dd, J = 8.3, 4.3 Hz, 1 H), 7.62 – 7.41
(m, 3 H), 5.14 (d, J = 5.0 Hz, 1 H), 5.00 (t, J = 5.6 Hz, 1 H), 4.65 – 4.43 (m, 2 H), 4.09 –
3.94 (m, 1 H), 3.60 (t, J = 5.3 Hz, 2 H); ESIMS m/z (rel intensity) 323 (MH+, 100);
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HRESIMS m/z calcd for C18H15N2O4 323.1032 (MH+), found 323.1038; HPLC purity:
100% (MeOH, 100%).
(2-Bromo-4-fluorophenyl)methanol (145).

Aldehyde 144 (5.014 g, 24.70

mmol) was dissolved in MeOH (50 mL) and the solution was cooled to 0–5 °C. NaBH4
(1.873 g, 49.51 mmol) was added all at once, and the mixture was stirred at 0–5 °C for 1
h, and then at room temperature for 24 h. Saturated NaHCO3 solution (50 mL) was
added to quench the reaction, and the mixture was concentrated in vacuo to remove
MeOH. The resulting suspension was extracted with EtOAc (3 x 75 mL). The combined
organic layers were washed with brine (1 x 50 mL), dried over Na2SO4, and concentrated
in vacuo. The obtained oil was purified by silica gel column chromatography, eluting
with CHCl3, to yield 145 (4.240 g, 84%) as a white solid: mp 63–66 °C. 1H NMR (300
MHz, CDCl3) δ 7.46 (dd, J = 8.6 Hz, J = 6.1 Hz, 1 H), 7.31 (dd, J = 8.2 Hz, J = 2.6 Hz, 1
H), 7.06 (td, J = 8.3 Hz, J = 2.6 Hz, 1 H), 4.72 (d, J = 6.4 Hz, 2 H), 2.02 (t, J = 6.3 Hz, 1
H).
6-Fluorophthalide (146).

(2-Bromo-4-fluorophenyl)methanol (145, 6.720 g,

32.78 mmol) and CuCN (5.891 g, 65.78 mmol) were diluted in DMF (35 mL). The
system was flushed with argon and then heated to reflux with stirring for 2 h 45 min. The
mixture was cooled to 100 C, H2O (3.5 mL) was added, and the mixture was stirred with
heating to reflux for 21 h. EtOAc (75 mL) was added to the reaction mixture once it
cooled to room temperature, and the mixture was filtered through a plug of Celite,
washing with EtOAc (25 mL). Brine (150 mL) was added, the mixture partitioned
between the two phases, and the organic layer was separated. The aqueous layer was
extracted with EtOAc (2 x 70 mL). The combined organic layers were washed with brine
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(2 x 70 mL) and saturated LiCl solution (70 mL), dried over Na2SO4, and concentrated in
vacuo. The residue was purified by silica gel column chromatography, eluting with
CHCl3, to provide 146 (2.945 g, 59%) as an off-white solid: mp 100–105 C. 1H NMR
(300 MHz, CDCl3) δ 7.58 (dd, J = 7.2, 2.3 Hz, 1 H), 7.53 – 7.37 (m, 2 H), 5.32 (s, 2 H);
CIMS m/z (rel intensity) 153 (MH+, 100).
Alternative Method. An oven-dried 500 mL pressure flask with a stir-bar was
charged with benzoic acid 227 (2.01 g, 14.3 mmol), KHCO3 (3.60 g, 36.0 mmol),
Pd(OAc)2 (0.48 mg, 15 mol%), and CH2Br2 (120 mL). The vessel was submerged in a
silicone oil bath to the top level of the reaction mixture and heated to 140 ºC with stirring
for 2 d. The black suspension was concentrated in vacuo. The residue was purified by
silica gel column chromatography (80:20  50:50 hexanes-EtOAc, 13.5 cm x 4 cm) and
the impure product-containing fractions were concentrated in vacuo. The oily residue
was triturated with hexanes (20 mL) and the solids were collected from filtration to yield
146 (0.46 g, 21%) as a faint yellowish-white solid: Rf (SiO2, 50:50 hexanes-EtOAc) 0.48,
mp 100–103 °C. 1H NMR is identical.
3-Bromo-6-fluorophthalide (147).

6-Fluorophthalide (146, 1.001 g, 6.580

mmol), NBS (1.204 g, 6.764 mmol), and AIBN (39 mg) were diluted in CCl 4 (25 mL)
and heated to reflux with stirring under argon for 1 h 30 min. The mixture was cooled to
room temperature, filtered, and the residue was washed with CCl4 (10 mL). The filtrate
was concentrated in vacuo to provide a yellow oil, which was purified by silica gel
column chromatography, eluting with 80:20 hexanes-EtOAc, to provide 147 (1.230 g,
81%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.64 (ddd, J = 8.4, 4.2, 0.7 Hz, 1 H),
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7.56 – 7.44 (m, 2 H), 7.40 (s, 1 H); CIMS m/z (rel intensity) 231/233 (MH+, 6/6); 153
(MH+ – Br, 100).
6-Fluoro-3-hydroxyphthalide (148). Potassium hydroxide (0.542 g, 9.66 mmol)
and H2O (15 mL) were added to 3-bromo-6-fluorophthalide (147, 1.077 g, 4.662 mmol).
The mixture was heated to reflux with stirring for 1 h, cooled to room temperature, and
EtOAc (20 mL) and NaHSO4 (1.8 g) were added. The organic layer was removed, and
the aqueous layer was extracted twice more with EtOAc (2 x 20 mL). The combined
organic layers were washed with brine (20 mL), dried over Na2SO4, and concentrated in
vacuo to yield 148 (0.617 g, 79%) as a white solid: mp 95–97 C. 1H NMR (300 MHz,
DMSO-d6) δ 8.26 (s, 1 H), 7.85 – 7.55 (m, 3 H), 6.66 (s, 1 H); CIMS m/z (rel intensity)
169 (MH+, 13), 151 (MH+ - H2O, 100).
3-Fluoroindeno[1,2-c]isochromene-5,11-dione

(149).

6-Fluoro-3-

hydroxyphthalide (148, 0.582 g, 3.46 mmol) and phthalide (52, 0.479 g, 3.57 mmol) were
suspended in EtOAc (10 mL) and a freshly prepared solution of NaOMe (0.349 g, 15.2
mmol of Na) in MeOH (10 mL) was added. The resulting solution was heated to reflux
with stirring for 18 h. The resulting mixture was cooled to room temperature, acidified to
pH 1 with 37% HCl (3 mL), concentrated in vacuo, and azeotroped with PhMe (10 mL).
Ac2O (20 mL) was added to the residue and the mixture was heated to reflux with stirring
for 1 h. The mixture was cooled to room temperature and hexanes (20 mL) were added.
The mixture was filtered, and the residue was washed with hexanes (20 mL) and H2O (10
mL) to provide 149 (196 mg, 31%) as an orange-red solid: mp 215–218 °C. 1H NMR
(300 MHz, CDCl3) δ 8.39 (dd, J = 8.8, 5.2 Hz, 1 H), 7.95 (dd, J = 8.6, 2.7 Hz, 1 H), 7.65
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– 7.37 (m, 5 H); EIMS m/z (rel intensity) 266 (M+, 100); HREIMS calcd for C16H8FO3
(M+) 266.0374, found 266.0380.
6-Aminophthalide (150). Phthalide 53 (12.0 g, 67.0 mmol) was suspended in
EtOAc (80 mL) and 37% HCl (20 mL). 10% Pd/C (210 mg) was added and the mixture
was shaken on a Parr apparatus under H2 (50 psi) for 2.5 d. The mixture was filtered
through Celite, and the filter cake was washed with dilute HCl (40 mL) and H2O (40 mL).
The filtrates were combined and concentrated in vacuo and azeotroped with PhMe to
yield 150 (11.7 g,) as a yellow solid: mp 220 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ
7.78 – 7.56 (m, 3 H), 5.40 (s, 2 H); CIMS m/z (rel intensity) 150 (MH+, 100).
6-Chlorophthalide (151). 3-Aminophthalide (150, 3.500 g, 23.49 mmol) was
suspended in 37% HCl (25 mL) 0 °C. An ice-cold solution of NaNO2 (1.713 g, 24.83
mmol) in H2O (10 mL) was added dropwise, and the resulting solution was stirred at 0–
5 °C for 10 min. An ice-cold suspension of CuCl (2.91 g, 29.4 mmol) in 37% HCl (10
mL) was added dropwise. The mixture was stirred at room temperature for 10 min, then
at reflux for 3 h, and room temperature for 16 h. The suspension was extracted with
EtOAc (3 x 80 mL), and the combined organic layers were washed with saturated
NaHCO3 solution (1 x 50 mL) and H2O (1 x 50 mL). The organic solution was dried
over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel column
chromatography, eluting with CHCl3, to yield 151 (2.852 g, 72%) as a white solid: mp
106–107 °C. 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 1.9 Hz, 1 H), 7.66 (dd, J = 8.2
Hz, J = 1.9 Hz, 1 H), 7.45 (dd, J = 8.2 Hz, J = 0.8 Hz, 1 H), 5.31 (s, 2 H); CIMS m/z (rel
intensity) 169/171 (MH+, 100/32).
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Alternative Method. An oven-dried 500 mL pressure flask with a stir-bar was
charged with benzoic acid 228 (2.00 g, 12.8 mmol), KHCO3 (3.19 g, 31.9 mmol),
Pd(OAc)2 (0.43 mg, 15 mol%), and CH2Br2 (120 mL). The vessel was submerged in a
silicone oil bath to the top level of the reaction mixture and heated to 140 ºC with stirring
for 2 d. The black suspension was concentrated in vacuo. The residue was purified by
silica gel column chromatography, eluting with CHCl3, to yield 151 (0.93 g, 43%) as a
white solid: Rf (SiO2, 50:50 hexanes-EtOAc) 0.59, mp 107–108 °C. 1H NMR is identical.
6-Bromophthalide (152).

3-Aminophthalide (150, 2.98 g, 20.0 mmol) was

suspended in 48% HBr (15 mL) and H2O (15 mL) at 0 °C. A room temperature solution
of NaNO2 (1.45 g, 21.0 mmol) in H2O (7 mL) was added dropwise, and the resulting
solution was stirred at 0–5 °C for 20 min. A room temperature suspension of CuBr (3.58
g, 25.0 mmol) in 48% HBr (20 mL) was added dropwise. The mixture was stirred at
room temperature for 20 min, at 80 °C for 2 h, and room temperature for 16 h. EtOAc
(70 mL) was added, the suspension shaken vigorously, the aqueous layer removed, and
the organic layer washed with 1 N HCl (2 x 25 mL), saturated NaHCO3 solution (1 x 25
mL), and H2O (2 x 25 mL), and concentrated. The residue was purified by silica gel
column chromatography, eluting with CHCl3, to yield 152 (2.71 g, 64%) as a white solid:
Rf (SiO2, 50:50 hexanes-EtOAc) 0.59, mp 96–98 °C. 1H NMR (300 MHz, CDCl3) δ 8.06
(d, J = 1.7 Hz, 1 H), 7.80 (dd, J = 8.1 Hz, J = 1.8 Hz, 1 H), 7.39 (dd, J = 8.1 Hz, J = 0.7
Hz, 1 H), 5.29 (s, 2 H); CIMS m/z (rel intensity) 213/215 (MH+, 100/100).
6-Iodophthalide (153).

3-Aminophthalide (150, 5.414 g, 36.34 mmol) was

suspended in 37% HCl (25 mL) at 0 °C. An ice-cold solution of NaNO2 (3.027 g, 43.87
mmol) in H2O (8 mL) was added dropwise, and the resulting solution was stirred at 0 °C
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for 25 min. A solution of KI (30.5 g, 184 mmol) in H2O (30 mL) was added dropwise.
The mixture was stirred at room temperature for 18 h. The aqueous suspension was
extracted with EtOAc (3 x 100 mL), and the combined organic layers were washed with
saturated aq Na2S2O3 (2 x 100 mL) and brine (50 mL), dried over Na2SO4, and
concentrated in vacuo. The residue was purified by silica gel column chromatography,
eluting with CHCl3, to provide 153 (5.973 g, 63%) as an off-white solid: Rf (SiO2, 50:50
hexanes-EtOAc) 0.59, mp 87–90 °C. 1H NMR (300 MHz, CDCl3) δ 8.26 (dd, J = 1.5 Hz,
J = 0.7 Hz, 1 H), 7.99 (dd, J = 8.0 Hz, J = 1.5 Hz, 1 H), 7.29 (d, J = 0.8 Hz, 1 H), 5.28 (s,
2 H); CIMS m/z (rel intensity) 261 (MH+, 100).
6-Cyanophthalide (154). 3-Aminophthalide (150, 1.100 g, 7.375 mmol) was
suspended in 37% HCl (2 mL) and H2O (12 mL) at 0 °C. An ice-cold solution of NaNO2
(691 mg, 10.0 mmol) in H2O (2 mL) was added dropwise, and the resulting mixture was
added dropwise to a prepared solution of CuCN (804 mg, 9.00 mmol) and NaCN (1.240
g, 25.30 mmol) in H2O (10 mL) stirring at 0 °C. The mixture was stirred with warming
to room temperature for 3.5 h, and then filtered through a plug of Celite (2 cm height)
which was then washed with EtOAc (50 mL). The aqueous layer of the filtrate was
extracted with EtOAc (50 mL), and the combined organic layers were washed with brine
(25 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by
silica gel column chromatography, eluting with a 50:50 EtOAc-hexanes  80:20 EtOAchexanes gradient, to provide 154 (498 mg, 42%) as a yellow solid: mp 185–190 °C. 1H
NMR (300 MHz, CDCl3) δ 8.23 (s, 1 H), 7.97 (dd, J = 7.9, 1.5 Hz, 1 H), 7.67 (dq, J =
7.9, 0.9 Hz, 1 H), 5.41 (s, 2 H).
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6-Chloro-3-hydroxyphthalide (159). 6-Chlorophthalide (151, 2.786 g, 16.58
mmol), NBS (2.962 g, 16.64 mmol), and benzoyl peroxide (33 mg) were suspended in
CCl4 (22 mL). The mixture was heated to reflux with stirring under an argon atmosphere
for 1 h, cooled to room temperature, and filtered. The residue was washed with CCl4 (2 x
20 mL) and the filtrate was concentrated in vacuo. H2O (25 mL) and KOH (1.88 g, 33.5
mmol) were added to the obtained yellow oil, and the mixture was heated to reflux with
stirring for 1 h. After cooling to room temperature, the mixture was acidified with
NaHSO4 (1.9 g) and extracted with EtOAc (3 x 50 mL). The combined organic layers
were dried over Na2SO4 and concentrated in vacuo to provide 159 (2.60 g, 85%) as a
white solid: mp 111–116 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.29 (d, J = 7.4 Hz, 1 H),
7.98 – 7.77 (m, 2 H), 7.77 – 7.59 (m, 1 H), 6.67 (d, J = 8.2 Hz, 1 H); CIMS m/z (rel
intensity) 185/187 (MH+, 15/4), 167/169 (MH+ - H2O, 100/47).
6-Bromo-3-hydroxyphthalide (160).

6-Bromophthalide (152, 2.69 g, 12.6

mmol), NBS (2.25 g, 12.6 mmol), and benzoyl peroxide (30 mg) were suspended in CCl4
(15 mL). The mixture was heated to reflux with stirring under an argon atmosphere for
50 min, cooled to room temperature, and filtered. The residue was washed with CCl4 (2
x 10 mL) and the filtrate was concentrated in vacuo. H2O (25 mL), THF (10 mL), and
KOH (1.409 g, 25.11 mmol) were added to the obtained yellow oil, and the mixture was
heated to reflux with stirring for 1 h. After cooling to room temperature, the mixture was
acidified with NaHSO4 (1.9 g) and extracted with EtOAc (3 x 50 mL). The combined
organic layers were dried over Na2SO4 and concentrated in vacuo to provide 160 (2.78 g,
96%) as a white solid: mp 118–120 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.28 (d, J =
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7.0 Hz, 1 H), 8.06 – 7.92 (m, 2 H), 7.64 (dd, J = 7.9 Hz, J = 3.9 Hz, 1 H), 6.65 (d, J = 7.6
Hz, 1 H).
3-Hydroxy-6-iodophthalide (161). 6-Iodophthalide (153, 0.806 g, 3.10 mmol),
NBS (0.553 g, 3.11 mmol), and benzoyl peroxide (23 mg) were suspended in CCl4 (15
mL). The mixture was heated to reflux with stirring under an argon atmosphere for 2.5 h,
cooled to room temperature, and filtered. The residue was washed with CCl4 (2 x 20 mL)
and the filtrate was concentrated in vacuo. H2O (25 mL) and KOH (0.34 g, 6.1 mmol)
were added to the obtained yellow oil, and the mixture was heated to reflux with stirring
for 3.5 h. After cooling to room temperature, the mixture was acidified with NaHSO4
(2.0 g) and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried
over Na2SO4 and concentrated in vacuo to provide 161 (0.954 g, 96%) as a white solid:
mp 127–130 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.26 (d, J = 7.0 Hz, 1 H), 8.19 – 8.09
(m, 2 H), 7.49 (d, J = 7.8 Hz, 1 H), 6.63 (d, J = 7.6 Hz, 1 H); CIMS m/z (rel intensity)
277 (MH+, 8), 259 (MH+ - H2O), 100.
6-Cyano-3-hydroxyphthalide (162).

6-Cyanophthalide (154, 802 mg, 5.04

mmol), NBS (990 mg, 5.56 mmol), and AIBN (57 mg) were suspended in CCl4 (50 mL).
The mixture was heated to reflux with stirring under an argon atmosphere for 2 h, cooled
to room temperature, and concentrated in vacuo. The residue was purified by flash silica
gel column chromatography (10 cm x 3 cm, 80:20 hexanes-EtOAc 50:50 hexanes-EtOAc,
10 mL fractions). The product-containing fractions were pooled and concentrated in
vacuo to yield a solid residue. H2O (15 mL) was added to the solid, and the mixture was
heated to reflux with stirring for 18 h. The product 162 (408 mg, 46%) precipitated from
solution upon cooling to room temperature as a yellowish-white solid: mp 167–169 °C
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(lit.37 mp 138–140 °C). 1H NMR (300 MHz, DMSO-d6) δ 8.43 (s, 1 H), 8.39 (s, 1 H),
8.24 (dd, J = 7.9, 1.4 Hz, 1 H), 7.89 (d, J = 7.9 Hz, 1 H), 6.77 (s, 1 H).
3-Chloroindeno[1,2-c]isochromene-5,11-dione

(163).

6-Chloro-3-

hydroxyphthalide (159, 2.437 g, 13.24 mmol) and phthalide (52, 1.779 g, 13.28 mmol)
were suspended in EtOAc (20 mL) and a freshly prepared solution of NaOMe (1.16 g,
50.4 mmol of Na) in MeOH (40 mL) was added. The resulting solution was heated to
reflux with stirring under an argon atmosphere for 23 h. The resulting mixture was
cooled to room temperature, acidified to pH 1 with 37% HCl (4.5 mL), concentrated in
vacuo, and azeotroped with PhMe (1 x 25 mL). Ac2O (75 mL) was added to the residue
and the mixture was heated to reflux with stirring under an argon atmosphere for 21 h.
After cooling to room temperature, the mixture was concentrated in vacuo, the residue
taken up in CHCl3 (100 mL), and the organic solution washed with H2O (3 x 30 mL).
The organic solution was dried over Na2SO4 and concentrated in vacuo. The residue was
washed with 70:30 hexanes-EtOAc (3 x 30 mL) to provide 163 (2.009 g, 54%) as an
orange solid: mp 244–246 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.24 – 8.14 (m, 2 H),
7.98 (dd, J = 8.5 Hz, J = 2.3 Hz, 1 H), 7.70 – 7.48 (m, 4 H); CIMS m/z (rel intensity)
283/285 (MH+, 100/36); HRCIMS calcd for C16H8ClO3 (MH+) 283.0162, found 283.0153.
3-Bromoindeno[1,2-c]isochromene-5,11-dione

(164).

6-Bromo-3-

hydroxyphthalide (160, 2.52 g, 11.0 mmol) and phthalide (52, 1.47 g, 11.0 mmol) were
suspended in EtOAc (20 mL) and a freshly prepared solution of NaOMe (0.91 g, 40
mmol of Na) in MeOH (40 mL) was added. The resulting solution was heated to reflux
with stirring under an argon atmosphere for 72 h. The resulting mixture was cooled to
room temperature, acidified to pH 1 with 37% HCl (4 mL), concentrated in vacuo, and
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azeotroped with PhMe (1 x 25 mL). Ac2O (50 mL) was added to the residue and the
mixture was heated to reflux with stirring under an argon atmosphere for 17 h. After
cooling to room temperature, H2O (30 mL) and CHCl3 (50 mL) were added and the
mixture was filtered to obtain some product. The filtrate was washed with H2O (2 x 20
mL) and brine (1 x 20 mL), concentrated in vacuo, and azeotroped with PhMe (2 x 10
mL) to provide additional product. The combined crude products were washed with
CHCl3 (2 x 30 mL) and EtOAc (1 x 30 mL) to provide 160 (1.920 g, 53%) as an orange
solid: mp 236–238 °C (lit.99 mp 230–232 °C). 1H NMR (300 MHz, DMSO-d6) δ 8.26 (d,
J = 1.6 Hz, 1 H), 8.13 – 8.08 (m, 2 H), 7.64 – 7.48 (m, 4 H); CIMS m/z (rel intensity)
327/329 (MH+, 100/96), 248 (MH+ – Br, 77).
3-Iodoindeno[1,2-c]isochromene-5,11-dione (165). 3-Hydroxy-6-iodophthalide
(161, 0.465 g, 1.68 mmol) and phthalide (52, 0.232 g, 1.73 mmol) were suspended in
EtOAc (10 mL) and a freshly prepared solution of NaOMe (0.19 g, 8.3 mmol of Na) in
MeOH (10 mL) was added. The resulting solution was heated to reflux with stirring for
27 h. The resulting mixture was cooled to room temperature, acidified to pH 1 with 37%
HCl (1.5 mL), concentrated in vacuo, and azeotroped with PhMe (15 mL). Ac2O (20 mL)
was added to the residue and the mixture was heated to reflux with stirring for 4 h. The
mixture was concentrated in vacuo, the residue taken up in CHCl3 (30 mL), and the
organic layer washed with H2O (2 x 15 mL). The organic solution was dried over
Na2SO4 and concentrated in vacuo. The crude product was washed with 80:20 hexanesEtOAc (2 x 10 mL) to provide 165 (196 mg, 31%) as an orange-red solid: mp 199–201°C.
1

H NMR (300 MHz, DMSO-d6) δ 8.43 (d, J = 1.8 Hz, 1 H), 8.24 (dd, J = 8.3 Hz, J = 1.9
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Hz, 1 H), 7.97 (d, J = 8.3 Hz, 1 H), 7.64 – 7.48 (m, 4 H); CIMS m/z (rel intensity) 375
(MH+, 100); HRCIMS calcd for C16H8IO3 (MH+) 374.9518, found 374.9512.
3-Cyanoindeno[1,2-c]isochromene-5,11-dione

(166).

6-Cyano-3-

hydroxyphthalide (162, 404 mg, 2.31 mmol) and phthalide (52, 318 mg, 2.37 mmol) were
suspended in EtOAc (10 mL) and a freshly prepared solution of NaOMe (0.20 g, 8.7
mmol of Na) in MeOH (20 mL) was added. The resulting solution was heated to reflux
with stirring for 17.5 h. The resulting mixture was cooled to room temperature, acidified
to pH 1 with 37% HCl (1 mL), concentrated in vacuo, and azeotroped with PhMe (2 x 10
mL). Ac2O (20 mL) was added to the residue and the mixture was heated to reflux with
stirring for 18.5 h. The resulting mixture was azeotroped with PhMe (4 x 10 mL) to
remove the solvents. The residue was purified by silica gel column chromatography,
eluting with CHCl3, to provide an oil, which was triturated with hexanes (10 mL) and
filtered to collect a solid. Lactone 166 (225 mg, 36%) was obtained as a yellow-orange
solid: mp 215–218 °C. 1H NMR (300 MHz, CDCl3) δ 8.57 (dd, J = 1.7, 0.6 Hz, 1 H),
8.49 (dd, J = 8.3, 0.7 Hz, 1 H), 8.00 (dd, J = 8.3, 1.8 Hz, 1 H), 7.66 (dt, J = 6.4, 1.2 Hz, 1
H), 7.61 – 7.45 (m, 3 H); CIMS m/z (rel intensity) 274 (MH+, 100).
5-(Trifluoromethyl)isobenzofuran-1,3-dione (169).

Diacid 168 (2.519 g,

10.759 mmol) was suspended in AcCl (15 mL) and the mixture was heated to reflux with
stirring for 17 h. The mixture was concentrated in vacuo and the product was purified by
silica gel column chromatography, eluting with 4:1 EtOAc-hexanes, to yield a yellow oil.
The yellow oil was dried under high vacuum to provide 169 (1.683 g, 72%) as a faint
yellow solid: mp 54–58 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.47 (dt, J = 1.5, 0.7 Hz, 1
H), 8.41 – 8.23 (m, 2 H).
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5-(Trifluoromethyl)phthalide (170) and 6-(Trifluoromethyl)phthalide (167).
Anhydride 169 (2.476 g, 11.46 mmol) was dissolved in THF (20 mL) with stirring and
the mixture was cooled to 0 °C. NaBH4 (436 mg, 11.5 mmol) was added all at once, and
the mixture was stirred at 0 °C for 1 h 25 min. The mixture was concentrated in vacuo,
and a solution of H2O (5 mL) and aqueous HCl (37%, 1 mL) was added to the residue.
The aqueous solution was extracted with CHCl3 (3 x 25 mL) and the combined organic
layers were washed with H2O (10 mL) and brine (10 mL), dried over Na2SO4, and
concentrated in vacuo. The products were first purified on a silica gel column, eluting
with 50:50 hexanes-EtOAc, to obtain a mixture of 170 and 167, and then the two
regioisomers were separated on a second silica gel column, eluting with 80:20 hexanesEtOAc. Products 170 (405 mg, 17%) and 167 (408 mg, 18%) were each obtained as
white solids: 170 mp 65–68 °C (lit.78 mp 65–67 °C); 167 mp 88–89 °C (lit.78 mp 88–
90 °C). 170 1H NMR (300 MHz, CDCl3) δ 8.06 (d, J = 7.9 Hz, 1 H), 7.86 – 7.78 (m, 2 H),
5.41 (s, 2 H); 167 1H NMR (300 MHz, CDCl3) δ 8.20 (s, 1 H), 7.95 (dd, J = 8.1 Hz, J =
0.8 Hz, 1 H), 7.67 (d, J = 8.0 Hz, 1 H), 5.41 (s, 2 H).
3-Hydroxy-5-(trifluoromethyl)phthalide (173). Phthalide 170 (1.101 g, 5.447
mmol), NBS (982 mg, 5.52 mmol), and AIBN (39 mg) were suspended in CCl 4 (25 mL)
with stirring and the mixture was heated to reflux for 2 h. The product mixture was then
cooled and filtered to remove succinimide. The residue was washed with CCl4 (10 mL)
and the combined filtrate was concentrated in vacuo to provide an oil that was purified by
silica gel column chromatography eluting with 80:20 hexanes-EtOAc. The pure productcontaining fractions were concentrated in vacuo to provide a red oil. H2O (20 mL) and
KOH (630 mg, 11.2 mmol) were added to the oil, and the mixture was stirred and heated
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to reflux for 2 h 30 min. NaHSO4 (1.1 g) was added to the obtained solution, and the
product was extracted with EtOAc (3 x 20 mL). The combined organic layers were
washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo to provide 173
(480 mg, 40%) as a yellow solid: mp 110–112 °C. 1H NMR (300 MHz, CDCl3) δ 8.17 (s,
1 H), 8.00 (dd, J = 8.1, 0.8 Hz, 1 H), 7.82 (d, J = 8.0 Hz, 1 H), 6.75 (s, 1 H), 3.81 (s, 1 H);
CIMS m/z (rel intensity) 201 [(M + H+ – H2O)+, 100], 219 (MH+, 92).
3-Hydroxy-6-(trifluoromethyl)phthalide (174). Phthalide 167 (873 mg, 4.32
mmol), NBS (784 mg, 4.40 mmol), and AIBN (32 mg) were suspended in CCl 4 (25 mL)
with stirring and the mixture was heated to reflux for 2 h 10 min. The product mixture
was then cooled and filtered to remove succinimide. The residue was washed with CCl4
(10 mL) and the combined filtrate was concentrated in vacuo to provide an oil which was
purified by silica gel column chromatography, eluting with 80:20 hexanes-EtOAc. The
pure product-containing fractions were concentrated in vacuo to provide a colorless oil.
H2O (20 mL) and KOH (538 mg, 9.59 mmol) were added to the oil, and the mixture was
stirred and heated to reflux for 3 h 10 min. NaHSO4 (1.1 g) was added to the obtained
solution, and the product was extracted with EtOAc (3 x 20 mL). The combined organic
layers were washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo to
provide 174 (595 mg, 63%) as a white solid: mp 107–110 °C. 1H NMR (300 MHz,
CDCl3) δ 8.03 (d, J = 8.0 Hz, 1 H), 7.95 (s, 1 H), 7.90 (d, J = 8.2 Hz, 1 H), 6.86 (s, 1 H),
5.08 (s, 1 H); CIMS m/z (rel intensity) 219 (MH+, 100).
2-(Trifluoromethyl)indeno[1,2-c]isochromene-5,11-dione (175). 3-Hydroxy-5(trifluoromethyl)phthalide (173, 480 mg, 2.20 mmol) and phthalide (52, 310 mg, 2.31
mmol) were suspended in EtOAc (5 mL) and a freshly prepared solution of NaOMe (0.21
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g, 9.0 mmol of Na) in MeOH (10 mL) was added. The solution was heated to reflux with
stirring for 20.5 h. The mixture was cooled to room temperature, acidified to pH 1 with
37% HCl (1 mL), concentrated in vacuo, and azeotroped with PhMe (10 mL). Ac2O (10
mL) was added to the residue and the mixture was heated to reflux with stirring for 5 h.
After cooling to room temperature, the mixture was azeotroped with PhMe (2 x 20 mL).
The orange solid residue was taken up in CHCl3 (50 mL) and washed with H2O (2 x 25
mL). The organic solution was dried over Na2SO4 and concentrated in vacuo. The
residue was washed with 50:50 CHCl3-hexanes (15 mL) to yield 175 (220 mg, 32%) as
an orange solid: mp 224–225 °C. 1H NMR (300 MHz, CDCl3) δ 8.56 (s, 1 H), 8.51 (d, J
= 8.4 Hz, 1 H), 8.01 (dd, J = 8.5 Hz, J = 1.9 Hz, 1 H), 7.65 (dt, J = 6.6 Hz, J = 1.1 Hz, 1
H), 7.57 – 7.45 (m, 3 H); CIMS m/z (rel intensity) 317 (MH+, 100); HRCIMS calcd for
C17H8F3O3 (MH+) 317.0420, found 317.0412.
3-(Trifluoromethyl)indeno[1,2-c]isochromene-5,11-dione (176). 3-Hydroxy-6(trifluoromethyl)phthalide (174, 595 mg, 2.73 mmol) and phthalide (52, 377 mg, 2.81
mmol) were suspended in EtOAc (5 mL) and a freshly prepared solution of NaOMe (0.25
g, 11 mmol of Na) in MeOH (10 mL) was added. The solution was heated to reflux with
stirring for 20.5 h. The mixture was cooled to room temperature, acidified to pH 1 with
37% HCl (1 mL), concentrated in vacuo, and azeotroped with PhMe (10 mL). Ac2O (10
mL) was added to the residue and the mixture was heated to reflux with stirring for 5 h.
After cooling to room temperature, the mixture was azeotroped with PhMe (2 x 10 mL).
The orange solid residue was taken up in CHCl3 (50 mL) and washed with H2O (2 x 25
mL). The organic solution was dried over Na2SO4 and concentrated in vacuo. The
residue was washed with 50:50 CHCl3-hexanes (15 mL) to yield 176 (287 mg, 33%) as
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an orange solid: mp 200–202 °C. 1H NMR (300 MHz, CDCl3) δ 8.64 (s, 1 H), 8.42 (d, J
= 8.4 Hz, 1 H), 7.73 (dd, J = 8.4 Hz, J = 1.4 Hz, 1 H), 7.65 (dt, J = 6.7 Hz, J = 1.1 Hz, 1
H), 7.58 – 7.42 (m, 3 H); CIMS m/z (rel intensity) 317 (MH+, 100); HRCIMS calcd for
C17H8F3O3 (MH+) 317.0420, found 317.0433.
3-Hydroxy-6-(methylthio)phthalide (189).

6-Fluoro-3-hydroxyphthalide 148

(1.604 g, 9.541 mmol) was dissolved with stirring in DMF (11 mL) and solid NaSMe
(1.358 mg, 19.38 mmol) was added. The mixture was heated to 115–120 °C for 2 h 30
min. The reaction mixture was cooled and H2O (20 mL) and 37% HCl (3 mL) were
added. The product was extracted with Et2O (6 x 30 mL). The combined Et2O layers
were washed with brine (2 x 30 mL), dried over Na2SO4, and concentrated in vacuo to
provide a yellow-orange oil. The oil was purified by silica gel column chromatography,
eluting with 4:1 EtOAc-hexanes, to yield 189 (1.299 g, 69%) as a peach-colored solid:
mp 95–100 °C. 1H NMR (300 MHz, CDCl3) δ 7.72 (s, 1 H), 7.65 – 7.47 (m, 2 H), 2.55 (s,
3 H); CIMS m/z (rel intensity) 197 (MH+, 100).
3-(Methylthio)indeno[1,2-c]isochromene-5,11-dione

(190).

3-Hydroxy-6-

(methylthio)phthalide (189, 1.000 g, 5.096 mmol) and phthalide (52, 692 mg, 5.159
mmol) were suspended in EtOAc (15 mL) and a freshly prepared solution of NaOMe
(0.50 g, 22 mmol of Na) in MeOH (30 mL) was added. The solution was heated to reflux
with stirring under an argon atmosphere for 24.5 h. The mixture was cooled to room
temperature, acidified to pH 1 with 37% HCl (2 mL), concentrated in vacuo, and
azeotroped with PhMe (2 x 10 mL). Ac2O (15 mL) was added to the residue and the
mixture was heated to reflux with stirring under an argon atmosphere for 1 h 10 min. The
obtained suspension was azeotroped with PhMe (3 x 20 mL) to provide a red solid
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residue, which was suspended in CHCl3 (125 mL) and washed with H2O (2 x 25 mL).
The organic solution was dried over Na2SO4 and concentrated in vacuo. The residue was
washed with CHCl3-hexanes (50:50, 50 mL) and filtered. The filtrate was concentrated
in vacuo until 10 mL of solvent remained, and the suspension was filtered. The collected
solids were combined, yielding 190 (844 mg, 56%) as an orange solid: mp 220–222 °C.
1

H NMR (300 MHz, CDCl3) δ 8.26 (dd, J = 8.4 Hz, J = 0.5 Hz, 1 H), 8.05 (d, J = 2.1 Hz,

1 H), 7.65 (dd, J = 8.4 Hz, J = 2.1 Hz, 1 H), 7.58 (td, J = 6.8 Hz, J = 0.9 Hz, 1 H), 7.51 –
7.36 (m, 3 H), 2.59 (s, 3 H); CIMS m/z (rel intensity) 295 (MH+, 100); HRCIMS calcd
for C17H11O3S (MH+) 295.0423, found 295.0429.
3-(Methylsulfonyl)indeno[1,2-c]isochromene-5,11-dione (191).

Lactone 190

(224 mg, 0.761 mmol) was dissolved with stirring in CHCl3 (35 mL) at room temperature,
and m-CPBA (labeled 57-86%, assumed 57%, 477 mg, 1.58 mmol) was added. The
color of the solution changed from orange to yellow-orange almost instantaneously upon
addition of m-CPBA. After stirring for 48.5 h, the reaction mixture color had changed
back to orange. The suspension was filtered to yield 191 (131 mg, 53%) as an orange
solid: mp 305 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ 8.60 (t, J = 1.2 Hz, 1 H), 8.40
(d, J = 1.3 Hz, 2 H), 7.70 – 7.54 (m, 4 H), 3.34 (s, 3 H); CIMS m/z (rel intensity) 327
(MH+, 100); HRESIMS calcd for C17H10O5SNa (MNa+) 349.0147, found 349.0130.
(S)-3-Fluoro-5,6-dihydro-6-(2,3-dihydroxypropyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (193). Lactone 149 (86 mg, 0.32 mmol) was suspended in
MeOH (15 mL) and CHCl3 (10 mL), and (S)-3-amino-1,2-propanediol (82, 75 mg, 0.82
mmol) was added with stirring. The mixture was heated to reflux for 15 h, cooled to
room temperature, and filtered to provide a red-orange solid.

The filtrate was
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concentrated in vacuo, suspended in CHCl3 (5 mL), and filtered to provide additional
product. The products were combined and washed with CHCl3 (5 mL) and hexanes (10
mL) to yield 193 (88 mg, 81%) as a red-orange solid: mp 183–185 °C. IR (film) 3369,
1692, 1647, 1554, 1509 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 8.64 (dd, J = 9.0, 5.4 Hz,
1 H), 8.04 (d, J = 7.5 Hz, 1 H), 7.88 (dd, J = 9.5, 2.8 Hz, 1 H), 7.74 (td, J = 8.8, 2.9 Hz, 1
H), 7.65 – 7.41 (m, 3 H), 5.14 (d, J = 5.1 Hz, 1 H), 4.99 (t, J = 5.6 Hz, 1 H), 4.65 – 4.41
(m, 2 H), 4.06 – 3.94 (m, 1 H), 3.59 (t, J = 5.2 Hz, 2 H); CIMS m/z (rel intensity) 340
(MH+, 84); HRCIMS calcd for C19H15FNO4 (MH+) 340.0980, found 340.0977; HPLC
purity, 95.01% (MeOH–H2O, 90:10).
(S)-3-Chloro-5,6-dihydro-6-(2,3-dihydroxypropyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (194). Lactone 163 (88 mg, 0.31 mmol) was suspended in
MeOH (15 mL) and CHCl3 (10 mL), and (S)-3-amino-1,2-propanediol (82, 64 mg, 0.70
mmol) was added with stirring. The mixture was heated to reflux for 15 h, cooled to
room temperature, and filtered to provide a red-orange solid. The product was washed
with CHCl3 (5 mL) and hexanes (10 mL) to yield 194 (62 mg, 56%) as a red-orange solid:
mp 240–242 °C. IR (film) 3435, 1690, 1647, 1540, 1500 cm-1; 1H NMR (300 MHz,
DMSO-d6) δ 8.59 (d, J = 8.7 Hz, 1 H), 8.14 (d, J = 2.3 Hz, 1 H), 8.06 (d, J = 7.4 Hz, 1 H),
7.87 (dd, J = 8.7, 2.4 Hz, 1 H), 7.63 – 7.43 (m, 3 H), 5.13 (d, J = 5.0 Hz, 1 H), 4.98 (t, J =
5.6 Hz, 1 H), 4.62 – 4.46 (m, 2 H), 3.99 (s, 1 H), 3.58 (t, J = 5.3 Hz, 2 H); ESIMS m/z
(rel intensity) 378/380 (MNa+, 100/42); HRCIMS calcd for C19H14ClNO4Na (MNa+)
378.0509, found 378.0504; HPLC purity, 95.09% (MeOH–H2O, 85:15).
(S)-3-Bromo-5,6-dihydro-6-(2,3-dihydroxypropyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (195). Lactone 164 (84 mg, 0.26 mmol) was suspended in
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MeOH (15 mL) and CHCl3 (10 mL), and (S)-3-amino-1,2-propanediol (82, 55 mg, 0.60
mmol) was added with stirring. The mixture was heated to reflux for 15 h, cooled to
room temperature, and filtered to provide a red-orange solid. The product was washed
with CHCl3 (5 mL) and hexanes (10 mL) to yield 195 (44 mg, 42%) as a red-orange solid:
mp 224–226 °C. IR (film) 3436, 1664, 1643, 1540, 1315 cm-1; 1H NMR (300 MHz,
DMSO-d6) δ 8.49 (d, J = 8.7 Hz, 1 H), 8.26 (d, J = 2.2 Hz, 1 H), 8.14 – 7.89 (m, 2 H),
7.65 – 7.37 (m, 3 H), 5.13 (d, J = 5.0 Hz, 1 H), 4.99 (t, J = 5.5 Hz, 1 H), 4.68 – 4.39 (m, 2
H), 3.98 (d, J = 9.8 Hz, 1 H), 3.57 (t, J = 5.2 Hz, 2 H); CIMS m/z (rel intensity) 400/402
(MH+, 94/100); HRCIMS calcd for C19H15BrNO4 (MH+) 400.0184/402.0166, found
400.0192/402.0173; HPLC purity, 95.18% (MeOH–H2O, 85:15).
(S)-5,6-Dihydro-6-(2,3-dihydroxypropyl)-3-iodo-5,11-dioxo-11H-indeno[1,2c]isoquinoline (196). Lactone 165 (52 mg, 0.14 mmol) was dissolved in MeOH/CHCl3
(15:10 mL) and (S)-3-amino-1,2-propanediol (82, 32 mg, 0.35 mmol) was added. The
mixture was heated at reflux under Ar overnight, cooled, and concentrated. The residue
was suspended in CHCl3/hexanes (10:5 mL), and the suspension was filtered to provide
196 (58 mg, 93%) as orange solid: mp 186–193 °C (dec). IR (film) 3488, 1706, 1624,
1533, 1304 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 8.49 (d, J = 1.9 Hz, 1 H), 8.36 (d, J =
8.5 Hz, 1 H), 8.13 (dd, J = 8.5, 1.9 Hz, 1 H), 8.07 (d, J = 7.6 Hz, 1 H), 7.62 – 7.44 (m, 3
H), 5.14 (d, J = 5.1 Hz, 1 H), 4.99 (t, J = 5.5 Hz, 1 H), 4.63 – 4.45 (m, 2 H), 4.06 – 3.93
(m, 1 H), 3.59 (t, J = 5.3 Hz, 2 H); ESIMS m/z (rel intensity) 470 (MNa+, 52); HRESIMS
calcd for C19H14INO4Na (MNa+) 469.9865, found 469.9855; HPLC purity, 96.81%
(MeOH–H2O, 90:10).
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(S)-3-Cyano-5,6-dihydro-6-(2,3-dihydroxypropyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (197). Lactone 166 (67 mg, 0.25 mmol) was suspended in
MeOH (10 mL) and CHCl3 (15 mL), and (S)-3-amino-1,2-propanediol (82, 56 mg, 0.61
mmol) was added with stirring. The mixture was heated to reflux for 19 h, cooled to
room temperature, and concentrated until ~1 mL of solvent remained. The mixture was
filtered and the solid residue was washed with hexanes (5 mL) to yield 197 (44 mg, 52%)
as a red-orange solid: mp 314–315 °C. IR (film) 3583, 1734, 1671, 1608, 1534 cm-1; 1H
NMR (300 MHz, DMSO-d6) δ 8.66 (dd, J = 8.4, 0.7 Hz, 1 H), 8.54 (dd, J = 1.8, 0.6 Hz, 1
H), 8.22 – 8.05 (m, 2 H), 7.67 – 7.46 (m, 3 H), 5.15 (d, J = 5.0 Hz, 1 H), 5.01 (t, J = 5.6
Hz, 1 H), 4.54 (dd, J = 6.8, 3.6 Hz, 2 H), 3.99 (dt, J = 9.3, 5.0 Hz, 1 H), 3.66 – 3.52 (m, 2
H); CIMS m/z (rel intensity) 347 (MH+, 100); HRESIMS calcd for C20H13N2O4 (M - H+)
345.0875, found 345.0865; HPLC purity, 95.12% (MeOH–H2O, 90:10).
(S)-2-(Trifluoromethyl)-5,6-dihydro-6-(2,3-dihydroxypropyl)-5,11-dioxo11H-indeno[1,2-c]isoquinoline (198). Lactone 175 (66 mg, 0.21 mmol) was suspended
in MeOH (10 mL) and CHCl3 (15 mL), and (S)-3-amino-1,2-propanediol (82, 52 mg,
0.42 mmol) was added with stirring. The mixture was heated to reflux for 14 h, cooled to
room temperature, and concentrated until ~1 mL of solvent remained. Precipitation of
product occurred upon standing for 30 min, and the mixture was filtered. The product
was washed with hexanes (5 mL) to provide 198 (60 mg, 73%) as a bright, orange solid:
mp 214–215 °C. IR (film) 3583, 3294, 1665, 1546, 1314, 1109 cm-1; 1H NMR (300 MHz,
DMSO-d6) δ 8.72 (d, J = 8.7 Hz, 1 H), 8.38 (s, 1 H), 8.13 – 8.07 (m, 2 H), 7.60 – 7.46 (m,
3 H), 5.13 (d, J = 5.0 Hz, 1 H), 5.00 (t, J = 5.5 Hz, 1 H), 4.62 – 4.46 (m, 2 H), 3.99 (dt, J
= 9.3 Hz, J = 4.9 Hz, 1 H), 3.59 (t, J = 5.5 Hz, 2 H); CIMS m/z (rel intensity) 390 (MH+,
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100); HRCIMS calcd for C20H15F3NO4 (MH+) 390.0948, found 390.0951; HPLC purity,
97.24% (MeOH–H2O, 90:10).
(S)-3-(Trifluoromethyl)-5,6-dihydro-6-(2,3-dihydroxypropyl)-5,11-dioxo11H-indeno[1,2-c]isoquinoline (199). Lactone 176 (62 mg, 0.20 mmol) was suspended
in MeOH (10 mL) and CHCl3 (15 mL), and (S)-3-amino-1,2-propanediol (82, 54 mg,
0.43 mmol) was added with stirring. The mixture was heated to reflux for 14 h, cooled to
room temperature, and concentrated until ~1 mL of solvent remained. Hexanes (2 mL)
were added, and the suspension was filtered. The product was washed with hexanes (5
mL) to yield 199 (49 mg, 63%) as a red-orange solid: mp 228–230 °C. IR (film) 3401,
1668, 1559, 1501, 1312, 1128 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 8.87 (s, 1 H), 8.40
(d, J = 8.4 Hz, 1 H), 8.10 (d, J = 7.4 Hz, 1 H), 7.81 (dd, J = 8.5 Hz, J = 1.9 Hz, 1 H), 7.62
– 7.46 (m, 3 H), 5.15 (d, J = 5.0 Hz, 1 H), 5.00 (t, J = 5.6 Hz, 1 H), 4.59 – 4.47 (m, 2 H),
4.06 – 3.95 (m, 1 H), 3.59 (t, J = 5.4 Hz, 2 H); CIMS m/z (rel intensity) 390 (MH+, 100);
HRCIMS calcd for C20H15F3NO4 (MH+) 390.0948, found 390.0952; HPLC purity, 96.12%
(MeOH–H2O, 90:10).
(S)-5,6-Dihydro-6-(2,3-dihydroxypropyl)-3-(methylthio)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (200). Lactone 190 (57 mg, 0.19 mmol) was suspended in
MeOH (10 mL) and CHCl3 (15 mL), and (S)-3-amino-1,2-propanediol (82, 39 mg, 0.43
mmol) was added as a solution in MeOH (1 mL) with stirring. The mixture was heated to
reflux with stirring under an argon atmosphere for 14.5 h, cooled to room temperature,
and concentrated to a volume of ~1 mL. Hexanes (0.5 mL) were added, the mixture was
vigorously stirred, and the mixture was filtered. The solid residue that collected was
washed with hexanes (1 mL) to yield 200 (51 mg, 72%) as a red-orange solid: mp 195 °C.
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IR (film) 3401, 1698, 1656, 1647, 1498, 1424 cm-1; 1H NMR (300 MHz, DMSO-d6) δ
8.50 (d, J = 8.6 Hz, 1 H), 8.02 (d, J = 7.5 Hz, 1 H), 7.95 (d, J = 2.1 Hz, 1 H), 7.72 (dd, J
= 8.6, 2.2 Hz, 1 H), 7.60 – 7.37 (m, 3 H), 5.13 (d, J = 5.0 Hz, 1 H), 4.97 (t, J = 5.6 Hz, 1
H), 4.65 – 4.41 (m, 2 H), 4.07 – 3.89 (m, 1 H), 3.57 (t, J = 5.3 Hz, 2 H), 2.57 (s, 3 H);
CIMS m/z (rel intensity) 368 (MH+, 100); HRESIMS calcd for C20H16NO4S (M - H+)
366.0800, found 366.0794; HPLC purity, 96.39% (MeOH–H2O, 90:10).
(S)-5,6-Dihydro-6-(2,3-dihydroxypropyl)-3-(methylsulfonyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (201). Lactone 191 (62 mg, 0.19 mmol) was suspended in
MeOH (anhydrous, 10 mL) and CHCl3 (15 mL), and (S)-3-amino-1,2-propanediol (82, 36
mg, 0.40 mmol) was added with stirring. The mixture was heated to reflux for 16 h,
cooled to room temperature, and concentrated in vacuo. 80:20 Hexanes-EtOAc (10 mL)
was added to the residue and the suspension was filtered. The product was washed with
MeOH (5 mL) to yield 201 (49 mg, 65%) as a red-orange solid: mp 185 °C (dec). IR
(film) 3468, 1702, 1670, 1647, 1605, 1539 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 8.78
(d, J = 8.6 Hz, 1 H), 8.65 (d, J = 1.9 Hz, 1 H), 8.28 (dd, J = 8.6, 2.1 Hz, 1 H), 8.14 (d, J =
7.4 Hz, 1 H), 7.71 – 7.48 (m, 3 H), 5.16 (d, J = 5.0 Hz, 1 H), 5.02 (t, J = 5.5 Hz, 1 H),
4.65 – 4.51 (m, 2 H), 4.14 – 3.93 (m, 1 H), 3.61 (t, J = 5.3 Hz, 2 H), 3.30 (s, 3 H);
APCIMS m/z (rel intensity) 400 (MH+, 100); HRESIMS calcd for C20H17NO6SNa (MNa+)
422.0674, found 422.0670; HPLC purity, 97.27% (MeOH, 100).
(S)-5,6-Dihydro-6-(2,3-dihydroxypropyl)-3-(methoxycarbonyl)-5,11-dioxo11H-indeno[1,2-c]isoquinoline (202). Lactone 192 (42 mg, 0.14 mmol) was dissolved
in MeOH/CHCl3 (15:10 mL) and (S)-3-amino-1,2-propanediol (82, 31 mg, 0.34 mmol)
was added. The mixture was heated at reflux under Ar overnight, cooled, and
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concentrated. The residue was suspended in CHCl3/hexanes (10:5 mL), and the
suspension was filtered to provide 202 (44 mg, 86%) as a dark orange solid: mp 174–
175 °C (dec). IR (film) 3503, 1719, 1637, 1612, 1541, 1438, 1278 cm-1; 1H NMR (300
MHz, DMSO-d6) δ 8.71 (d, J = 1.8 Hz, 1 H), 8.64 (d, J = 8.5 Hz, 1 H), 8.27 (dd, J = 8.5,
1.9 Hz, 1 H), 8.10 (d, J = 7.3 Hz, 1 H), 7.64 – 7.44 (m, 3 H), 5.15 (d, J = 5.0 Hz, 1 H),
5.01 (t, J = 5.5 Hz, 1 H), 4.65 – 4.44 (m, 2 H), 4.08 – 3.94 (m, 1 H), 3.90 (s, 3 H), 3.60 (t,
J = 5.4 Hz, 2 H); CIMS m/z (rel intensity) 380 (MH+, 78); HRCIMS calcd for C21H18NO6
(MH+) 380.1129, found 380.1134; HPLC purity, 95.02% (MeOH–H2O, 85:15).
3-Fluoro-5,6-dihydro-6-(3-(1H-imidazol-1-yl)propyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (203). Lactone 149 (78 mg, 0.29 mmol) was dissolved in
CHCl3 (25 mL) with stirring and 1-(3-aminopropyl)imidazole (18, 73 mg, 0.58 mmol)
was added. The mixture was heated to reflux for 26 h, cooled, and concentrated to ~1
mL. Hexanes (5 mL) were added and the suspension was filtered to provide 203 (74 mg,
68%) as a red-orange solid: mp 220–222 °C. IR (film) 1698, 1660, 1556, 1509, 1432 cm-1;
1

H NMR (300 MHz, CDCl3) δ 8.71 (dd, J = 9.0 Hz, J = 5.3 Hz, 1 H), 7.97 (dd, J = 9.2 Hz,

J = 2.8 Hz, 1 H), 7.64 (s, 1 H), 7.59 (dd, J = 6.8 Hz, J = 1.6 Hz, 1 H), 7.47 (td, J = 8.5 Hz,
J = 2.7 Hz, 1 H), 7.40 – 7.29 (m, 2 H), 7.23 – 7.17 (m, 1 H), 7.11 – 7.02 (m, 1 H), 6.66 (d,
J = 7.2 Hz, 1 H), 4.58 – 4.47 (m, 2 H), 4.24 (t, J = 6.4 Hz, 2 H), 2.37 (p, J = 6.7 Hz, 2 H);
APCIMS m/z 374 (MH+, 100); HRESIMS calcd for C22H17FN3O2 (MH+) 374.1305,
found 374.1307; HPLC purity, 95.21% (1% TFA in MeOH–H2O, 85:15).
3-Chloro-5,6-dihydro-6-(3-(1H-imidazol-1-yl)propyl)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (204). Lactone 163 (82 mg, 0.29 mmol) was dissolved in
CHCl3 (25 mL) with stirring and 1-(3-aminopropyl)imidazole (18, 73 mg, 0.58 mmol)
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was added. The mixture was heated to reflux for 20 h, cooled, and concentrated to ~1
mL. Hexanes (5 mL) were added and the suspension was filtered to provide 204 (87 mg,
77%) as a red solid: mp 215–217 °C. IR (film) 1698, 1664, 1541, 1500, 1317 cm-1; 1H
NMR (300 MHz, CDCl3) δ 8.62 (d, J = 8.7 Hz, 1 H), 8.28 (d, J = 2.3 Hz, 1 H), 7.80 –
7.52 (m, 3 H), 7.41 – 7.28 (m, 2 H), 7.20 (d, J = 1.1 Hz, 1 H), 7.15 – 7.00 (m, 1 H), 6.64
(d, J = 7.4 Hz, 1 H), 4.51 (t, J = 7.8 Hz, 2 H), 4.24 (t, J = 6.4 Hz, 2 H), 2.35 (p, J = 6.7 Hz,
2 H); ESIMS m/z 390/392 (MH+, 100/37); HRESIMS calcd for C22H17ClN3O2 (MH+)
390.1009, found 390.1009; HPLC purity, 95.04% (1% TFA in MeOH, 100).
5,6-Dihydro-6-(3-(1H-imidazol-1-yl)propyl)-3-iodo-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (205). Lactone 165 (72 mg, 0.19 mmol) was dissolved in
CHCl3 (25 mL) with stirring and 1-(3-aminopropyl)imidazole (18, 51 mg, 0.41 mmol)
was added. The mixture was heated to reflux for 17 h, cooled, and concentrated to ~1
mL. Hexanes (5 mL) were added and the suspension was filtered to provide 205 (92 mg,
100%) as a red-orange solid: mp 248–250 °C. IR (film) 3401, 1693, 1662, 1601, 1534,
1495, 1424 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.68 (d, J = 1.9 Hz, 1 H), 8.42 (d, J = 8.5
Hz, 1 H), 7.99 (dd, J = 8.6 Hz, J = 1.9 Hz, 1 H), 7.90 – 7.76 (m, 1 H), 7.60 (d, J = 6.5 Hz,
1 H), 7.43 – 7.29 (m, 2 H), signal for 1 H obscured by CDCl3, 7.18 – 7.05 (m, 1 H), 6.75
(d, J = 7.2 Hz, 1 H), 4.64 – 4.44 (m, 2 H), 4.27 (t, J = 6.5 Hz, 2 H), 2.37 (s, 2 H); ESIMS
m/z 482 (MH+, 100); HRESIMS calcd for C22H17IN3O2 (MH+) 482.0366, found 482.0364;
HPLC purity, 100% (MeOH–H2O, 85:15).
2-(Trifluoromethyl)-5,6-dihydro-6-(3-(1H-imidazol-1-yl)propyl)-5,11-dioxo11H-indeno[1,2-c]isoquinoline (206). Lactone 175 (74 mg, 0.23 mmol) was dissolved
in CHCl3 (25 mL) with stirring and 1-(3-aminopropyl)imidazole (18, 59 mg, 0.47 mmol)
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was added. The mixture was heated to reflux for 17 h, cooled to room temperature, and
hexanes (5 mL) were added. The suspension was stirred for 5 min and filtered to give 206
(97 mg, 100%) as a red-orange solid: mp 220–223 °C. IR (film) 1698, 1669, 1516, 1436,
1314, 1122 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.81 (d, J = 8.6 Hz, 1 H), 8.61 (s, 1 H),
7.91 (dd, J = 8.6 Hz, J = 2.0 Hz, 1 H), 7.68 – 7.61 (m, 2 H), 7.45 – 7.29 (m, 2 H), 7.22 (s,
1 H), 7.08 (s, 1 H), 6.69 (d, J = 7.4 Hz, 1 H), 4.56 (t, J = 8.2 Hz, 2 H), 4.26 (t, J = 6.3 Hz,
2 H), 2.38 (p, J = 6.6 Hz, 1 H); CIMS m/z (rel intensity) 424 (MH+, 100); HRESIMS
calcd for C23H17F3N3O2 (MH+) 424.1273, found 424.1278; HPLC purity, 95.27%
(MeOH–H2O, 90:10).
3-(Trifluoromethyl)-5,6-dihydro-6-(3-(1H-imidazol-1-yl)propyl)-5,11-dioxo11H-indeno[1,2-c]isoquinoline (207). Lactone 176 (76 mg, 0.24 mmol) was dissolved
in CHCl3 (25 mL) with stirring and 1-(3-aminopropyl)imidazole (18, 63 mg, 0.50 mmol)
was added. The mixture was heated to reflux for 17 h, cooled to room temperature, and
hexanes (5 mL) were added. The suspension was stirred for 5 min and filtered to yield
207 (91 mg, 90%) as a red-orange solid: mp 194–195 °C. IR (film) 1697, 1669, 1561,
1504, 1312, 1128 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.97 (s, 1 H), 8.43 (d, J = 8.4 Hz,
1 H), 7.74 – 7.56 (m, 3 H), 7.41 – 7.30 (m, 2 H), 7.21 (t, J = 1.1 Hz, 1 H), 7.07 (t, J = 1.3
Hz, 1 H), 6.68 (d, J = 7.4 Hz, 1 H), 4.64 – 4.46 (m, 2 H), 4.26 (t, J = 6.3 Hz, 2 H), 2.47 –
2.29 (m, 2 H); CIMS m/z (rel intensity) 424 (MH+, 100); HRESIMS calcd for
C23H17F3N3O2 (MH+) 424.1273, found 424.1266; HPLC purity, 98.31% (1% TFA in
MeOH–H2O, 90:10).
5,6-Dihydro-6-(3-(1H-imidazol-1-yl)propyl)-3-(methylthio)-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (208). Lactone 190 (64 mg, 0.22 mmol) was dissolved in
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CHCl3 (20 mL) with stirring and a solution of 1-(3-aminopropyl)imidazole (18, 58 mg,
0.46 mmol) dissolved in CHCl3 (1 mL) was added. The mixture was heated to reflux
with stirring under an argon atmosphere for 14.5 h, cooled to room temperature, and
concentrated to a volume of ~1 mL. Hexanes (0.5 mL) were added, the mixture was
vigorously stirred, and the mixture was filtered. The solid residue that collected was
washed with hexanes (1 mL) to yield 208 (71 mg, 81%) as a blood-red solid: mp 234 °C
(dec). IR (film) 1693, 1641, 1573, 1497, 1423 cm-1; 1H NMR (300 MHz, DMSO-d6) δ
8.49 (d, J = 8.5 Hz, 1 H), 7.97 (d, J = 2.1 Hz, 1 H), 7.82 (s, 1 H), 7.74 (dd, J = 8.6, 2.2 Hz,
1 H), 7.62 – 7.37 (m, 3 H), 7.34 (s, 1 H), 7.22 (d, J = 7.0 Hz, 1 H), 7.01 (s, 1 H), 4.47 (t, J
= 7.6 Hz, 2 H), 4.24 (t, J = 6.7 Hz, 2 H), 2.59 (s, 3 H), 2.35 – 2.15 (m, 2 H); EIMS m/z
(rel intensity) 401 (M+, 100); HRESIMS calcd for C23H19N3O2S (MH+) 402.1276, found
402.1262; HPLC purity, 95.37% (1% TFA in MeOH–H2O, 85:15).
5,6-Dihydro-6-(3-(1H-imidazol-1-yl)propyl)-3-(methylsulfonyl)-5,11-dioxo11H-indeno[1,2-c]isoquinoline (209). Lactone 191 (45 mg, 0.14 mmol) was dissolved in
CHCl3 (20 mL) with stirring and 1-(3-aminopropyl)imidazole (18, 36 mg, 0.29 mmol)
was added. The mixture was heated to reflux for 15.5 h, cooled to room temperature, and
concentrated in vacuo. 80:20 Hexanes-EtOAc (10 mL) was added to the residue and the
suspension was filtered. The product was washed with MeOH (5 mL) to provide 209 (34
mg, 57%) as a red-orange solid: mp 142 °C (dec). IR (film) 1698, 1668, 1606, 1505,
1304, 1148 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 8.73 (d, J = 8.6 Hz, 1 H), 8.65 (d, J =
2.0 Hz, 1 H), 8.28 (dd, J = 8.5, 2.1 Hz, 1 H), 7.75 (s, 1 H), 7.66 – 7.43 (m, 3 H), 7.33 –
7.22 (m, 2 H), 6.97 (s, 1 H), 4.49 (t, J = 7.7 Hz, 2 H), 4.24 (t, J = 6.7 Hz, 2 H), 3.31 (s, 3
H), 2.34 – 2.14 (m, 2 H); EIMS m/z 433 (rel intensity) (M+, 37), 95 (100); HRESIMS
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calcd for C23H19N3O4SNa (MNa+) 456.0994, found 456.0972; HPLC purity, 95.27%
(MeOH–H2O, 90:10).
3-Fluoro-5,6-dihydro-6-(3-morpholinopropyl)-5,11-dioxo-11H-indeno[1,2c]isoquinoline (210). Lactone 149 (88 mg, 0.33 mmol) was dissolved in CHCl3 (25 mL)
with stirring and 3-morpholinopropylamine (17, 95 mg, 0.66 mmol) was added. The
mixture was heated to reflux for 21.5 h, cooled, and concentrated to ~1 mL. Hexanes (5
mL) were added and the suspension was filtered to provide 210 (108 mg, 83%) as a
brick-red solid: mp 200–202 °C. IR (film) 1693, 1655, 1511, 1456, 1112, 909 cm-1; 1H
NMR (300 MHz, CDCl3) δ 8.73 (dd, J = 8.9 Hz, J = 5.3 Hz, 1 H), 7.97 (dd, J = 9.3 Hz, J
= 2.8 Hz, 1 H), 7.74 (d, J = 7.4 Hz, 1 H), 7.63 (dd, J = 6.8 Hz, J = 1.7 Hz, 1 H), 7.51 –
7.36 (m, 3 H), 4.67 – 4.55 (m, 2 H), 3.73 (t, J = 4.7 Hz, 4 H), 2.60 (t, J = 6.3 Hz, 2 H),
2.53 (s, 4 H), 2.08 (p, J = 6.5 Hz, 2 H); ESIMS m/z 393 (MH+, 100); HRESIMS calcd for
C23H22FN2O3 (MH+) 393.1614, found 393.1612; HPLC purity, 95.05% (1% TFA in
MeOH–H2O, 90:10).
3-Chloro-5,6-dihydro-6-(3-morpholinopropyl)-5,11-dioxo-11H-indeno[1,2c]isoquinoline (211). Lactone 163 (79 mg, 0.28 mmol) was dissolved in CHCl3 (25 mL)
with stirring and 3-morpholinopropylamine (17, 82 mg, 0.57 mmol) was added. The
mixture was heated to reflux for 22 h, cooled, and concentrated to ~1 mL. Hexanes (5
mL) were added and the suspension was filtered to provide 211 (111 mg, 97%) as a redorange solid: mp 199–200 °C. IR (film) 1698, 1654, 1500, 1427, 1113 cm-1; 1H NMR
(300 MHz, DMSO-d6) δ 8.58 (d, J = 8.7 Hz, 1 H), 8.16 (d, J = 2.3 Hz, 1 H), 7.97 – 7.84
(m, 2 H), 7.70 – 7.48 (m, 3 H), 4.56 (t, J = 7.5 Hz, 2 H), 3.49 (t, J = 4.3 Hz, 4 H), 2.42 –
2.24 (m, 4 H), 2.03 – 1.87 (m, 2 H); 2 H obscured by solvent; APCIMS m/z 409/411
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(MH+, 100/35); HRESIMS calcd for C23H22ClN2O3 (MH+) 409.1319, found 409.1318;
HPLC purity, 96.24% (1% TFA in MeOH–H2O, 85:15).
5,6-Dihydro-3-iodo-6-(3-morpholinopropyl)-5,11-dioxo-11H-indeno[1,2c]isoquinoline (212). Lactone 165 (69 mg, 0.18 mmol) was dissolved in CHCl3 (25 mL)
with stirring and 3-morpholinopropylamine (17, 53 mg, 0.37 mmol) was added. The
mixture was heated to reflux for 22 h, cooled, and concentrated to ~1 mL. Hexanes (5
mL) were added and the suspension was filtered to provide 212 (78 mg, 87%) as a redorange solid: mp 231–232 °C. IR (film) 1698, 1654, 1493, 1424, 1110 cm-1; 1H NMR
(300 MHz, CDCl3) δ 8.66 (d, J = 1.7 Hz, 1 H), 8.41 (d, J = 8.4 Hz, 1 H), 7.96 (dd, J = 8.5
Hz, J = 1.7 Hz, 1 H), 7.74 (d, J = 6.4 Hz, 1 H), 7.62 (dd, J = 6.7 Hz, J = 1.8 Hz, 1 H),
7.51 – 7.36 (m, 2 H), 4.66 – 4.54 (m, 2 H), 3.75 (t, J = 4.4 Hz, 4 H), 2.71 – 2.44 (m, 6 H),
2.24 – 1.98 (m, 2 H); APCIMS m/z 501 (MH+, 100); HRESIMS calcd for C23H22IN2O3
(MH+) 501.0675, found 501.0671; HPLC purity, 96.88% (1% TFA in MeOH, 100).
3-Fluoro-8,9-methylenedioxyindeno[1,2-c]isochromene-5,12-dione (231).

3-

Hydroxyphthalide 148 (506 mg, 3.01 mmol) and phthalide 7 (538 mg, 3.02 mmol) were
suspended in EtOAc (10 mL) and a freshly prepared solution of NaOMe (0.27 g, 12
mmol of Na) in MeOH (20 mL) was added. The solution was heated to reflux with
stirring under an argon atmosphere for 23 h.

The mixture was cooled to room

temperature, acidified to pH 1 with 37% HCl (1.5 mL), concentrated in vacuo, and
azeotroped with PhMe (2 x 10 mL). Ac2O (20 mL) was added to the residue and the
mixture was heated to reflux with stirring under an argon atmosphere for 1 h 20 min. The
suspension was azeotroped with PhMe (4 x 10 mL) to provide a purple residue, which
was sequentially washed with hexanes (50 mL) and H2O (50 mL) and hexanes (20 mL).
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The impure solid residue was purified by silica gel column chromatography (CHCl 3).
The product-containing fractions were pooled and concentrated in vacuo to give lactone
231 (140 mg, 15%) as a dull purple solid: mp 324–330 °C. 1H NMR (300 MHz, DMSOd6) δ 8.17 (dd, J = 9.0 Hz, J = 5.6 Hz, 1 H), 7.91 (dd, J = 9.0 Hz, J = 2.9 Hz, 1 H), 7.87 –
7.75 (m, 1 H), 7.29 – 7.22 (m, 2 H), 6.20 (s, 2 H); EIMS m/z 310 (M+, 100); HRCIMS
calcd for C17H8FO5 311.0350 (MH+), found 311.0353.
3-Chloro-8,9-methylenedioxyindeno[1,2-c]isochromene-5,12-dione (232).

3-

Hydroxyphthalide 159 (570 mg, 3.09 mmol) and phthalide 7 (561 mg, 3.15 mmol) were
suspended in EtOAc (10 mL) and a freshly prepared solution of NaOMe (0.30 g, 13
mmol of Na) in MeOH (20 mL) was added. The solution was heated to reflux with
stirring under an argon atmosphere for 18 h.

The mixture was cooled to room

temperature, acidified to pH 1 with 37% HCl (1.5 mL), concentrated in vacuo, and
azeotroped with PhMe (2 mL). Ac2O (20 mL) was added to the residue and the mixture
was heated to reflux with stirring under an argon atmosphere for 18 h. The suspension
was azeotroped with PhMe (3 x 5 mL) to provide a purple residue that was partitioned
between saturated NaHCO3 (150 mL) and CHCl3 (50 mL). The aqueous layer was
removed. H2O (25 mL) and hexanes (10 mL) were added to the organic layer, and the
mixture was filtered. The solid residue that was collected was washed with 1:1 hexanesEtOAc (10 mL) and dried under high vacuum to provide lactone 232 (557 mg, 55%) as a
a purple solid: mp 335–336 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.20 – 8.05 (m, 2 H),
8.01 – 7.88 (m, 1 H), 7.26 (d, J = 8.9 Hz, 2 H), 6.21 (s, 2 H); CIMS m/z (rel intensity)
327/329 (MH+, 100/42); HRCIMS calcd for C17H8ClO5 327.0055 (MH+), found 327.0051.
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5,6-Ethylenedioxyphthalide (233).

Catechol 12 (1.018 g, 6.128 mmol) and

Cs2CO3 (4.036 g, 12.39 mmol) were suspended with stirring in anhydrous DMF (15 mL)
under Ar. 1,2-Dibromoethane (1.1 mL, 13 mmol) was added via syringe and the mixture
was heated to 70 °C for 14.5 h under Ar. DMF was removed from the reaction mixture
via bulb-to-bulb distillation under high vacuum with heating. H2O (25 mL) was added to
the residue and product was extracted with EtOAc (3 x 50 mL). The combined organic
layers were washed with brine (25 mL) and dried over MgSO4 and concentrated in vacuo
to provide 233 (481 mg, 41%) as a light yellow, shiny solid: Rf (SiO2, 50:50 hexanesEtOAc) 0.55: mp 201-204 °C. 1H NMR (300 MHz, CDCl3) δ 7.38 (s, 1 H), 6.92 (s, 1 H),
5.18 (s, 2 H), 4.41 – 4.22 (m, 4 H); EIMS m/z 192 (M+, 100).
6-Methoxyisobenzofuran-1(3H)-one (237). 3-Methoxybenzoic acid (236, 5.00 g,
32.9 mmol) was dissolved with stirring in a solution of 37% HCHO (3.4 mL), 37% HCl
(4.0 mL), and glacial AcOH (37 mL). The solution was heated to 90–110 °C for 19.5 h
with stirring, and then concentrated in vacuo at 80 °C. PhMe (20 mL) was added to the
residue which was concentrated in vacuo once more to azeotrope residual AcOH. The
residue was then dissolved in EtOAc (60 mL) and washed with saturated NaHCO3
solution (2 x 20 mL) and brine (1 x 20 mL). The organic solution was concentrated in
vacuo, and the residue was recrystallized from EtOH (200 proof, ~50 mL) to yield 237 as
a faint yellow crystalline solid (1.205 g, 22%): mp 118–120 °C. 1H NMR (300 MHz,
CDCl3) δ 7.40 – 7.34 (m, 2 H), 7.27 – 7.22 (m, 1 H), 5.27 (s, 2 H), 3.87 (s, 3 H).
(S)-3-Fluoro-6-(2,3-dihydroxypropyl)-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (243). Lactone 231 (46 mg, 0.15 mmol) was suspended in
CHCl3 (15 mL) with stirring and a solution of (S)-2,3-dihydroxypropylamine (82, 33 mg,
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0.36 mmol) in MeOH (anhydrous, 10 mL) was added. The mixture was heated to reflux
for 16 h, cooled to room temperature, and concentrated in vacuo. Chloroform (5 mL) and
hexanes (1 mL) were added to the residue, and the suspension was filtered. The product
was washed with hexanes (5 mL) and methanol (5 mL) and dried under high vacuum to
provide 243 (38 mg, 66%) as a purple solid: mp 174 °C (dec). 1H NMR (300 MHz,
DMSO-d6) δ 8.50 (t, J = 6.8 Hz, 1 H), 7.79 (d, J = 9.7 Hz, 1 H), 7.67 (s, 1 H), 7.08 (s, 1
H), 6.17 (s, 2 H), 5.14 (d, J = 5.0 Hz, 1 H), 5.05 (t, J = 5.3 Hz, 1 H), 4.56 – 4.29 (m, 2 H),
3.95 (s, 1 H), 3.57 (t, J = 5.0 Hz, 2 H); CIMS m/z (rel intensity) 384 (MH+, 100);
HRESIMS calcd for C20H14FNO6Na 406.0703 (M + Na+), found 406.0705; HPLC purity,
95.14% (MeOH, 100%).
(S)-3-Chloro-6-(2,3-dihydroxypropyl)-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (244). Lactone 232 (73 mg, 0.22 mmol) was suspended in
MeOH (10 mL) and CHCl3 (15 mL), and a solution of (S)-2,3-dihydroxypropylamine (82,
40 mg, 0.44 mmol) in MeOH (1 mL) was added with stirring. The mixture was heated to
reflux with stirring under an argon atmosphere for 14.5 h, cooled to room temperature,
and filtered. The solid residue that collected was washed with hexanes (2 mL) and dried
under high vacuum to yield 244 (67 mg, 75%) as a brownish-purple solid: mp 303–
304 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.44 (d, J = 8.7 Hz, 1 H), 8.04 (d, J = 2.3 Hz, 1
H), 7.78 (dd, J = 8.7, 2.4 Hz, 1 H), 7.70 (s, 1 H), 7.09 (s, 1 H), 6.18 (s, 2 H), 5.13 (d, J =
5.0 Hz, 1 H), 5.11 – 4.97 (m, 1 H), 4.53 – 4.31 (m, 2 H), 4.00 – 3.86 (m, 1 H), 3.57 (t, J =
5.1 Hz, 2 H); MALDI m/z (rel intensity) 400/402 (MH+, 100/38); HRESIMS calcd for
C23H17ClN3O4 400.0588 (MH+), found 400.0580; HPLC purity, 100% (MeOH, 100%).
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(2’S,3’S,4’R)-3-Chloro-5,6-dihydro-6-(2’,3’,4’,5’-tetrahydroxypentyl)-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (245). D-Ribitylamine (63,
78 mg, 0.24 mmol) was dissolved in H2O (0.5 mL), and the solution was added to a
stirring suspension of lactone 232 (41 mg, 0.27 mmol) in CHCl3 (20 mL) and MeOH (15
mL). The reaction mixture was heated at reflux with stirring for 24 h. The mixture was
concentrated in vacuo until ~2 mL solvent remained and filtered. The collected solid was
sonicated in CHCl3-hexanes (2:1, 2 mL). After sitting ca. 10 min, additional solids had
precipitated from the filtrate. Both of the suspensions were filtered. The combined solids
were dried under high vacuum with heating to ~100 °C. Product 245 (15 mg, 12%) was
obtained as a purple solid: mp 231 °C (dec). 1H NMR (500 MHz, DMSO-d6) δ 8.41 (d, J
= 8.6 Hz, 1 H), 8.00 (d, J = 2.4 Hz, 1 H), 7.86 (s, 1 H), 7.74 (dd, J = 8.6, 2.4 Hz, 1 H),
7.04 (s, 1 H), 6.14 (d, J = 3.3 Hz, 2 H), 5.26 (d, J = 5.5 Hz, 1 H), 4.97 (d, J = 5.2 Hz, 1 H),
4.69 (d, J = 5.2 Hz, 1 H), 4.59 – 4.27 (m, 3 H), 4.13 (s, 1 H), 3.58 (m, 3 H), 3.41 (m, 1 H);
ESIMS m/z (rel intensity) 482/484 (M + Na+, 100/40); HRESIMS calcd for C22H19ClNO8
460.0800 (MH+), found 460.0801; HPLC purity, 100% (MeOH, 100%).
(2’S,3’R,4’R)-3-Fluoro-5,6-dihydro-6-(2’,3’,4’,5’-tetrahydroxypentyl)-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (246). D-Xylitylamine (69,
48 mg, 0.32 mmol) was dissolved in H2O (1 mL), and the solution was added to a stirring
suspension of lactone 231 (88 mg, 0.28 mmol) in CHCl3 (20 mL) and MeOH (15 mL).
The reaction mixture was heated at reflux with stirring for 24 h.

Additional D-

xylitylamine (20 mg, 0.13 mmol) dissolved in H2O (0.25 mL) was added and heating to
reflux was continued for 16 h. The mixture was concentrated in vacuo until ~2 mL of
solvent remained, and the suspension was filtered to get a solid, which was dried under
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high vacuum with heating. Indenoisoquinoline 246 (39 mg, 31%) was obtained as a redviolet solid: mp 260–272 °C (dec). 1H NMR (500 MHz, DMSO-d6) δ 8.50 (dd, J = 9.0,
5.4 Hz, 1 H), 7.83 (s, 1 H), 7.78 (dd, J = 9.4, 2.9 Hz, 1 H), 7.65 (td, J = 8.8, 2.9 Hz, 1 H),
7.07 (s, 1 H), 6.14 (s, 2 H), 5.03 (d, J = 5.2 Hz, 1 H), 4.94 (d, J = 5.7 Hz, 1 H), 4.64 (d, J
= 5.5 Hz, 1 H), 4.59 – 4.49 (m, 2 H), 4.42 (dd, J = 14.2, 3.6 Hz, 1 H), 4.11 – 4.03 (m, 1
H), 3.69 – 3.62 (m, 1 H), 3.61 – 3.54 (m, 1 H), 3.50 – 3.43 (m, 1 H), 3.42 – 3.35 (m, 1 H);
ESIMS m/z (rel intensity) 466 (M + Na+, 100); HRESIMS calcd for C22H19FNO8
444.1095 (MH+), found 444.1086; HPLC purity, 100% (MeOH, 100%).
3-Fluoro-5,6-dihydro-6-(3-morpholinopropyl)-8,9-methylenedioxy-5,11dioxo-11H-indeno[1,2-c]isoquinoline Trifluoroacetate (247). Lactone 231 (29 mg,
0.093 mmol) was dissolved in CHCl3 (9 mL) with stirring and a solution of 3morpholinopropylamine (17, 14 mg, 0.096 mmol) in CHCl3 (1 mL) was added. The
mixture was heated to reflux with stirring under an argon atmosphere for 20 h and
concentrated in vacuo until ~1 mL solvent remained. Hexanes (1 mL) was added and the
suspension was filtered. The product was dried under high vacuum to provide 247 (15
mg, 37%) as a red-violet solid: mp 294–296 °C. 1H NMR (300 MHz, CDCl3) δ 8.64 (dd,
J = 9.0, 5.3 Hz, 1 H), 7.94 (dd, J = 9.3, 2.9 Hz, 1 H), 7.49 (s, 1 H), 7.43 (td, J = 8.6, 2.8
Hz, 1 H), 7.12 (s, 1 H), 6.11 (s, 2 H), 4.60 – 4.46 (m, 2 H), 3.85 – 3.65 (m, 4 H), 2.64 –
2.40 (m, 6 H), 2.12 – 1.92 (m, 2 H); ESIMS m/z (rel intensity) 437 (MH+, 100);
HRESIMS calcd for C24H22FN2O5 437.1513 (MH+), found 437.1493; HPLC purity,
99.35% (MeOH, 100%).
3-Chloro-5,6-dihydro-6-(3-morpholinopropyl)-8,9-methylenedioxy-5,11dioxo-11H-indeno[1,2-c]isoquinoline Trifluoroacetate (248). Lactone 232 (34 mg,
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0.10 mmol) was dissolved in CHCl3 (9 mL) with stirring and a solution of 3morpholinopropylamine (17, 15 mg, 0.11 mmol) in CHCl3 (1 mL) was added. The
mixture was heated to reflux with stirring under an argon atmosphere for 20 h and
concentrated in vacuo until ~1 mL solvent remained. Hexanes (1 mL) was added and the
suspension was filtered. The product was dried under high vacuum to provide 248 (15
mg, 33%) as a dark purple solid: mp 290–294 °C. 1H NMR (300 MHz, CDCl3) δ 8.56 (d,
J = 8.7 Hz, 1 H), 8.26 (d, J = 2.3 Hz, 1 H), 7.62 (dd, J = 8.7, 2.3 Hz, 1 H), 7.50 (s, 1 H),
7.13 (s, 1 H), 6.12 (s, 2 H), 4.59 – 4.46 (m, 2 H), 3.76 (t, J = 4.7 Hz, 4 H), 2.62 – 2.44 (m,
6 H), 2.08 – 1.93 (m, 2 H); ESIMS m/z (rel intensity) 453/455 (MH+, 100/29); HRESIMS
calcd for C24H22ClN2O5 (MH+) 453.1217, found 453.1211; HPLC purity, 95.04%
(MeOH, 100%).
3-Fluoro-6-(3-(1H-imidazol-1-yl)propyl)-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline (249). Lactone 231 (53 mg, 0.17 mmol) was dissolved in
CHCl3 (20 mL) with stirring and 3-imidazolylpropylamine (18, 43 mg, 0.34 mmol) was
added. The mixture was heated to reflux for 16 h, cooled, and concentrated to ~5 mL.
Hexanes (1 mL) were added and the suspension was filtered. The product was washed
with hexanes (5 mL) and MeOH (5 mL) and dried under high vacuum with heating to
125 °C to furnish 249 (54 mg, 76%) as a purple solid: mp 235 °C (dec). 1H NMR (300
MHz, DMSO-d6) δ 8.50 (dd, J = 8.9, 5.4 Hz, 1 H), 7.83 (dd, J = 9.5, 2.8 Hz, 1 H), 7.78 –
7.64 (m, 2 H), 7.26 (s, 1 H), 7.15 (s, 1 H), 7.10 (s, 1 H), 6.91 (s, 1 H), 6.20 (s, 2 H), 4.41
(t, J = 7.4 Hz, 2 H), 4.18 (t, J = 6.8 Hz, 2 H), 2.32 – 2.09 (m, 2 H); EIMS m/z (rel
intensity) 417 (M+, 100); HRESIMS calcd for C23H17FN3O4 418.1203 (MH+), found
418.1208; HPLC purity, 100% (MeOH, 100%).
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3-Chloro-6-(3-(1H-imidazol-1-yl)propyl)-8,9-methylenedioxy-5,11-dioxo11H-indeno[1,2-c]isoquinoline (250). Lactone 232 (77 mg, 0.24 mmol) was dissolved in
CHCl3 (20 mL) with stirring and a solution of 3-imidazolylpropylamine (18, 59 mg, 0.47
mmol) in CHCl3 (1 mL) was added. The mixture was heated to reflux with stirring under
an argon atmosphere for 14.5 h, cooled to room temperature, and filtered. The product
was washed with hexanes (2 mL) and dried under high vacuum at 60 °C to provide 250
(81 mg, 79%) as a dark purple solid: mp 286–287 °C. 1H NMR (300 MHz, DMSO-d6) δ
8.46 (d, J = 8.8 Hz, 1 H), 8.31 (s, 1 H), 8.09 (d, J = 2.3 Hz, 1 H), 7.82 (dd, J = 8.6, 2.3 Hz,
1 H), 7.69 (s, 1 H), 7.24 (d, J = 1.1 Hz, 1 H), 7.18 (s, 1 H), 7.13 (s, 1 H), 6.89 (d, J = 1.4
Hz, 1 H), 6.21 (s, 2 H), 4.41 (t, J = 7.3 Hz, 2 H), 4.17 (t, J = 6.9 Hz, 2 H), 2.33 – 2.09 (m,
2 H); MALDI m/z (rel intensity) 434/436 (MH+, 100/83); HRESIMS calcd for
C23H17ClN3O4 434.0908 (MH+), found 434.0887; HPLC purity, 100% (MeOH, 100%).
3-Fluoro-5,6-dihydro-6-(3-((2-hydroxyethyl)amino)-8,9-methylenedioxy-5,11dioxo-11H-indeno[1,2-c]isoquinoline (251). Lactone 231 (69 mg, 0.22 mmol) was
dissolved

in

CHCl3

(15

mL)

with

stirring

and

a

solution

of

3-(2-

hydroxyethyl)propylamine (19, 36 mg, 0.30 mmol) in CHCl3 (1 mL) was added. The
mixture was heated to reflux with stirring under an argon atmosphere for 3.5 h and
concentrated in vacuo until ~1 mL solvent remained. Hexanes (1 mL) was added and the
suspension was filtered. The product was dried under high vacuum to provide 251 (69
mg, 76%) as a dull purple solid: mp 170 °C. 1H NMR (500 MHz, DMSO-d6) δ 8.45 (dd,
J = 9.0, 5.4 Hz, 1 H), 7.77 (dd, J = 9.5, 2.8 Hz, 1 H), 7.71 – 7.53 (m, 2 H), 7.10 (s, 1 H),
6.17 (s, 2 H), 4.56 – 4.27 (m, 3 H), 3.43 (d, J = 6.3 Hz, 2 H), 2.73 – 2.51 (m, 2 H), 1.92 –
1.65 (m, 2 H); ESIMS m/z (rel intensity) 411 (MH+, 100); HRESIMS calcd for
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C22H20FN2O5 411.1357 (MH+), found 411.1363; HPLC purity, 95.00% (0.1% TFA in
MeOH, 100%).
3-Chloro-5,6-dihydro-6-(3-((2-hydroxyethyl)amino)propyl)-8,9methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (252). Lactone 232 (84 mg,
0.26 mmol) was dissolved in CHCl3 (15 mL) with stirring and a solution of 3-(2hydroxyethyl)propylamine (19, 35 mg, 0.30 mmol) in CHCl3 (1 mL) was added. The
mixture was heated to reflux with stirring under an argon atmosphere for 22 h and
concentrated in vacuo until ~1 mL solvent remained. Hexanes (1 mL) was added and the
suspension was filtered. The product was dried under high vacuum to provide 252 (93
mg, 84%) as a purple solid: mp 198 °C. 1H NMR (500 MHz, DMSO-d6) δ 8.38 (d, J =
8.7 Hz, 1 H), 8.02 (d, J = 2.4 Hz, 1 H), 7.76 (dd, J = 8.7, 2.4 Hz, 1 H), 7.63 (s, 1H), 7.10
(s, 1 H), 6.18 (s, 2 H), 4.59 – 4.27 (m, 3 H), 3.44 (t, J = 5.7 Hz, 2 H), 2.67 (t, J = 6.4 Hz,
2 H), 2.58 (t, J = 5.8 Hz, 2 H), 1.92 – 1.71 (m, 2 H); ESIMS m/z (rel intensity) 427/429
(MH+, 100/31); HRESIMS calcd for C22H20ClN2O5 427.1061 (MH+), found 427.1067;
HPLC purity, 98.60% (0.1% TFA in MeOH, 100%).
(2-Bromo-4,5-difluorophenyl)methanol (254). Benzoic acid 253 (5.05 g, 21.3
mmol) was dissolved with stirring in THF (25 mL). A solution of BH3 in THF (1.0 M,
21.3 mL, 21.3 mmol) was added dropwise at room temperature with frequent pausing to
allow violent bubbling to subside. The mixture was heated to reflux with stirring for 4 h.
A solution of aqueous KOH (2 M, 11 mL) was added and the mixture was cooled to room
temperature with stirring for 30 min. The mixture was extracted with Et2O (6 x 25 mL).
The combined organic layers were washed with brine (1 x 25 mL) and dried over Na2SO4.
The organic solution was concentrated in vacuo to yield a yellow-tinted liquid. Drying
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under high vacuum with heating to ca. 100 °C afforded 254 (4.01 g, 84%) as an off-white
solid: mp 59–66 °C. 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.32 (m, 2 H), 4.68 (d, J = 1.3
Hz, 2 H), 2.12 (br s, 1 H); EIMS m/z (rel intensity) 222/224 (M+, 70/70), 143 [(M - Br)+,
93], 115 [(M - Br - H2O)+, 100].
5,6-Difluorophthalide (255). Benzylic alcohol 254 (4.01 g, 18.0 mmol) and
CuCN (3.33 g, 37.2 mmol) were suspended with stirring in DMF (20 mL) with heating to
reflux under Ar atmosphere for 2.5 h. The mixture was cooled to room temperature, H2O
(2 mL) was added, and the mixture was heated to 100 °C for 1.5 h. After cooling to room
temperature, H2O (80 mL) and EtOAc (100 mL) were added to the mixture, and it was
filtered through a Celite plug (1.5 cm height). The organic layer of the filtrate was
removed. The aqueous layer of the filtrate was extracted with EtOAc (2 x 100 mL). The
combined organic layers were washed with brine (3 x 50 mL), dried over MgSO 4, and
concentrated in vacuo. The obtained orange, semisolid residue was purified by column
chromatography (SiO2, CHCl3, 12 cm x 4 cm, 25 mL fractions), and the pure productcontaining fractions were pooled and concentrated in vacuo to give a solid contaminated
with visible residual DMF. The solid was washed with hexanes (~10 mL) and dried
under high vacuum to provide 255 (1.17 g, 38%) as an off-white solid: Rf (SiO2, CHCl3)
0.31, mp 109–112 °C. 1H NMR (300 MHz, CDCl3) δ 7.72 (dd, J = 8.2, 7.0 Hz, 1 H), 7.32
(dd, J = 8.6, 6.3 Hz, 1 H), 5.29 (s, 2 H); CIMS m/z (rel intensity) 171 (MH+, 100); EIMS
m/z (rel intensity) 170 (M+, 44), 141 [(M - CHO)+, 100].
5,6-Difluoro-3-hydroxyphthalide (257). Phthalide 255 (1.00 g, 5.88 mmol),
NBS (1.06 g, 5.96 mmol), and AIBN (0.05 g) were suspended with stirring in CCl 4 and
the mixture was heated to reflux under Ar atmosphere for 1 h 10 min. The suspension
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was cooled to room temperature and filtered. The filtered solids were washed with CCl4
(10 mL). The combined filtrates were concentrated in vacuo to yield a yellow oil. The
oily residue was purified by column chromatography (SiO2, CHCl3, 22 cm x 2.5 cm, 10
mL fractions). The pure product-containing fractions were pooled and concentrated in
vacuo, and the obtained residue was heated to reflux with stirring in H2O (20 mL) for 1 h.
The mixture was cooled to room temperature and acidified with NaHSO4 (1.45 g).
Product was extracted with EtOAc (3 x 20 mL). The combined organic layers were
washed with brine (20 mL) and dried over Na2SO4.

The organic solution was

concentrated in vacuo and dried under high vacuum with heating to yield 257 (727 mg,
66%) as a white solid: Rf (SiO2, CHCl3) 0, mp 104–107 °C. 1H NMR (300 MHz,
DMSO-d6) δ 7.81 (dd, J = 8.9, 7.0 Hz, 1 H), 7.66 (dd, J = 9.2, 6.8 Hz, 1 H), aldehydic
acid peaks not observed; CIMS m/z (rel intensity) 187 (MH+, 94), 169 (MH+ - H2O, 100).
2,3-Difluoro-8,9-methylenedioxyindeno[1,2-c]isochromene-5,12-dione

(258).

3-Hydroxyphthalide 257 (408 mg, 2.19 mmol) and phthalide 7 (393 mg, 2.21 mmol)
were suspended in EtOAc (10 mL) and a freshly prepared solution of NaOMe (0.21 g, 9.1
mmol of Na) in MeOH (20 mL) was added. The solution was heated to reflux with
stirring under Ar atmosphere for 24 h. The mixture was cooled to room temperature,
acidified to pH 1 with 37% HCl (2 mL), concentrated in vacuo, and azeotroped with
PhMe (10 mL). Ac2O (20 mL) was added to the residue and the mixture was heated to
90 °C with stirring under an argon atmosphere for 2 h. The mixture was cooled to room
temperature, H2O (20 mL) was added, and the suspension was filtered. The solid was
split into two portions which were separately purified by column chromatography (SiO2,
CHCl3, 10 cm x 4 cm, 25 mL fractions). The pure product-containing fractions were
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pooled, concentrated in vacuo, and dried under high vacuum to provide lactone 258 (86
mg, 12%) as a dark purple solid: Rf (SiO2, CHCl3) 0.60, mp 300–301 °C. 1H NMR (300
MHz, CDCl3) δ 8.12 – 7.99 (m, 2 H), 7.10 (s, 1 H), 6.97 (s, 1 H), 6.12 (s, 2 H); CIMS m/z
(rel intensity) 329 (MH+, 100); HRESIMS calcd for C17H7F2O5 329.0256 (MH+), found
329.0244.
(S)-2,3-Difluoro-6-(2,3-dihydroxypropyl)-8,9-methylenedioxy-5,11-dioxo11H-indeno[1,2-c]isoquinoline (259). Lactone 258 (28 mg, 0.085 mmol) was suspended
in CHCl3 (5 mL), and a solution of (S)-2,3-dihydroxypropylamine (82, 14 mg, 0.15 mmol)
in MeOH (2 mL) was added with stirring. The mixture was heated to reflux with stirring
under Ar atmosphere for 18.5 h. The suspension was cooled to room temperature,
concentrated in vacuo until ~1 mL of solvent remained, and hexanes (0.5 mL) were
added. The suspension was filtered and the solid residue that collected was dried under
high vacuum to yield 259 (32 mg, 94%) as a red-violet solid: mp 256–261 °C. 1H NMR
(300 MHz, DMSO-d6) δ 8.28 (dd, J = 11.6, 7.8 Hz, 1 H), 8.06 (dd, J = 11.1, 8.2 Hz, 1 H),
7.74 (s, 1 H), 7.14 (s, 1 H), 6.19 (dd, J = 2.4, 1.0 Hz, 2 H), 5.16 (d, J = 5.0 Hz, 1 H), 5.06
(t, J = 5.3 Hz, 1 H), 4.50 – 4.37 (m, 2 H), 3.94 (s, 1 H), 3.57 (t, J = 5.0 Hz, 2 H);
APCIMS m/z (rel intensity) 402 (MH+, 100); HPLC purity, 100% (MeOH, 100%).
2,3-Difluoro-6-(3-(1H-imidazol-1-yl)propyl)-8,9-methylenedioxy-5,11-dioxo11H-indeno[1,2-c]isoquinoline (260). Lactone 258 (26 mg, 0.079 mmol) was dissolved
in CHCl3 (5 mL) with stirring and a solution of 3-imidazolylpropylamine (18, 13 mg,
0.10 mmol) in CHCl3 (1 mL) was added. The mixture was heated to reflux with stirring
under Ar atmosphere for 18.5 h, cooled to room temperature, and filtered. The product
was washed with CHCl3 (1 mL) and dried under high vacuum to provide 260 (37 mg,
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100%) as a dark purple solid: mp > 400 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.25 (dd, J
= 11.5, 7.7 Hz, 1 H), 8.07 (dd, J = 11.0, 8.2 Hz, 1 H), 7.71 – 7.67 (m, 1 H), 7.25 (t, J =
1.2 Hz, 1 H), 7.17 (s, 1 H), 7.13 (s, 1 H), 6.95 – 6.85 (m, 1 H), 6.21 (s, 2 H), 4.39 (t, J =
7.2 Hz, 2 H), 4.17 (t, J = 6.8 Hz, 2 H), 2.26 – 2.12 (m, 2 H); ESIMS m/z (rel intensity)
436 (MH+, 100); HRESIMS calcd for C23H16F2N3O4 436.1109 (MH+), found 436.1107;
HPLC purity, 98.41% (0.1% TFA in MeOH, 100%).
5,6-Dichlorophthalic Anhydride (262). Diacid 261 (10.00 g, 42.55 mmol) was
suspended in AcCl (50 mL) and the mixture was heated to reflux with stirring for 2 h.
The obtained suspension was concentrated in vacuo and azeotroped with hexanes (2 x 10
mL) and PhMe (2 x 10 mL) to provide anhydride 262 (9.23 g, 100%) as a peach powder:
Rf (SiO2, CHCl3) 0.64, mp 185–189 °C. 1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1 H);
CIMS m/z (rel intensity) 217/219/221 (MH+, 100/69/12).
5,6-Dichlorophthalide (263). Anhydride 262 (9.53 g, 42.6 mmol) was dissolved
with stirring in THF (80 mL) and the solution was cooled to 0 °C under an Ar atmosphere.
NaBH4 (1.63 g, 43.1 mmol) was added slowly in a single portion, and the mixture was
stirred with cooling to 0 °C for 50 min. The mixture was removed from the ice-water
bath and warmed to room temperature for 17 h. MeOH (20 mL) was added slowly and
cautiously to the obtained suspension. The mixture was concentrated in vacuo. Dilute,
aqueous HCl (0.1 M, 24 mL) was added to the residue. After stirring the mixture for 10
min, it was filtered. The collected solids were vigorously refluxed in PhMe (100 mL)
with pTsOH•H2O (0.15 g), using a Dean-Stark trap to collect H2O, for 30 h 15 min. The
mixture was concentrated in vacuo. The residue was washed with H2O (50 mL) and the
solid was azeotroped with PhMe (10 mL) and dried under high vacuum to provide 263
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(6.41 g, 74%) as a white solid: Rf (SiO2, CHCl3) 0.55, mp 157–160 °C. 1H NMR (300
MHz, DMSO-d6) δ 8.14 (s, 1 H), 8.04 (s, 1 H), 5.40 (s, 2 H); CIMS m/z (rel intensity)
203/205/207 (MH+, 100/71/14).
5,6-Dichloro-3-hydroxyphthalide (265). Phthalide 263 (1.05 g, 5.17 mmol),
NBS (0.93 g, 5.22 mmol), and AIBN (0.10 g) were suspended with stirring in CCl 4 (25
mL) and the mixture was heated to reflux under Ar atmosphere for 3 h 15 min. The
suspension was cooled to room temperature and filtered. The filtered solids were washed
with CCl4 (10 mL). The combined filtrates were concentrated in vacuo to yield a yellow
oil. The oily product was purified by column chromatography (SiO2, CHCl3, 15 cm x 2.5
cm, 10 mL fractions).

The pure product-containing fractions were pooled and

concentrated in vacuo, and the residue was heated to reflux with stirring in a solution of
KOH (0.59 g, 11 mmol) in H2O (15 mL) for 2 h. The mixture was cooled to room
temperature and NaHSO4 (1.7 g) was added to acidify. Product was extracted with
EtOAc (3 x 15 mL). The combined organic layers were washed with brine (15 mL) and
dried over Na2SO4. The organic solution was concentrated in vacuo and dried under high
vacuum at room temperature to yield 265 (574 mg, 51%) as a yellow-white solid: Rf
(SiO2, CHCl3) 0.03, mp 163 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ 10.41 (br s, 0.2
H), 8.41 (d, J = 7.7 Hz, 1 H), 8.05 (s, 1 H), 7.97 (s, 0.3 H), 6.66 (d, J = 7.8 Hz, 1 H);
CIMS m/z (rel intensity) 219/221/223 (MH+, 50/32/6), 201/203/205 (MH+ - H2O,
100/72/14).
2,3-Dichloro-8,9-methylenedioxyindeno[1,2-c]isochromene-5,12-dione (266).
3-Hydroxyphthalide 265 (494 mg, 2.26 mmol) and phthalide 7 (405 mg, 2.27 mmol)
were suspended in EtOAc (10 mL) and a freshly prepared solution of NaOMe (0.24 g, 10
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mmol of Na) in MeOH (20 mL) was added. The solution was heated to reflux with
stirring under Ar atmosphere for 4 d. The mixture was cooled to room temperature,
acidified to pH 1 with 37% HCl (1.5 mL), concentrated in vacuo, and azeotroped with
PhMe (10 mL). Ac2O (20 mL) was added to the residue and the mixture was heated to
90 °C with stirring under Ar atmosphere for 3 h. The suspension was azeotroped with
PhMe (10 mL) and H2O (20 mL) was added to the residue. The mixture was filtered.
The residue was washed sequentially with 3:2 CHCl3-hexanes (2 x 30 mL), 1:1 hexanesEtOAc (25 mL) and 3:2 CHCl3-Et2O (25 mL). The solid was dried under high vacuum to
provide lactone 266 (448 mg, 55%) as a dark purple solid: Rf (SiO2, CHCl3) 0.63, mp
301–302 °C. 1H NMR (300 MHz, CDCl3) δ 8.36 (s, 1 H), 8.31 (s, 1 H), 7.11 (s, 1 H),
6.96 (s, 1 H), 6.12 (s, 2 H); CIMS m/z (rel intensity) 361/363/365 (MH+, 100/76/20);
HRCIMS calcd for C17H7Cl2O5 360.9665 (MH+), found 360.9670.
(S)-2,3-Dichloro-6-(2,3-dihydroxypropyl)-8,9-methylenedioxy-5,11-dioxo11H-indeno[1,2-c]isoquinoline (267). Lactone 266 (77 mg, 0.21 mmol) was suspended
in MeOH (10 mL) and CHCl3 (15 mL), and a solution of (S)-2,3-dihydroxypropylamine
(82, 44 mg, 0.48 mmol) in MeOH (1 mL) was added with stirring. The mixture was
heated to reflux with stirring under an argon atmosphere for 19.5 h, cooled to room
temperature, and filtered. The solid residue that collected was washed with hexanes (2
mL) and dried under high vacuum to yield 267 (77 mg, 84%) as a brownish purple solid:
mp 314–315 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.46 (s, 1 H), 8.15 (s, 1 H), 7.67 (s, 1
H), 7.06 (s, 1 H), 6.18 (s, 2 H), 5.18 (d, J = 4.9 Hz, 1 H), 5.13 (t, J = 5.2 Hz, 1 H), 4.52 –
4.23 (m, 2 H), 4.01 – 3.85 (m, 1 H); CIMS m/z (rel intensity) 434/436/438 (MH+,
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100/82/28); HREIMS calcd for C20H13Cl2NO6 433.0114 (M+), found 433.0112; HPLC
purity, 100% (MeOH, 100%).
2,3-Dichloro-6-(3-(1H-imidazol-1-yl)propyl)-8,9-methylenedioxy-5,11-dioxo11H-indeno[1,2-c]isoquinoline (268). Lactone 266 (82 mg, 0.23 mmol) was dissolved
in CHCl3 (20 mL) with stirring and a solution of 3-imidazolylpropylamine (18, 56 mg,
0.45 mmol) in CHCl3 (1 mL) was added. The mixture was heated to reflux with stirring
under an argon atmosphere for 19.5 h, cooled to room temperature, and filtered. The
product was washed with hexanes (2 mL) and dried under high vacuum to provide 268
(90 mg, 84%) as a brownish purple solid: mp 309–310 °C. 1H NMR (300 MHz, DMSOd6) δ 8.54 (s, 1 H), 8.32 (s, 1 H), 8.25 (s, 1 H), 7.69 (s, 1 H), 7.25 (s, 1 H), 7.19 (s, 1 H),
7.16 (s, 1 H), 6.91 (s, 1 H), 6.23 (s, 2 H), 4.40 (t, J = 7.0 Hz, 2 H), 4.18 (t, J = 6.9 Hz, 2
H), 2.27 – 2.14 (m, 2 H); CIMS m/z (rel intensity) 468/470/472 (MH+, 100/92/31);
HRESIMS calcd for C23H16Cl2N3O4 468.0518 (MH+), found 468.0521; HPLC purity,
99.90% (MeOH, 100%).
Bis-[(5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline)-6-ethyl]amine (281). Amine 275 (16 mg, 0.16 mmol) was
added to a stirring solution of lactone 9 (113 mg, 0.321 mmol) in CHCl3 (35 mL). The
mixture was stirred and heated to reflux for 24 h under an Ar atmosphere. The mixture
was concentrated in vacuo, and the residue was absorbed onto silica gel and purified by
flash chromatography (SiO2, 95:5:1 CHCl3-MeOH-NEt3). The product fractions were
concentrated to yield 281 as a purple solid (45 mg, 18%): mp 141–143 °C. IR (KBr) 3372,
2911, 1705, 1662, 1612, 1474, 1303 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 2 H),
7.55 (s, 2 H), 6.84 (s, 2 H), 6.69 (s, 2 H), 5.81 (s, 4 H), 4.39 (m, 4 H), 4.07 (s, 6 H), 3.99
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(s, 6 H), 3.17 (m, 4 H); ESIMS m/z (rel intensity) 772 (MH+, 100); HRESIMS calcd for
C42H34N3O12 772.2143 (MH+), found 772.2141; HPLC purity: 99.85% (95% MeOH, 5%
H2O).
Bis-1,2-[(5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline)-6-ethylamino]ethane Bis(trifluoroacetate) (282). Amine
276 (15 mg, 0.10 mmol) was added as a solution in MeOH (2 mL) to a stirring solution of
lactone 9 (70 mg, 0.20 mmol) in CHCl3 (20 mL). The mixture was stirred and heated to
reflux for 18 h under an Ar atmosphere. After cooling to room temperature, the reaction
mixture was filtered and the obtained solid was stirred in TFA (5 mL) for 10 min. The
obtained solid was washed with CHCl3 (10 mL) to provide 282 as a purple solid (57 mg,
27%): mp 255–257 °C. IR (KBr) 3480, 2935, 1781, 1702, 1682, 1668, 1654, 1313, 1036
cm-1. 1H NMR (500 MHz, DMSO-d6) δ 8.25 (s, 4 H), 7.86 (s, 2 H), 7.25 (s, 2 H), 6.89 (s,
2 H), 6.65 (s, 2 H), 5.80 (s, 4 H), 4.80 (s, 4 H), 3.87-3.80 (m, 16 H), 3.61 (s, 4 H); ESIMS
m/z (rel intensity) 815 (MH+, 100); HRESIMS calcd for C44H39N4O12 815.2564 (MH+),
found 815.2562; HPLC purity: 99.05% (90% MeOH, 10% H2O).
Bis-1,3-[(5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline)-6-ethylamino]propane (283).

Amine 277 (27 mg, 0.17

mmol) was added to a stirring solution of lactone 9 (122 mg, 0.346 mmol) in CHCl3 (35
mL). The mixture was stirred and heated to reflux for 16 h under an Ar atmosphere.
After cooling to room temperature, 3 N HCl in Et2O (5 mL) was added, and the mixture
was allowed to stir for 2 h. The solid was filtered off from the mixture, and was
partitioned between CHCl3 (20 mL) and 1 M aqueous KOH solution (10 mL). After
removing and keeping the organic layer, the aqueous layer was extracted twice more with
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CHCl3 (2 x 20 mL).

The organic layers were combined, dried over Na2SO4, and

concentrated to yield 283 as a purple solid (40 mg, 14%): mp 270–273 °C. IR (KBr) 3470,
2949, 1696, 1655, 1637, 1621, 1484, 1398, 1305 cm-1. 1H NMR (300 MHz, CDCl3) δ
7.87 (s, 2 H), 7.55 (s, 2 H), 7.09 (s, 2 H), 6.92 (s, 2 H), 5.96 (s, 4 H), 4.45 (t, J = 5.0 Hz, 2
H), 3.97(s, 6 H), 3.92 (s, 6 H), 3.06 (t, J = 6.1 Hz, 2 H), 2.83 (t, J = 5.7 Hz, 2 H), 1.35 (m,
2 H); ESIMS m/z (rel intensity) 829 (MH+, 100); HRESIMS calcd for C45H41N4O12
829.2721 (MH+), found 829.2738; HPLC purity: 99.70% (95% MeOH, 5% H2O).
Bis-1,2-[(5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline)-6-propylamino]ethane (284). Amine 278 (31 mg, 0.18
mmol) was added to a stirring solution of lactone 9 (129 mg, 0.366 mmol) in CHCl3 (35
mL). The mixture was stirred and heated to reflux for 24 h under an Ar atmosphere. The
mixture was concentrated, absorbed onto silica gel, and purified by flash chromatography
(SiO2, 95:5:1 CHCl3-MeOH-NEt3). The product fractions were concentrated to yield 284
as a purple solid (43 mg, 14%): mp 201–204 °C. IR (KBr) 3502, 2936, 1686, 1649, 1521,
1474, 1309, 1027 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.75 (s, 2 H), 7.45 (s, 2 H), 6.99 (s,
1 H), 6.76 (s, 2 H), 5.97 (s, 4 H), 4.38 (m, 2 H), 3.98 (s, 6 H), 3.93 (s, 6 H), 2.98-2.95 (m,
8 H), 2.13 (m, 4 H); ESIMS m/z (rel intensity) 843 (MH+, 100); HRESIMS calcd for
C46H43N4O12 843.2878 (MH+), found 843.2885; HPLC purity: 99.01% (95% MeOH, 5%
H2O).
Bis-1,3-[(5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline)-6-propylamino]propane (285). Amine 279 (28 mg, 0.15
mmol) was added to a stirring solution of lactone 9 (105 mg, 0.298 mmol) in CHCl3 (35
mL). The mixture was stirred and heated to reflux for 16 h under an Ar atmosphere.
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After cooling to room temperature, 3 N HCl in Et2O (5 mL) was added, and the mixture
was allowed to stir for 2 h. The solid was filtered off from the mixture, and was
partitioned between CHCl3 (20 mL) and 1 M aqueous KOH solution (10 mL). After
removing the organic layer, the aqueous layer was extracted twice more with CHCl 3 (2 x
20 mL). The organic layers were combined, dried over Na2SO4, and concentrated to
yield 285 as a purple solid (44 mg, 17%): mp 244–248 °C. IR (KBr) 3531, 2967, 1695,
1683, 1649, 1554, 1389, 1039 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.79 (s, 2 H), 7.47 (s,
2 H), 7.15 (s, 2 H), 6.75 (s, 2 H), 5.96 (s, 4 H), 4.40 (t, J = 7.5, 4 H), 4.01 (s, 6 H), 3.92 (s,
6 H), 2.82 (dd, J = 14.5, 6.7 Hz, 7 H), 2.02 (m, 4 H); ESIMS m/z (rel intensity) 857 (MH+,
100); HRESIMS calcd for C47H45N4O12 857.3034 (MH+), found 857.3044; HPLC purity:
100% (90% MeOH, 10% H2O), 100% (80% MeOH, 20% H2O).
Bis-1,4-[(5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline)-6-propyl]piperazine Bis(trifluoroacetate) (286). Amine
280 (38 mg, 0.19 mmol) was added as a solution in MeOH (3 mL) to a stirring solution of
lactone 9 (130 mg, 0.369 mmol) in CHCl3 (35 mL). The solution was stirred and heated
to reflux for 72 h under an Ar atmosphere. After cooling to room temperature, the
reaction mixture was filtered and the solid was stirred in TFA (5 mL) for 10 min. The
solid was washed with CHCl3 (10 mL) to provide 286 as a purple solid (120 mg, 30%):
mp 253–256 °C. IR (KBr) 3477, 2986, 1695, 1665, 1479, 1392, 1182 cm-1. 1H NMR (300
MHz, DMSO-d6) δ 7.91 (s, 2 H), 7.50 (s, 2 H), 7.41 (s, 2 H), 7.13 (s, 2 H), 6.20 (s, 4 H),
3.90 (s, 6 H), 3.85 (s, 6 H), 4.48 (m, 4 H), 3.09 (m, 8 H), 2.07 (m, 4 H), 1.16 (t, J = 7.3
Hz, 12 H); MALDI m/z (rel intensity) 869 (MH+, 100); HRESIMS calcd for C48H45N4O12
869.3033 (MH+), found 869.3051; HPLC purity: 96.18% (1% TFA in MeOH).

214
5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-6-(pent-4-ynyl)11H-indeno[1,2-c]isoquinoline (288). Amine 287 (0.75 mL, 7.8 mmol) was added to a
stirring solution of lactone 9 (124 mg, 0.352 mmol) in CHCl3 (20 mL). The solution was
heated to reflux with stirring for 48 h under an Ar atmosphere. After cooling to room
temperature, more CHCl3 (10 mL) was added and the organic solution was washed with
H2O (2 x 10 mL) and brine (1 x 10 mL) and dried over Na2SO4. The resulting solution
was concentrated in vacuo to provide 288 as a purple solid (137 mg, 93%): mp 280–
282 °C. IR (KBr) 3458, 2906, 2115, 1694, 1636, 1391, 1029 cm-1. 1H NMR (300 MHz,
CDCl3) δ 8.00 (s, 1 H), 7.61 (s, 1 H), 7.39 (s, 1 H), 7.04 (s, 1 H), 6.05 (s, 2 H), 4.64–4.42
(m, 2 H), 4.01 (s, 3 H), 3.95 (s, 3 H), 2.45 (td, J = 6.5, 2.7 Hz, 2 H), 2.14 (t, J = 2.6 Hz, 1
H), 2.11-2.00 (m, 2 H); APCI m/z (rel intensity) 418 (MH+, 100); HRESIMS calcd for
C24H19NO6 417.1212 (M+), found 417.1210.
Bis-1,4-[(5,6-Dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11Hindeno[1,2-c]isoquinoline)-6-propyl]-1H-1,2,3-triazole (290). Azide 289 (54 mg, 0.12
mmol) and alkyne 288 (52 mg, 0.12 mmol) were suspended in anhydrous DMF (15 mL)
with stirring. CuSO4·5H2O (37 mg, 0.15 mmol), sodium ascorbate (51 mg, 0.26 mmol),
and NEt3 (1 mL) were added, and the suspension was allowed to stir under an Ar
atmosphere at room temperature for 20 h. The reaction mixture was concentrated under
high vacuum. The residue was dissolved in CHCl3 (20 mL) and solids were precipitated
with the addition of 1:1 EtOAc-hexanes (10 mL).

The solid that precipitated was

collected by filtration, washed with H2O (20 mL), and dried in vacuo to provide 292 as a
purple solid (79 mg, 77%): mp 245 °C (dec). IR (KBr) 3459, 2944, 1775, 1675, 1620,
1390, 1137 cm-1. 1H NMR (500 MHz, TFA) δ 9.29 (s, 1 H), 8.83 (s, 2 H), 8.40 (s, 1 H),
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8.38 (s, 1 H), 7.86 (s, 2 H), 7.79 (s, 2 H), 6.79 (s, 4 H), 5.71 (m, 2 H), 5.50 (m, 2 H), 5.42
(m, 2 H), 4.79-4.74 (4 s, 12 H), 4.01 (m, 2 H), 3.52 (m, 2 H), 3.23 (m, 2 H); ESIMS m/z
(rel intensity) 852 (MH+, 100); HRESIMS calcd for C46H38N5O12 852.2517 (MH+), found
852.2545.
Topoisomerase IB-Mediated DNA Cleavage Reactions. These assays were
performed/supervised by our group’s collaborators, Drs. Keli Agama and Yves Pommier
and their staff, all of the National Cancer Institute. A 3'-[32P]-labeled 117-bp DNA
oligonucleotide was prepared as previously described. The oligonucleotide contains
previously identified Top1 cleavage sites in 161-bp pBluescript SK(–) phagemid DNA.
Approximately 2 nM radiolabeled DNA substrate was incubated with recombinant Top1
in 20 μL of reaction buffer [10 mM Tris-HCl (pH 7.5), 50 mM KCl, 5 mM MgCl2, 0.1
mM EDTA, and 15 μg/mL BSA] at 25 °C for 20 min in the presence of various
concentrations of test compounds. The reactions were terminated by adding SDS (0.5%
final concentration) followed by the addition of two volumes of loading dye (80%
formamide, 10 mM sodium hydroxide, 1 mM sodium EDTA, 0.1% xylene cyanol, and
0.1% bromophenol blue). Aliquots of each reaction mixture were subjected to 20%
denaturing PAGE. Gels were dried and visualized by using a phosphoimager and
ImageQuant software (Molecular Dynamics).

For simplicity, cleavage sites were

numbered as previously described in the 161-bp fragment.7
Recombinant TDP1 assay. These assays were performed/supervised by our
group’s collaborators, Drs. Christophe Marchand and Yves Pommier and their staff, all of
the National Cancer Institute. A 5′-[32P]-labeled single-stranded DNA oligonucleotide
containing a 3′-phosphotyrosine (N14Y)65 was incubated at 1 nM with 10 pM
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recombinant TDP1 in the absence or presence of inhibitor for 15 min at room temperature
in the LMP1 assay buffer containing 50 mM Tris HCl, pH 7.5, 80 mM KCl, 2 mM EDTA,
1 mM DTT, 40 μg/mL BSA, and 0.01% Tween-2038. Reactions were terminated by the
addition of 1 volume of gel loading buffer [99.5% (v/v) formamide, 5 mM EDTA, 0.01%
(w/v) xylene cyanol, and 0.01% (w/v) bromophenol blue]. Samples were subjected to a
16% denaturing PAGE with multiple loadings at 12-min intervals. Gels were dried and
exposed to a PhosphorImager screen (GE Healthcare). Gel images were scanned using a
Typhoon 8600 (GE Healthcare), and densitometry analyses were performed using
ImageQuant software (GE Healthcare).

The full sequence of the 14-mer DNA

oligonucleotide is: 5’-GATCTAAAAGACTT-3’.
Recombinant TDP2 assay. These assays were performed/supervised by our
group’s collaborators, Drs. Christophe Marchand and Yves Pommier and their staff, all of
the National Cancer Institute. TDP2 reactions were carried out as described previously100
with the following modifications. The 19-mer single-stranded oligonucleotide DNA
substrate containing a 5’ phosphotyrosine (Y19, α32P-cordycepin-3’-labeled) was
incubated at 1 nM with 25 pM recombinant human TDP2 in the absence or presence of
inhibitor for 15 min at room temperature in the LMP2 assay buffer containing 50 mM
Tris-HCl, pH 7.5, 80 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 40 µg/mL
BSA, and 0.01% Tween 20.

Reactions were terminated and treated similarly to

recombinant TDP1 reactions (see above).

The full sequence of the 19-mer DNA

oligonucleotide is: 3’-ATTTCGTCCGAAGTTGCCT-5’.
Molecular Mechanics Calculations. The 1SC7 X-ray crystal structure file was
prepared for molecular modeling by correcting several atom types, removing all of the
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water molecules, and adding hydrogens. The hydrogens were energy minimized while
the remaining atoms were frozen in aggregate, in SYBYL.101 The details of this
minimization, and all of the other minimizations, were set as follows: Powell method;
MMFF94s force field102; MMFF94 charges; and 0.05 kcal/mol·Å energy gradient
convergence. Selected indenoisoquinolines were constructed in SYBYL and energy
minimized. The ligands were docked into the prepared crystal structure using GOLD 3.2
software.103 The centroid of the binding site was defined by the crystallized ligand. Ten
GOLD algorithm runs were executed per ligand. Default parameters were used. The top
ten docking poses per ligand were inspected visually following the docking runs. The
docking poses that had a favorable GOLD score and similar binding mode to the
crystallized ligand were selected for further analysis. Ligand atom types were inspected
and corrected as necessary.

Lone pairs added by GOLD were deleted, prior to a

subsequent energy minimization of the docked complexes. Minimization was executed
by allowing only the ligand to move while freezing the surrounding crystal structure as an
aggregate.
Models depicting the similarity between ligand binding modes (Figures 11, 16,
26, and 38) were constructed using SYBYL’s “Align Structures by Homology” tool. The
α-carbons were used as reference points. The PDB files used for the overlays in Figures
11, 16, and 38 were 1SC721 and 1SEU21, and the PDB files used in Figure 26 were 1SC7
and 1K4T92. In each figure, the Top1-DNA cleavage complex that is shown originates
from the 1SC7 file.
Quantum Mechanics Calculations. Preparation of model systems for quantum
mechanics study, execution of the calculations, and data processing was carried by Dr.
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Wei Lv, a former graduate student of this laboratory. The A-T and C-G base pairs and
indenoisoquinoline 223 were individually subjected to geometry optimization and
frequency calculation at the HF/6-31G** level in Gaussian 09.104 The original 1SC7 Xray crystal structure complex was then replaced with the geometry optimized parts. The
hydrogen in the 3-position of indenoisoquinoline 223 was replaced with a nitro group
(222), fluorine (224), chlorine (225), or a trifluoromethyl (226) group to make the first set
of model ligands. The hydrogens in the 2- and 3-positions were replaced by fluorines
(273) or chlorines (274) to make the second set of model ligands. The same geometry
optimizations were performed on these molecules before placing them into complexes
with the DNA base pairs. A schematic representation of the model “indenoisoquinolineTop1-DNA ternary complex” used in this study is shown in Figure 25.
After the complexes were assembled, single point energy calculations were
performed at the MP2/6-31G* level in Gaussian 09. The basis set superposition error
(BSSE) for each complex was calculated using the counterpoise correction method within
the Gaussian 09 package, specifying two fragments: (1) the two flanking DNA base pairs;
and (2) the indenoisoquinoline. The base pair-indenoisoquinoline interaction energy was
calculated as Eint = Ecomplex – Eligand – Ebp + BSSE, where Ecomplex, Eligand, and Ebp are the
corresponding MP2/6-31G* calculated energies of the complex, the ligand, and the DNA
base pairs at their normal distance in the absence of an intercalator.
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